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1 Introdution 1
1 Introdution
1.1 Priniples of miroarray tehnology
Miroarrays are one of the fundamental tools for researh in life sienes. The term
"miroarray" refers to its harateristi feature to arrange (or "array") a high number
of moleules on a very small ("miro") area. Despite the variety of tehnial solutions
for performing miroarray analysis, all are miniaturized hybridization assays, enabling
studies of thousands of targets simultaneously. All miroarray experiments share the
following key omponents:
• the array itself, ontaining the immobilized "targets" arranged in a regular pattern,
• the labelled sample or "probe" that is hybridized to the miroarray and
• a detetion system that quanties the hybridization signal [1, 2℄.
1.1.1 Miroarrays
Miroarrays onsist of a olletion of target moleules immobilized onto a solid support
so that they form tiny features, alled "spots". Spot size varies among systems, but is
usually less than two hundred mirometers in diameter. A glass slide or silion wafer
ats as the solid support providing reative groups (e.g. aldehyde, amine, epoxy or ester
modiations) enabling immobilization of the target moleules to the surfae. Miroar-
rays an be lassied aording to the nature of the spotted targets into DNA-, protein-
and tissue hips. DNA miroarrays are further divided into DNA and oligonuleotide
miroarrays referring to immobilization of either double-stranded PCR produts or
shorter single-stranded synthesized oligos. For DNA miroarrays more than one mil-
lion spots an be arrayed in a total area of a few square entimeters (Aymetrix).
Two parallel approahes have been developed for the prodution of miroarray slides.
Nulei aid targets an either be synthesized diretly onto the miroarray, or puri-
ed target moleules an be deposited in a ontat-dependent or independent printing
method using miroarray spotter equipment. This latter approah is inreasingly ad-
vantageous allowing easy spotting of ustomized miroarrays, while in-situ synthesis
(as pioneered by Aymetrix) is harateristi for ommerially available formats due
to higher eorts but also inreased purity [1, 2℄.
1.1.2 Probe labelling
The miroarray sample that is supposed to be analysed, e.g.mRNA for gene expression
studies or DNA derived from genomi analysis, is onverted to a labelled population
of several thousands of nulei aid moleules, the probe. Inorporation of tagged
nuleotides an be ahieved during DNA-synthesis as well as during an in vitro trans-
ription reation yielding RNA probes. Thereby, hybridization of RNA samples to
DNA miroarrays an be arried out at higher temperatures and thus inreased spei-
ity, beause RNA-DNA-hybridizations are energetially advantageous. Furthermore,
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RNA synthesis provides the possibility for linear ampliation of the original starting
material, allowing performane of miroarray experiments even for samples of very
small ell numbers. However, a disadvantage of the use of RNA as a probe is its
fragility, demanding espeially areful sample preparation to prevent RNA degrada-
tion. Fluoresent dyes, like the yanine dyes Cy3 and Cy5, have been established as the
predominant label in miroarray experiments and have almost ompletely replaed ra-
dioative methods. For diret labelling proedures, uoresene onjugated nuleotides,
suh as Cy5- or Cy3-UTP, are inorporated during DNA or RNA synthesis, while
indiret strategies are based on biotin- or aminoallyl-tagged nuleotides. The indiret
approah allows higher labelling eieny due to redued steri hindrane beause the
inorporated nuleotides possess a spaially smaller modiation. Additionally, it is
the more robust method, as labelling is only arried out after hybridization, thereby
preventing premature photobleahing of the used uoresene dye during sample hand-
ling in the light. Reently, two-hannel or ompetitive hybridization approahes are
gaining more importane. Therefore, the ontrol sample and the probe-of-interest are
labelled with dierent uoresene dyes, enabling omparative analysis of both samples
on the same miroarray thereby reduing tehnial variane [1, 2℄.
1.1.3 Miroarray hybridization
For miroarray hybridization, the labelled fragments in the probe are expeted to form
duplexes with their immobilized omplementary targets. This requires that the nulei
aids are single-stranded and omplementary as well as aessible to eah other. The
number of duplexes formed reets the relative number of eah spei fragment in
the probe, as long as the amount of immobilized target is in exess and not limiting
hybridization kinetis. By measuring the uoresene signals assoiated with eah spot,
the relative abundane of spei sequenes in the sample an be determined [1, 2℄.
1.1.4 Sanning and data analysis
Miroarray sanner typially ontain two dierent lasers that emit light at wavelengths
suitable to exite the uoresent dyes used as labels. A onfoal mirosope attahed
to a detetor system reords the emitted light from eah of the miroarray spots, al-
lowing high-resolution detetion of the hybridization signals. Despite their small size,
miroarrays generate large quantities of data even from a single experiment. As a ty-
pial experiment will involve analysis of several samples on repliate arrays, the use of
omputerized data proessing is neessary to handle the huge amount of data reated
and to gain maximum information. This an be ahieved by speialized software that
alulates raw signal intensities from sanned miroarray slide images and normalizes
this data to remove the inuene of experimental variation. Appliation of statistial
tools failitates extration of signiant data and inreases reliability of drawn biologi-
al onlusions. Additionally, visualization software an be used for further data mining
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providing helpful features, suh as data integration and pattern reognition. Clustering
data points an be used to identify o-regulated genes whih possibly belong to the
same pathway [1, 2℄.
1.1.4.1 SAM - Signiane analysis of miroarrays As DNA miroarrays en-
able expression measurement of thousands of genes in a single hybridization experiment,
massive amounts of data are generated. That is why methods are needed to determine
whether hanges in gene expression are experimentally signiant. Clustering analysis
of miroarray data an nd oherent patterns of gene expression [3℄ but provides only
little information about statistial signiane. Methods based on onventional t tests
alulate the probability (P) that a dierene in gene expression oured by hane.
But while P = 0.01 is signiant for evaluation of experiments involving small numbers
of genes, already 100 false positive genes would be identied in a miroarray experiment
inluding 10,000 genes [4℄. This problem led to the development of Signiane Ana-
lysis of Miroarrays (SAM), a statistial method adapted speially for miroarrays
[5℄. SAM identies genes with statistially signiant hanges in expression by assimi-
lating a set of gene-spei t tests. To eah gene a sore is assigned on the basis of its
hange in gene expression relative to the standard deviation of repeated measurements
for that gene. SAM uses permutations of the repeated measurements to estimate the
perentage of genes identied by hane, the false disovery rate (FDR). Genes with
sores greater than an adjustable threshold are deemed potentially signiant.
1.1.4.2 Hierarhial lustering Transriptional proling tehniques promise a
wealth of data that an be used to develop a more omplete understanding of gene
funtion, regulation and interations. The simplest way to nd interesting andidate
genes is to searh for those that are onsistently up- or down-regulated by running
a statistial data mining tool suh as SAM (see hapter 1.1.4.1). But identifying
ommon patterns of gene expression and grouping genes into expression lasses might
provide muh greater insight into their biologial funtion and relevane. Based on our
understanding of ellular proesses, genes that are ontained in a partiular pathway,
or that respond to a partiular environmental hallenge, should be o-regulated and
onsequently, show similar patterns of expression. To identify those genes with similar
expression patterns, a large group of statistial methods exists, generally referred to
as "luster analysis". First, an "expression vetor" for eah gene is dened repre-
senting its loation in n-dimensional "expression spae", where n is the number of
experiments. Afterwards, distanes between all objets are alulated so that lustering
algorithms an sort the data and group similar genes together. In parallel, it is also
possible to apply the lustering algorithm to analyse and group experiments. Various
lustering tehniques exist diering in distane similarity measurement and the data
sorting algorithm. Most of them are hierarhial where the generated lassiation has
an inreasing number of nested lasses and the result resembles a phylogeneti tree.
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To failitate interpretation of the results of a lustering analysis, an intuitive visual
representation is helpful. One approah is to reate an expression matrix in whih eah
olumn represents a single experiment and eah row represents the expression vetor for
a partiular gene. Eah matrix element is oloured on the basis of its expression value
thereby reating a visual representation of gene expression patterns aross experiments.
The most ommonly used method is to olour up-regulated genes in red, down-regulated
genes in green and genes without hange in expression in blak - with their relative
intensity representing their relative expression [6℄.
1.1.4.3 From genes to pathways Identifying hundreds of genes whose expres-
sion is markedly dierent in one sample than in another provides a large amount of
potentially valuable data. The trik is to fous on the genes that are relevant to the
questions being asked. One way to do so is to nd a subset of genes that are fun-
tionally onneted through ommon pathways [7℄. Reently, software for metaboli
pathway analysis supports examination of gene expression prole data by enabling
determination of diret binding and interating moleules.
1.1.5 Appliations of miroarray analysis
The versatility of miroarray analysis is onrmed by its rapid development as a ge-
neral tehnique in moleular biology. Miroarrays have not beome a replaement to
established proedures but a novel, high-throughput approah. Enabling simultaneous
measurement of thousands of targets in a single assay, miroarrays have emerged as
an alternative for previously time-onsuming analyses. They oer almost unlimited
appliations and are thus employed for gene expression and genome analysis as well
as for drug disovery, analysis of protein-protein- or DNA-protein-interations, identi-
ation of spei antibodies and promoter regions. Completion of the human genome
projet, together with emerging information about genomes of many pathogens, addi-
tionally oers new possibilities for exploring the moleular pathogenesis of infetious
diseases. Alone in this eld, hip tehnology an be applied to a wide variety of sienti
questions, suh as interation studies between miroorganisms and the host, pathogen
studies to identify known or novel organisms as well as investigations of pathogeni
determinants [8℄. In biomedial researh, miroarrays have beome essential tools for
haraterizing transriptomes of dierent ell types in diverse diseases, suh as inam-
matory bowel disease [9℄, renal ell arinoma [10, 11℄ and severe aplasti anemia [12℄
or to study e.g. immune responses as a whole [13℄.
1.1.5.1 Gene expression analysis Gene expression analysis examines the ompo-
sition of ellular mRNA populations. Identity and expression levels of transripts on-
stituting the ell's transriptome provide insights into ell state and gene ativity. As
the preursors of translated proteins, hanges in mRNA levels an be linked to hanges
in the proteome. A typial miroarray gene expression experiment ompares relative
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expression levels of spei transripts in two probes, one ontrol and another sample,
derived from ells whose response or status is being investigated [1, 14℄. These studies
examine e.g. the eets of treating ells or patients with ertain substanes (hemials,
pharmaeutials, infetion with pathogens, [12℄), the onsequenes of over-expression
of genes-of-interest in transfeted ells [10, 15, 16℄, and mutant versus parental strains
to delineate funtional pathways [17, 18℄. Furthermore, time ourse experiments an
help to reveal moleular proesses during development and dierentiation of diverse
ell types [19℄. In aner researh, miroarrays are used to reveal dierentially ex-
pressed genes in transformed ells and metastases, to identify diagnosti markers, and
to lassify tumors based on their harateristi gene expression proles [20, 21℄. The
obtained data are often orrelated to prognosis and/or response to therapy [11℄. Not
only in aner, but in human diseases in general, gene expression proling studies
have allowed better understanding of pathophysiologial proesses. They may lead to
the developement of new linial tools to improve diagnosis and prognosis of patients
[9, 12℄.
1.1.5.2 Genomi analysis Miroarrays are useful tools for genomi analyses. Iden-
tiation of new genes by examining nulei aid sequenes derived from open reading
frames has proven to be an eient approah of annotating the human genome [1, 2℄.
Eluidation of interations between transription fators and their target genes an ad-
vane understanding of gene regulation. That is why ChIP-hip-tehnology ombines
immunopreipitation of transription fator-DNA omplexes and genomi miroarray-
based hybridization of these DNA fragments [22℄. Furthermore, miroarrays an be
applied for predition of splie variants of transripts and are reently used for geno-
typing of single nuleotide polymorphisms (SNP) reeting DNA sequene variations
among individuals [23℄. Samples an be sequened by miroarray hybridization, thus
providing onvenient means for identifying new geneti variants. Correlation of expres-
sion data and SNP genotyping in so alled linkage analysis may reveal new suseptibility
genes of diverse diseases [24, 25℄.
1.1.5.3 Drug disovery As a typial drug disovery proess takes several years,
inurs high osts and turns only a few andidates into approved drugs, methods for
inreasing eieny of this proedure are highly welomed. Miroarrays an provide
useful information in the dierent stages of drug disovery. Identiation of potential
drug targets an be supported by eluidating metaboli pathways when looking at
oexpressed genes. One drug targets have been seleted, miroarrays an be used
to dene their toxiity by examining expression proles indued by drug treatments.
Additionally, dierent funtion modes of drugs an be revealed based on the gene
expression hanges they eliit [1, 2, 26℄.
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1.1.6 Customized versus ommerial miroarrays
The amount of both biologial and tehnial repliates required for reliable biologial
results inreases the number of arrays needed for linial trials or disease proling and
sreening. Utilization of ommerial platforms usually targeted at global sreening
of gene expression is relatively expensive, espeially when multiple samples should
be analysed. Customized miroarrays oering a targeted seletion of genes-of-interest
an be an aordable method-of-hoie for foussed studies, often following genome-
wide expression proling [13℄. That is why apart from ommerially available formats
(e. g.Aymetrix, CodeLink...), diverse ustomized miroarrays have reently aptured
the market. Suh speialized miroarray approahes have been desribed for dierent
purposes enabling mostly aner [11, 27℄, disease [9℄ or immunologial studies [13, 28℄.
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1.2 The immune system
The immune system is a soiety of interating ells onsisting of T and B lymphoytes,
natural killer (NK) ells, marophages, professional antigen-presenting ells (APCs)
and their various sublasses. Marophages and dendriti ells are part of the innate
immune system, while the lymphoytes onstitute the arm of adaptive immunity. B
lymphoytes, NK ells and marophages mature in the bone marrow and in the fetal
liver, while T ells develop in the bone marrow and in the thymus. T and B ell devel-
opment share many features, yet dier in others [29℄. Cells of the immune system work
together as a team to protet the host against foreign pathogens. After an attak by
infetious agents, professional APCs, dendriti ells (DCs) in partiular, present anti-
geni peptides of the intruders to T ells. Antigen presenting major histoompatibility
omplexes (MHC), ostimulating ell-surfae moleules on APCs and ytokines drive T
ells into lonal expansion. Then these T ells in turn ommuniate with other T or B
ells to regulate their responses. After a peak phase with the highest lonal expansion
of reative ells, the immune response undergoes a down phase. Most lymphoytes are
eliminated, while the few that survive onstitute the pool of memory ells [30℄.
1.2.1 B lymphoytes
B ells express ell membrane reeptors (antibodies) with a single antigen speiity.
Millions of dierent B ells produe antibodies that an potentially apture millions of
antigens thereby making up the so-alled antibody repertoire. B ells are seleted in the
bone marrow on the basis of the anity of their antibodies: ells equipped with B ell
reeptors of high anity for proteins derived from self tissues are eliminated. Mature
B lymphoytes leave the bone marrow and populate the seondary lymphoid organs -
spleen and lymph nodes as well as the gut-assoiated lymphoid tissues. One ativated
by an antigen, B ells undergo a seond round of seletion in the folliles of seondary
lymphoid organs, mature into plasma ells produing and sereting antigen-spei
antibodies and then reirulate to the bone marrow [30℄. These sereted antibodies are
the main eetors of the humoral immunity as they bind and thereby neutralize their
spei extraellular antigen [29℄.
1.2.2 T lymphoytes
Pre-T lymphoytes emigrate from the bone marrow into the thymus. There, they
mature and are positively or negatively seleted, depending on the anity of their T
ell reeptors (TCRs) for self antigens presented by MHC. MHC lass I and II are
moleules that sample peptide fragments from foreign and self proteins, respetively.
They display these peptides at the ell's surfae for srutiny by T ells in a proess
known as antigen presentation. Eah MHC lass I or II protein presents a unique
fragment and thousands of MHC moleules protrude from every ell. Most of the
peptides presented in the thymus are derived from self proteins. T ells with a high
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anity for self MHC moleules and peptides are eliminated to ensure tolerane to
normal tissue and to prevent autoimmunity. T ells that interat with MHC lass I
moleules develop into CD8
+
T lymphoytes, while those with anity for MHC lass II
proteins turn into CD4
+
T ells. Only mature T ells with a funtional TCR leave the
thymus and populate the seondary lymphoid organs. Mature CD4
+
T ells funtion as
T helper (T
H
) ells and serete ytokines that regulate either ellular immune responses
by ativating marophages (T
H
1 or inammatory T ells) or antibody responses by
driving dierentiation of naive B ells into plasma ells (T
H
2 ells). Ativated CD8
+
T
lymphoytes serve as ytotoxi eetor ells by eliminating ells infeted with viruses
or bateria [29, 30℄.
1.2.2.1 T ell ativation The rst step in adaptive immunity is the ativation
of naive antigen-spei T ells by APCs. This proess takes plae in the lymphoid
tissues and organs through whih naive T ells are ontinuously passing. The most
important feature of APCs is the expression of o-stimulatory moleules, of whih B7.1
and B7.2 are the best haraterized. Naive T ells will respond to antigen only, when
an APC presents both a spei antigen (omplexed with MHC) to the TCR and a
B7 moleule to CD28, the orresponding reeptor on the T ell. Three ell types an
serve as APCs: DCs, marophages and B ells, eah possessing a distint funtion in
eliiting immune responses. Tissue DCs take up, proess and present antigens and are
stimulated by infetion to migrate to loal lymphoid tissues. There they dierentiate
into mature DCs expressing o-stimulatory ativity. They are the most important
ativators of naive T ells in vivo. Marophages eiently ingest partiulate antigens
suh as bateria and are indued by infetious agents to express MHC lass II and
o-stimulatory moleules. The unique ability of B ells to bind and internalize soluble
protein antigens via their reeptors may be important in ativating T ells to this lass
of antigen, provided that o-stimulatory moleules are also indued on the B ell. In
all three ell types of APC, the expression of o-stimulatory moleules is ativated
in response to signals from reeptors that also funtion in innate immunity to signal
the presene of infetious agents. The ativation of naive T ells by APCs leads to
their proliferation and dierentiation into armed eetor T ells. This proess depends
on the prodution of ytokines, in partiular the T ell growth fator interleukin-2
(IL2), whih binds to a high anity reeptor on the ativated T ell. T ells, whose
antigen reeptors are ligated in the absene of o-stimulatory signals, fail to produe
IL2 and instead beome anergi or die. This dual requirement for both TCR ligation
and o-stimulation by the same APC helps to prevent naive T ells from responding to
self-antigens on tissue ells, whih lak o-stimulatory ativity. Suiently ativated T
ells develop into armed eetors, the ritial event in most adaptive immune responses.
One an expanded lone of T ells ahieves eetor funtion, its progeny an at on any
target ell that displays antigen on its surfae - without further need of o-stimulatory
signals. Thereby, eetor T ells have a wide variety of funtions: CD8 ytotoxi T ells
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kill infeted ells, while T
H
1 ells ativate marophages, and both together make up
ell-mediated immunity. T
H
1 and T
H
2 ells are stimulating B ells to produe dierent
lasses of antibodies, thus driving humoral immune response [29℄.
1.2.2.2 Central versus peripheral tolerane One of the probably most stri-
king apaities of the immune system is its ability to disriminate between self and
non-self, thereby preventing autoimmune responses while allowing eetive immunity
against infetions. Several mehanisms have evolved for the maintenane of tolerane
and immune homeostasis [Figure 1℄: Self-reative T ells are deleted during their deve-
lopment in the thymus in a proess known as entral tolerane. Thereby, most T ells
are eliminated by positive or negative seletion, sparing only those T ells equipped
with reeptors exhibiting a moderate anity to foreign antigeni peptides presented
by self MHC moleules. All T ells that do not express a TCR or a TCR that fails
to reognize self MHC omplexes undergo apoptosis. Furthermore, T ells arrying a
TCR with a high anity to self MHC omplexes are also deleted by programmed ell
death.
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Figure 1: Mehanisms of entral and peripheral tolerane [34℄
But as this negative seletion is inomplete, self-reative T ells that have esaped
from lonal deletion, need to be ontrolled in the periphery. Peripheral tolerane me-
hanisms to prevent ativation of autoreative T ells inlude deletion, anergy and
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suppression [Figure 1℄. The so-alled regulatory T ells (T
Reg
) atively suppress a-
tivation and expansion of these self-reative esapees [31, 32, 33, 34℄. In this way,
T
Reg
ells ontrol the deliate balane between immunity and tolerane [35℄, explaining
their important role in autoimmune diseases [36, 37, 38℄, aner [39, 40, 41℄, trans-
plantation tolerane [42, 43, 44℄ and even allergy [45, 46℄ as well as for the outome of
infetions [47℄.
1.2.2.3 Regulatory T ell populations As summarized in Figure 2, several types
of T
Reg
ells have been desribed in both mie and humans, inluding naturally o-
urring or professional (CD4
+
CD25
+
) and adaptive or induible (T
H
3 and T
R
1) T
Reg
ells.
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Figure 2: Naturally ourring and induible regulatory T ells [34℄
Naturally ourring T
Reg
ells onstitutively express the ell surfae moleule CD25
[48℄ and the transriptional repressor FOXP3, an essential key gene ontrolling their
development and funtion [49, 50, 51℄. These ells mature and migrate diretly from
the thymus and onstitute approximately 2-4% of total human CD4
+
T ells [52, 53℄.
They represent an endogeneous long-lived population of self-antigen-spei T ells in
the periphery. As a potential onsequene of their positive seletion in the thymus
naturally ourring T
Reg
ells are rendered anergi and beome able to produe anti-
apoptoti moleules whih protet them from negative seletion [54℄. In humans, T
Reg
ell ativity is restrited to the CD4
+
CD25
high
population, while CD4
+
CD25
low
T ells
represent mainly previously ativated T helper ells and naive T ells reside within the
CD4
+
CD25
-
population [55, 56℄. Other populations of T
Reg
ells an be indued from
naïve CD4
+
CD25
-
or CD8
+
CD25
-
T ells in the periphery under partiular onditions
of suboptimal antigen exposure and/or o-stimulation, suh as the inuene of semi-
mature dendriti ells, interleukin-10 (IL10), transforming growth fator-b (TGF-b)
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and possibly interferon-a (IFN-a) [57, 58℄. Distint subtypes of these adaptive T
Reg
subpopulations are inluded in the CD4
+
T ell ompartment and are distinguished as
T regulatory 1 (T
R
1) and T helper 3 (T
H
3) ells aording to their dierent ytokine
proles [59, 60℄. T
R
1 ells serete high levels of IL10, no IL4 and no or low levels of IFN-
g, while T
H
3 ells serete high levels of TGF-b. Although CD8
+
T ells are normally
assoiated with ytotoxi T-lymphoyte funtion and IFN-g prodution, a subtype
of these ells has been desribed to serete IL10 and to possess regulatory apaities
[61, 62℄. Just to omplete the piture, NK and B ells an also display regulatory
ativity [29℄. All these dierent T ell subpopulations with regulatory funtion oexist
and ontribute to immunosuppression [63℄.
1.2.2.4 Marker moleules of regulatory T ells Isolation, denition and ha-
raterization of regulatory T ells remain diult as the availability of spei marker
moleules is still limited [35℄. Apart from CD25, additional surfae moleules have been
reported as assoiated with T
Reg
ell funtion [Figure 3℄, e.g. ytotoxi T-lymphoyte-
assoiated protein 4 (CTLA4) [64, 65, 66℄, tumor nerosis fator reeptor superfamily,
member 18 (TNFRSF18 or GITR) [67, 68℄ and seletin L (SELL or CD62L) [69, 70℄.
Furthermore, FACS analyses revealed that T
Reg
ells express high surfae levels of
HLA-DR, IL2 reeptor g-hain (IL2RG, CD122) and CD45RO [47℄.
C D 4 + C D 2 5 +
    T R e g  c e l l
I L 2 R A
( C D 2 5 )
C T L A 4
( C D 1 5 2 )
T N F R S F 1 8
( G I T R )
S E L L
( C D 6 2 L )
H L A - D R
I L 2 R G
( C D 1 2 2 )
C D 4 5 R O
N r p 1
T N F R S F 7
( C D 2 7 )
L G A L S 1
I T G A E
( C D 1 0 3 )
T N F R S F 9
( 4 - 1 B B )
T N F R S F 4
( O X - 4 0 )
L y 6
Figure 3: Surfae moleules on CD4
+
CD25
+
T
Reg
ells in mie and men.
Studies have reported several dierent moleules preferentially expressed on the surfae
of naturally ourring CD4
+
CD25
+
T
Reg
ells in mie and men. However, the vast
majority do not remain as faithful biomarkers after T ell ativation and do not appear
to be onviningly involved in the mehanisms underlying T ell suppression (modied
aording to [32℄).
IL2RA = interleukin-2 reeptor alpha, ITGAE = integrin alpha e, LGALS1 = galetin-1, IL2RG
= interleukin-2 reeptor gamma, TNFRSF = tumor nerosis fator reeptor superfamily, Nrp1 =
Neuropilin-1, CTLA4 = ytotoxi T-lymphoyte-assoiated protein 4, SELL = seletin L
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However, all these moleules are also expressed by naive CD4
+
CD25
-
T ells upon
ativation, thereby hampering disrimination between regulatory and onventionally
ativated CD4
+
T ells [31℄. Furthermore, CD25 as well as other T
Reg
ell moleules,
suh as GITR and CTLA-4, are not expressed on all CD4
+
T ells with regulatory
funtion [71℄. Reently, new genes like Neuropilin-1 (Nrp1) for mouse [15℄ and CD27
oexpression with CD25 for human [72℄ were suggested as useful markers to distin-
guish regulatory from eetor T ells. Like murine ells, human CD4
+
CD25
+
T
Reg
ells express signiantly more FOXP3 (forkhead box P3) mRNA and protein than
CD4
+
CD25
-
T ells do. But, in ontrast to data obtained from mouse models, over-
expression of FOXP3 in human CD4
+
CD25
-
T ells alone is not suient to generate
potent suppressor T ells in vitro, suggesting additional fators required for the de-
velopment, dierentiation and funtion of human T
Reg
ells [16℄. Reent reports in
humans even demonstrated indution of FOXP3 gene and protein expression in a-
tivated onventional T ells without suppressive ativity [16, 73℄. Furthermore, the
usefulness of FOXP3 as a marker of T
Reg
ells is limited by its nulear loalization,
preluding staining of living ells [74℄. However, human CD4
+
T ells expressing CD25
represent a heterogenous ell population ontaining not only regulatory but also re-
ently ativated eetor/memory T ells [75℄. Peripheral CD4
+
CD25
+
T
Reg
ells in
healthy adults display a memory phenotype (CD45RA
-
CD45RO
+
and CD45RB
low
)
indiating previous experiene with their antigen in vivo [76℄.
1.2.2.5 Charateristis and suppression by T
Reg
ells Despite reent ad-
vanes in T
Reg
ell biology, the mehanism of immunosuppression by human CD4
+
CD25
+
T
Reg
ells remains elusive. It has been shown that naturally ourring CD4
+
CD25
+
T
Reg
ells are haraterized by an anergi phenotype, beause they do not proliferate
upon TCR stimulation in vitro. They exist without spei antigen stimulation and
atively suppress immune responses in a ell-ell ontat-dependent manner [77℄. This
mehanism is related to the ombined ation of surfae CTLA4 and TGF-β leading
to the inhibition of the IL2 reeptor alpha hain on target T ells [54℄. In ontrast to
that, antigen-indued T
Reg
ells exert their immunosuppressive funtion through the
seretion of soluble fators, suh as IL10 or TGF-b, whih are both ytokines that an
inhibit T ell proliferation [77℄. Furthermore, both ytokines an also at on APCs
and DCs. IL10 e.g., an aet dierentiation of DCs by preventing the seretion of
IL12 and thus impairing the ability of DCs to promote T ell ativation and T
H
1 dif-
ferentiation [29℄. To suppress ativation, proliferation and IL2 prodution of CD4
+
as
well as CD8
+
T ells, both mouse and human T
Reg
ells need to be ativated via their
TCR [47℄. Antigen spei as well as polylonal TCR stimulation an indue T
Reg
ells
to show ative proliferation in vivo. Their suppressive apaity is most likely antigen
non-spei, i.e. they are able to suppress not only proliferation of T ells with the
same antigen speiity but also those direted against irrelevant antigens [76℄. Reent
in vitro studies suggest that there might be both a primary ontat-dependent and a
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seondary seretion-dependent suppression, whih seem to be antigen-nonspei. The
primary suppressive mehanism is thereby mediated through ell-ell-ontat by T
Reg
ells and CD4
+
CD25
-
T ells induing anergy due to ell yle arrest in the latter sub-
set. Seondary suppression is based on the ytokines IL10 and/or TGF-b sereted by
the anergized CD4
+
CD25
-
T ells, that in turn suppress proliferation and ativation
of other CD4
+
CD25
-
T ells. This model illustrates the phenomenon of "infetious
tolerane". Given the rather low proportion of T
Reg
ells and their dependeny on ell
ontat to mediate suppression, infetious tolerane might help to explain how T
Reg
ells an regulate immune homeostasis through this bystander mehanism in vivo [78℄.
Another interesting aspet is how T
Reg
ells themselves are regulated. To date it is
speulated, that ativation of T
Reg
ell mediated suppression depends on the strength
of TCR stimulation, o-stimulatory signals and ytokine repertoire. Thereby, self as
well as non-self antigens are apable to indue T
Reg
ell ativation [47℄. However, it
seems likely that T
Reg
ells possess multiple mehanisms of mediating suppression -
depending on the partiular biologial situation.
1.2.2.6 T
Reg
ells in autoimmunity Autoimmune diseases ait approximately
5% of the population and reet a failure in the immune system to disriminate be-
tween self and non-self resulting in the breakdown of self-tolerane. T
Reg
ells have
been shown to play an important role in the maintenane of immune homeostasis and
self-tolerane by ounterating the development and eetor funtions of potentially
autoreative T ells. Thus, an imbalane of natural T
Reg
ells and self-reative T
ells towards a dominane of the latter seems to be responsible for the development of
autoimmunity [79, 245℄.
1.2.2.6.1 Model systems In vivo studies on the role of T
Reg
ells in autoim-
mune diseases have been arried out in dierent murine model systems. Nude (nu/nu)
mie are T ell deient due to a mutation in the gene for the transription fator Whn,
whih makes them inapable of developing a thymi epithelium. Injetion of syngenei
peripheral CD4
+
CD25
-
T ells into nude mie leads to indution of organ-spei au-
toimmune diseases whih is ounterated by the o-transfer of T
Reg
ells onrming
their suppressive apaities [48℄. RAG
-/-
mie, whih are both B and T ell deient
due to non-funtional reombination-ativated genes, an also be used as reipients for
autoimmune-induing and protetion-mediating T ells. Severe ombined immunode-
ieny (SCID) mie (sid/sid) have very few mature B and T ells due to a mutation
in a DNA-dependent kinase responsible for the rearrangement of antigen reeptors. As
reipients these SCID mie develop autoimmune gastritis or a hroni olitis resembling
inammatory bowel disease (IBD) in humans. IBD is not an autoimmune disease per
se but is mediated by T ells reognizing antigens derived from the ommensal entero-
baterial ora. Other models of autoimmune disorders, in whih disease development
is ounterregulated by T
Reg
ells, should be mentioned. Non-obese diabeti (NOD)
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mie possess fewer CD4
+
CD25
+
T ells in their periphery and develop spontaneous
idiopathi autoimmune diabetes, losely resembling type I diabetes in humans. Expe-
rimental autoimmune enephalomyelitis (EAE) is a model for human multiple slerosis
whih is indued by injetion of myelin basi protein and adjuvant [79, 245℄. Surfy
mie, whih are deient in Foxp3, lak naturally ourring T
Reg
ells at all and de-
velop a severe autoimmune disorder resembling human IPEX (immunodysregulation,
polyendorinopathy and enteropathy, X-linked; see next hapter).
1.2.2.6.2 Role of T
Reg
ells in human autoimmunity Despite their riti-
al role in the ative suppression of experimental autoimmune disorders, only little
is known about T
Reg
ell involvement in human autoimmunity. In some disorders, a
signiant derease in CD4
+
CD25
+
T
Reg
ell frequeny ompared to healthy indivi-
duals ould be observed, inluding patients suering from multiple slerosis, systemi
lupus erythematosus or autoimmune liver disease [37, 38, 80℄. Apart from absolute
T
Reg
ell numbers, geneti defets in the CD4
+
CD25
+
T
Reg
ell ompartment inuene
pathogenesis of human autoimmune diseases. For example, a mutation in the FOXP3
gene auses the X-linked lymphoproliferative disorder IPEX, whih is haraterized by
autoimmune diseases in multiple endorine organs. As FOXP3 is generally aepted as
a key regulator in CD4
+
CD25
+
T
Reg
ells, IPEX is diretly linked to a loss of funtion in
this ell type [76℄. Furthermore, single nuleotide polymorphisms in various genes suh
as TNFRSF1B, CTLA4 and CCR5 have been reported to onfer high-risk suseptibility
to diverse human autoimmune failures like inammatory bowel disease, type I diabetes
and rheumatoid arthritis, respetively [81, 82, 83, 84℄.
1.2.2.7 T
Reg
ells in tumor immunity Although CD4
+
CD25
+
T
Reg
ells fun-
tion beneially in vivo to protet the host from the development of autoimmunity,
they may also impair anti-tumor immune responses. Although ytotoxi T lympho-
ytes (CTL) and natural killer (NK) ells that inltrate and reognize autologous tu-
mors are often identied, eetive anti-tumor immunity fails to develop. Sine tumor
ells largely express self-antigens, T
Reg
ells may ontribute to the immunosuppression
of tumor-spei T and NK ell mediated ytotoxiity thus failitating loal tumor
growth and metastasis [85℄. Inreasing evidene supports the existene of elevated
numbers of CD4
+
CD25
+
T
Reg
ells with potent immunosuppressive ativity in peri-
pheral blood (PB) and tumor-inltrating lymphoytes (TIL) in patients with solid
tumors and hematologi malignanies. Beyer and o-workers reported inreased fre-
quenies of funtional T
Reg
ells in PB of hroni lymphoyti leukemia patients with
dereasing inhibitory funtion and frequeny after udarabine therapy [41℄. Inreased
perentages of CD4
+
CD25
+
T
Reg
ells were also observed in TILs in non-small ell
lung aner (NSCLC), ovarian aner [86℄ and in Hodgkin lymphoma [87℄. Woo ould
demonstrate TGF-β seretion, high CTLA4-expression and potent inhibition of T ell
proliferation by T
Reg
ells in NSCLC-TILs thereby providing rst evidene for an a-
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tive suppression of anti-tumor immunity by T
Reg
ells. Furthermore, inreased T
Reg
ell
populations were found in PB and TILs in patients with gastri and esophageal [88, 89℄
as well as in breast aner [90℄. Interestingly, elevated frequenies of CD4
+
CD25
+
T
Reg
ells have thereby been orrelated with dereased survival rates and poor prognosis
[91℄. After urative resetions, previously inreased T
Reg
ell numbers were signi-
antly redued while T
Reg
ell frequeny reraised in patients having a relapse [92℄.
Furthermore, it has been reported that elimination or redution of CD4
+
CD25
+
T
Reg
ells an evoke eetive anti-tumor immunity. Targeting T
Reg
ells by administration of
CD25 monolonal antibody (mAb) abrogated immunologi unresponsiveness to tumors
in otherwise non-responding mie by ativating tumor-spei ytotoxi T lymphoytes
(CTL) and non-spei lymphokine-ativated killer (LAK) / natural killer (NK) ells
[93, 94℄. Combination of T
Reg
ell depletion and CTLA4 blokade was shown to be
synergisti and resulted in maximum tumor rejetion [63℄. In humans, enhanement
of vaine-mediated anti-tumor immunity in metastati renal ell arinoma (RCC)
patients was reently demonstrated after depletion of T
Reg
ells [95℄. Thus, removal of
T
Reg
ells might also be useful in vaination, espeially for weakly immunogeni va-
ines, resulting in a stronger immune response and a more diverse T ell population.
1.2.2.8 T
Reg
ells in transplantation tolerane The immune system reats vi-
gorously to all foreign antigens inluding allo-antigens presented in transplants. Cur-
rently, rejetion of MHC-mismathed grafts remains one of the major hallenges fol-
lowing transplantation. The predominant approah to ameliorate immunologial re-
ations direted against the allo-organ is the appliation of immunosuppressive drugs.
This therapeutial treatment is ompliated by severe side eets, suh as inreased
inidene of serious infetions, development of tumors or the inhibition of tolerane in
general [76℄. As part of their immunosuppressive ativity, T
Reg
ells are able to indue
transplantation tolerane thereby ontributing to graft survival [42, 44℄. Thus, removal
of CD4
+
CD25
+
T
Reg
ells from wildtype mie was shown to result in enhaned graft
rejetion, whereas an inrease in T
Reg
ell frequeny led to a signiantly prolonged
graft survival [46℄. In order to investigate involvement of T
Reg
ells in transplantation
tolerane in more detail, adoptive transfer studies were performed by several researh
groups. It was demonstrated that CD4
+
CD25
+
T
Reg
ells isolated from animals with
long-term surviving allografts an regulate rejetion of skin allografts mediated by
CD4
+
CD45
high
eetor ells from naive mie [97℄. These studies indiate that mainte-
nane of allografts is assoiated with T
Reg
ell funtion and an be adoptively trans-
ferred to seondary syngenei hosts. Although the funtion of human T
Reg
ells in
linial transplantation has not been laried, it was shown that human T
Reg
ells do
not only regulate aeptane of solid organ transplants, but an also ameliorate or even
prevent graft-versus-host disease (GvHD) [96℄. Besides infetions, severe GvHD is the
most relevant ompliation after allogenei stem ell transplantation. Immunologially,
GvHD is haraterized by an expansion of donor lymphoytes with ytotoxi reativity
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against reipient histoompatibility antigens. The resulting linial piture inludes life
threatening destrution of skin, gut and liver tissue as the GvHD target organs. In
GvHD the transferred immune system laks the apability to gain ontrol over allorea-
tive T ell lones. In dierent murine models, T
Reg
ells were demonstrated to delay or
even prevent GvH-reativity. Consistent to this, seletive depletion of T
Reg
ells led to
an inreased severity of aute GvHD in vivo [98℄. In ontrast to that, available data for
humans are ambiguous: On the one hand, elevated frequenies of CD4
+
CD25
high
T
Reg
ells in the peripheral blood of hroni GvHD patients were reported [101℄, while on
the other hand signiantly dereased FOXP3 mRNA expression levels were observed
in patients suering from allogenei or autologous GvHD [102℄. A very reent study,
analysing the number of inltrating CD4
+
CD25
+
FOXP3
+
T
Reg
ells in the intestinal
muosa, found an insuient up-regulation of T
Reg
ells in intestinal GvHD lesions [98℄.
Although the preise mehanisms in the establishment and maintenane of peripheral
allograft tolerane remains poorly understood, T
Reg
ells seem to play a ruial role in
this proess and might be a powerful tool for linial appliation in the prophylaxis of
GvHD.
1.2.2.9 T
Reg
ells in allergy Allergi diseases are hroni inammatory disorders
aused by aberrant immune responses of T
H
2 ells against ommon "innouous" en-
vironmental antigens (allergens) in suseptible individuals. As T
Reg
ells are able to
regulate T
H
2 ell responsiveness it has been suggested that geneti and/or environmen-
tal fators impairing T
Reg
ell development and/or suppressor funtion may ontribute
to the pathogenesis of allergi diseases. Reent studies have demonstrated that na-
turally ourring and antigen-indued IL10 produing T
Reg
ells have a physiologial
role in protetion against human allergies. Individuals with IPEX syndrome, aused
by a mutation in the FOXP3 gene, suer not only from diverse autoimmune but also
allergi pathologies inluding severe ezema, inreased serum IgE levels, eosinophilia,
and food allergies. Furthermore, PBMCs from allergi patients were shown to generally
proliferate more extensively and to produe more T
H
2 ytokines in response to aller-
gen stimulation than PBMCs from healthy individuals. Reversly, depletion of CD25
+
T ells from ontrol PBMC ultures signiantly enhaned immune responses, sug-
gesting ative T
Reg
ell mediated suppression of allergen-spei responses in healthy
individuals. Additional studies propose a entral role of IL10 and thereby IL10 pro-
duing T
R
1 ells in the ontrol of allergy, as this ytokine inhibits ativation of many
ell types and eetor funtions assoiated with allergi disorders. The frequeny of
allergen-spei, IL10 sereting T ells was signiantly inreased in healthy ontrols
ompared with allergi patients, while the reverse was true for T ells produing the
T
H
2 ytokine IL4. Similarly, it has been demonstrated that IL10 levels are inversely
orrelated to the severity of human allergi disease. Finally, therapies known to be
beneial for the treatment of allergy and asthma, suh as immuno- or gluoortioid
therapy, have been shown to inrease IL10 synthesis by T ells. It was additionally
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demonstrated that allergen-spei T
H
2 ells from allergi patients are less sensitive to
inhibition by CD4
+
CD25
+
T
Reg
ells suggesting a loss of inhibitory T
Reg
ell funtion
at the disease site. IL6, produed by ativated DCs, was proposed to ontribute to this
impaired regulatory ativity and elevated IL6 levels were indeed reported in asthmati
patients. Blokade of IL6 was demonstrated to evoke loal expansion of CD4
+
CD25
+
FOXP3
+
T
Reg
ells in the mouse lung showing an inreased suppressive apaity. Thus,
IL10 and IL6 emerge as two ytokines ontributing to CD4
+
CD25
+
T
Reg
ell ativity
in allergi disease [255℄.
1.2.2.10 T
Reg
ells in linial use T
Reg
ells have been demonstrated to play
an ative role in the prevention of autoimmune disorders as their removal or absene
may lead to disease development. But furthermore, T
Reg
ells are known as important
mediators tuning the strength of immune responses. These features render T
Reg
ells a
potential therapeuti intervention tool not only restrited to prevention and/or treat-
ment of autoimmunity but in a large number of disease senarios involving inappropri-
ate immune responses, suh as allergy, allotransplantation, aner and vaination [79℄.
Autoimmune diseases, allergy, allograft rejetion and graft-versus-host disease (GvHD)
in onnetion with transplantation are onditions reeting an exaggerated immune re-
sponse. In these ases, inreasing the numbers of T
Reg
ells ould be beneial whih
ould be reahed by two imaginable strategies: The rst is to raise T
Reg
ell frequeny
in vivo by administration of drugs, ytokines or o-stimulatory moleules. The seond
possibility is to expand T
Reg
ells in vitro by polylonal ativation and IL2 addition
followed by their transfer bak to the patient. If the antigen responsible for the di-
sease is known, antigen-spei T
Reg
ell ativation ould be arried out. Alternatively,
T
Reg
ells an be indued from naive CD4
+
T ells in vitro by the fored expression of
FOXP3 [79℄. As in aner the immune response towards the tumor appears too weak,
tumor immunity might be enhaned by T
Reg
ell depletion in vivo. In two murine
models, this strategy was suessfully applied using anti-CD25 mAb [93, 94℄. In a rat
olon aner model, administration of ylophoshamide destroyed T
Reg
ells and de-
layed the outgrowth of tumor. Combining this agent and immunotherapy even ured
the rats [246℄. Cylophoshamide not only redued numbers of T
Reg
ells but also led to
diminished funtion, enhaned apoptosis and dereased homeostati proliferation. As
reently shown by Dudley et al., ylophosphamide might be suessfully integrated
into hemoimmunotherapy. The ombination of adoptive transfer of ex vivo ativated
tumor-spei T ells to patients with lymphopeni melanoma after hemotherapy with
ylophosphamide and udarabine indued tumor-regression in up to 50% of treated
patients [247℄. In RCC patients, removal of T
Reg
ells by a reombinant IL2 diphte-
ria toxin onjugate resulted in enhaned vaine-mediated anti-tumor immunity [95℄.
Thus, removal of T
Reg
ells might also be useful in vaination, espeially for weakly
immunogeni vaines, resulting in a stronger immune response and a more diverse
T ell population. Approahes ombining T
Reg
ell depletion with other immunologi
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interventions, suh as transfer of ativated T ells or DC-based vainations, might be
a more beneial strategy in aner therapy [63℄.
Given the entral role T
Reg
ells seem to possess in balaning immune responses,
their manipulation ould ause severe ompliations. For example, T
Reg
ell depletion
resulting in tumor immunity might lead to autoimmune diseases, while enhaned T
Reg
ell frequeny and/or ativity in order to ontrol autoimmunity might at the same time
impair generation of a proper immune response to foreign pathogens. The ne balane
between benet and harm of manipulating T
Reg
ells was elegantly demonstrated by
Antony and o-workers. Transfer of a mixture of CD4
+
CD25
-
and CD4
+
CD25
+
T ells
prevented eetive adoptive immunotherapy of established melanoma. In ontrast,
adoptive transfer of CD4
+
CD25
-
T ells together with tumor- as well as self-reative
CD8
+
T ells into CD4
+
T ell deient host followed by vaination indued both
regression of established melanoma but also severe and undesired autoimmunity [248℄.
Similarly, depletion of T
Reg
ells with CD25 mAb in a mammary gland tumor model
resulted in tumor regression but signiantly inreased suseptibility to autoimmune
thyroiditis [249℄. Another hurdle for T
Reg
ell appliation in aner therapy is the n-
ding that T
Reg
ell depletion is only transiently maintained, with most ells returning
after two months [95℄. Caution should therefore be exerised for potential future use of
T
Reg
ells in patients, but nevertheless, manipulation of T
Reg
ells in terms of their fre-
queny and funtional ativity appears to oer an attrative and hallenging approah
in human mediine [79℄.
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1.3 Diseases
1.3.1 Renal ell arinoma
Renal ell arinoma (RCC) is an aggressive urologi tumor with a high propensity for
metastasis and aounts for approximately 3% of all human malignanies. Its inidene
has inreased steadily in reent deades. In 2000, 30,000 new ases were diagnosed in
the USA and more than 20,000 in the European Union. Annual mortality-to-inidene
ratio with RCC is signiantly higher ompared to other urologial malignanies. It
is estimated that 25-30% of all patients have metastases at rst presentation - due
to a lak of symptoms at the onset of disease. Even following omplete resetion
of the primary tumor by radial nephretomy, the mainstay of therapy for patients
with loalized disease, relapse ours in 20-30% of patients. Those who present with
metastases have a 5-year survival of less than 10%, whereas the overall 5-year survival
rate is 60%.
Metastati RCC remains one of the most treatment-resistant human malignanies
being insensitive to traditional ytotoxi agents as well as radiotherapy. Until today,
the most eetive agents used are reombinant ytokines, with single-agent interferon
(IFN) or interleukin-2 (IL2) showing objetive response rates in the 10-20% range.
Combination therapies of IFN-α and IL2 with or without additional hemotherapy in-
rease reponse rates to 20-35%, and most responses our in patients with pulmonary
or soft tissue metastases. However, responses are predominantly partial remissions
of short duration. Sine very reently, standard treatment for RCC patients was ex-
tended to the administration of reeptor tyrosin kinase inhibitors (e. g. Sorafenib and
Sunitinib). Both agents at by bloking signal transdution via the VEGF reeptor,
while Sorafenib additionally targets the RAF/RAS/MEK/ERK pathway. Until today,
there is no standard treatment for patients who fail both therapies resulting in a mul-
titude of experimental seond- and third-line therapeuti regimens published during
the last deade. Among them, espeially the appliation of monolonal antibodies
also targeting VEGF signaling as well as additional reeptor kinase inhibitors have
raised well-funded hope as novel approahes in seond-line treatment of patients with
metastati RCC [103℄.
RCC is one of the tumors responding well to immunotherapy. Spontaneous remis-
sions ourring in 0.1 - 1% of RCC patients presenting with lung metastases harate-
rize RCC as an immunogeni tumor. High-dose IL2 therapy has been approved for the
treatment of metastati RCC sine 1992. While the overall response rates are relatively
low, omplete linial responses appear to be durable in the majority of patients. The
mehanism of therapeuti IL2 ativity in vivo is still not well understood. This is par-
tiularly perplexing given reent ndings suggesting that IL2 regulates the homeostasis
and ativation of T
Reg
ell suppressor funtion. T
Reg
ells express all three subunits of
the IL2 reeptor (IL2R) onsisting of one α-hain (CD25), a β-hain (CD122) and a
ommon ytokine reeptor γ-hain (CD132). T
Reg
ells do not serete IL2 and there-
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fore, depend on exogeneous IL2 for survival and funtion. IL2 knokout mie are
haraterized by signiant impairment in T
Reg
ells resulting in the development of
severe autoimmunity that an be reversed by reonstitution of T
Reg
ells from normal
mie. Inreased numbers of T
Reg
ells were impliated in a variety of human aners
to prevent indution of eetive anti-tumor immunity and were additionally orrelated
to poor prognosis [198℄. T
Reg
ells from aner patients were demonstrated to possess
potent immunosuppressive apaity omparable or even higher than those observed
in healthy donors. They suppress proliferation of CD4
+
CD25
-
T ells and eetively
inhibit NK-ell mediated ytotoxiity [85℄. As inreasing evidene proposes T
Reg
ells
to ontribute to tumor immune evasion and given the fat that seleted RCC patients
benet from IL2 therapy aeting these ells led us to have a loser look on T
Reg
ells
in RCC patients.
1.3.2 Inammatory bowel disease
The intestinal immune system is a very large and omplex part of the immune system,
whih interfaes with a variety of endogenous and exogenous stimuli. As the gut mu-
osa enounters more antigens than any other part of the body, lear disrimination
between invasive pathogens and harmless antigens, suh as those derived from food and
ommensal bateria, is indispensably required. A disturbed balane between tolerane
and ative immunity may onsequently lead to severe inammatory disorders, among
them inammatory bowel disease (IBD). Apart from T ell anergy and lonal deletion
by apoptosis, ative suppression by T
Reg
ells ontributes to the maintenane of im-
munologial tolerane towards self- and entero-antigens [193℄. Transfer of T
Reg
ells
annot only prevent the development of olitis in animal models but also ure estab-
lished disease, ating both systemially and at the site of inammation. Importane of
T
Reg
ells in the maintenane of intestinal homeostasis is further emphasized in IPEX
patients, whih suer from a deieny in T
Reg
ells due to impaired FOXP3 funtion
resulting in multiorgan immune disorders, inluding severe intestinal lesions [74℄.
Two main forms of IBD exist: Crohn's disease (CD) and ulerative olitis (UC) are
both hroni inammatory disorders aiting 0.3% of the Western population. CD an
aet any part of the gastrointestinal trat, from the oral avity to the anus, whereas
UC is restrited to olon and retum. A transmural, granulomatous inammatory pro-
ess assoiated with T
H
1-type responses is harateristi in CD, whereas inammation
in UC tends to be limited to the muosa and ontains large numbers of immunoglobulin-
sereting plasma ells that appear to be assoiated with T
H
2 responses [239℄. Etiology
of CD and UC remains poorly understood, but probably involves a omplex interplay
of environmental fators, geneti suseptibility and abnormalities in immune regula-
tion. IBD is haraterized by an exaggerated muosal immune response thought to be
triggered by baterial antigens, underlined by a heavy inux of T ells, B ells, mono-
ytes and neutrophiles into the intestinal muosa [9, 105, 193℄. The main problem in
IBD is a loss of tolerane towards the autologous baterial ora reeted in a disturbed
1 Introdution 21
interation between ommensal bateria and the intestinal epithelium. For example,
lak of inhibition of TLR signaling an lead to a breakdown of tolerane by indution
of ostimulatory moleules on DCs and IL6 prodution resulting in bloked suppres-
sor ativity of T
Reg
ells [192℄. On the simplest level, an imbalane between pro- and
anti-inammatory mediators leads to hroni inammation in the gastrointestinal trat
of IBD patients. Spei ytokines important for the indution of muosal immunity
and regulation of the muosal immune responses inlude IL1, IL6, IL12 and TNF-α,
whih are all pro-inammatory mediators produed by monoytes and marophages.
Additionally, CD4
+
T ells inltrating the lamina propria (LP) of IBD patients dis-
play an altered ytokine prole ompared to healthy individuals. LP-derived CD4
+
T ells from CD patients produe elevated levels of IFN-γ and IL2, whereas CD4+ T
ells from the LP of UC patients serete inreased amounts of IL4 and IL5. These
observations suggest that the immune responses are T
H
1 and T
H
2 skewed in CD and
UC patients, respetively [193℄. This ytokine seretion attrats inammatory ells like
neutrophils and marophages, whih in turn produe a number of mediators, suh as
leukotrienes, platelet-ativating fator and reative oxygen intermediate whih nally
lead to the destrution of gut epithelial ells. Defets in apoptosis of ativated immune
ells may result in the hroniation of the inammatory reation and may launh a
viious yle [192℄.
Fortunately, a number of dierent mediations are available that help to treat IBD
symptoms and to keep the disease in remission. The most ommon therapeutial
regimen involves 5-aminosaliyli aid (5-ASA), that redues inammation of the in-
testinal wall. Gluoortiosteroids are applied in a seond-line strategy to ontrol the
inammation, when 5-ASA failed. Furthermore, dierent immunosuppressive drugs
may be onsidered to dampen the inammatory response. Among them, Iniximab,
a monolonal antibody against TNF has proven to be most eetive. Alternatively,
mirobiologial treatment options suh as appliation of "probiotis" (e.g.Esherihia
oli NISSLE or latobailli) may have a beneial eet [192℄.
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1.4 Aim of this projet
T
Reg
ells are involved in the ontrol of autoimmune diseases as well as anti-tumor
immunity and inuene the outome of infetions. Despite reent advanes in T
Reg
ell researh, requirements for their development, maintenane, and mode of ation
espeially in humans remain poorly understood. Miroarrays have illustrated their po-
tential to unravel gene expression in various subsets of leukoytes. Furthermore, we
and others have suessfully applied this tehnology to reate signatures of murine reg-
ulatory T ells in dierent mouse models, ontributing to a better understanding of the
mehanisms underlying T
Reg
ell mediated tolerane and autoimmunity [15, 256, 257℄.
Thus far, these genomi studies on T
Reg
ells have been restrited to murine systems.
However, dierenes between humans and mie are highly suggestive and may present
obstales in the transfer from mouse models to atual human disease [258℄. These fats
led us to diret the aim of this projet towards an improved moleular haraterization
of human T
Reg
ells in health and disease by the development and appliation of a non-
redundant ustomized miroarray. Therefore, genes should be arefully seleted from
whole genome expression data previously obtained from regulatory and naive T ells
of mouse and human origin, FOXP3 transdued CD4
+
T ells and extensive literature
searh. To gain reliable transriptional proles, it is ruial to preisely evaluate the
performane of the onstruted miroarray. T
Reg
and naive T ells from healthy donors,
RCC and IBD patients suering from distint stages of disease should be isolated by
MACS in adequate purity and appropriately further proessed to enable hybridization
of individual samples to the miroarray. Suitable statistial tools and normalization
strategies should be tested to gain the optimal gene expression patterns distinguishing
T
Reg
from naive T ells and to allow omparison of transriptional patterns between
health and disease as well as between dierent stages of disease. To broaden the know-
ledge about human T
Reg
ells, signaling modules underlying T
Reg
ell funtion should be
extrated by appliation of pathway analysis and ompared between healthy donors,
RCC and IBD patients. Furthermore, miroarray results of interesting target genes
should be veried by quantitative real-time RT-PCR and orrelation of mRNA and
protein expression should be examined by FACS analyses. As the restrited availabili-
ty of spei marker moleules is still limiting isolation of human T
Reg
ells, putative
andidates emerging from the obtained expression patterns should be investigated re-
garding their qualiation as new T
Reg
ell markers. Apart from funtional deits,
T
Reg
ells in disease have additionally been shown to display numerial aberrations,
thus also T
Reg
ell frequenies should be assessed and ompared in health and disease.
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2 Materials and methods
2.1 Materials
2.1.1 Blood samples and donors' harateristis
Blood samples were olleted from 17 healthy donors, 13 RCC and 9 IBD patients
after informed onsent aording to institutional guidelines. The Ethis Committee
of Hanover Medial Shool approved the study protool. All donors did not suer
from allergies or (additional) autoimmune diseases and were free of lateral or aute
infetions. Basi harateristis of all volunteers are summarized in Table 1. Mean age
was 37±13, 64±10 and 35±11 years for the healthy ontrol group, the RCC and IBD
patients, respetively. Altogether, 14 female and 25 male volunteers were analysed.
2.1.2 Primers
Primers used for (real-time) RT-PCR are summarized in Table 2.
2.2 Cell ulture
2.2.1 Cell ulture onditions
MACS separated human CD4
+
CD25
+
T
Reg
and CD4
+
CD25
-
naive T ells were ul-
tured in IMDM + Glutamax I (Gibo, Invitrogen) medium supplemented with 2% of
human serum and a nal onentration of 50 µg/ml Gentamiin (PAA Laboratories).
Cells were inubated at 37
◦
C and 5% CO
2
in the atmosphere.
2.2.2 Freezing and thawing of ells
For later FACS analysis, PBMCs of some donors were sedimented and ell pellets were
resuspended in serum-free ell freezing medium (Sigma Aldrih). Afterwards, ells were
slowly ooled down to -70
◦
C in speial ryo vials using isopropanol. For thawing, ells
were shortly inubated in a 37
◦
C water bath and rapidly transferred into appropriate
ulture medium.
2.2.3 Counting ells
During MACS separation of human CD4
+
CD25
+
T
Reg
and CD4
+
CD25
-
naive T ells,
ells had to be ounted several times in order to alulate optimal antibody and
bead onentrations. Cell numbers were determined in a Neubauer ounting ham-
ber. Therefore, an aliquot of a diluted ell suspension was mixed with trypanblue,
a dye seletively intruding dead ells, while the ytoplasmi membrane of living ells
is impermeable for the dye. The number of living ells in 1 ml an be alulated by
multipliation of the ounted living ells per big square with the dilution fator and 10
4
.
• trypanblue solution: 0.5 g trypanblue, 0.9 g NaCl, add to 1000 ml water, sterile
ltered
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donor age sex linial diagnosis Array % purity
healthy donors
A 58 male healthy ontrols yes 93.9 / 89.2
B 57 female healthy ontrols yes 92.5 / 85.5
C 27 female healthy ontrols yes 83.0 / 69.6
D 27 female healthy ontrols yes 95.5 / 84.8
E 36 male healthy ontrols yes 91.9 / NA
F 39 male healthy ontrols yes 81.9 / 91.1
G 39 male healthy ontrols yes 93.7 / 96.9
H 26 female healthy ontrols yes 97.6 / NA
I 62 female healthy ontrols yes 92.7 / 76.5
J 54 female healthy ontrols yes 98.2 / 91.6
K 26 male healthy ontrols yes 90.3 / 94.3
L 29 male healthy ontrols no NA / NA
M 30 female healthy ontrols no NA / NA
N 27 male healthy ontrols no NA / NA
O 37 male healthy ontrols no NA / NA
P 31 female healthy ontrols no NA / NA
Q 23 male healthy ontrols no NA / NA
RCC patients
1 71 male lear ell RCC, loalized tumor growth yes 98.7 / 79.5
2 75 male lear ell RCC, metastati tumor growth yes 93.8 / 86.8
3 63 female lear ell RCC, loalized tumor growth yes 98.3 / 95.7
4 62 male papillary RCC, loalized tumor growth yes 97.5 / 85.5
5 61 male loalized tumor growth yes 99.2 / 83.6
6 65 male lear ell RCC, loalized tumor growth yes 93.6 / 81.4
7 51 male lear ell RCC, metastati tumor growth yes 93.4 / 91.2
8 50 female metastati tumor growth no 94.2 / NA
9 80 male metastati tumor growth yes 91.7 / 75.2
10 72 male loalized tumor growth yes 94.7 / 75.1
11 48 male loalized tumor growth, VHL syndrome yes 89.3 / 86.4
12 68 male metastati tumor growth yes 97.0 / 84.3
13 68 female metastati tumor growth yes 97.9 / 81.9
IBD
i 29 male inative UC yes 94.5 / 66.7
ii 31 male inative UC yes 95.8 / 63.3
iii 27 male inative UC yes 97.1 / 70.6
iv 44 male ative MC yes 95.8 / 66.7
v 25 male ative MC yes NA / NA
vi 29 female ative MC yes 95.8 / 85.0
vii 60 female inative MC yes 95.2 / 72.2
viii 40 female inative MC yes 97.9 / 58.4
ix 29 male inative MC yes 96.5 / 71.3
Table 1: Donors' harateristis.
Column %purity summarizes ahieved purities of CD4
+
CD25
+
regulatory/CD4
+
CD25
-
naive T ells after MACS separation from PBMCs as assessed by FACS analysis.
NA = not assessed
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Genes Primer sequenes produt
length
5':3'
primer
[nM℄
Primer-
Annealing
FOXP3 5'-GAA CGC CAT CCG CCA CAA CCT GA-3'
5'-CCC TGC CCC CAC CAC CTC TGC-3'
224 bp 900 / 900 58
◦
C
CTLA4 5'-TGC AGC AGT TAG TTC GGG GTT GTT-3'
5'-CTG GCT CTG TTG GGG GCA TTT TC-3'
128 bp 50 / 900 58
◦
C
CCR5 5'-CCC GTA AAT AAA CCT TCA GAC CAG-3'
5'-AGG CGA AAA GAA TCA GAG AAC AGT-3'
92 bp 900 / 300 54
◦
C
CCR7 5'-TGG CCT GCA GGA AAC ACC-3'
5'-GGG AGA CTT CTT GGC TTG GTG AG-3'
105 bp 300 / 300 54
◦
C
CCR10 5'-CAC TCC CGG CCG CGC ACA CTT G-3'
5'-GCG CTC GCC CCC TTC ACC GTC GT-3'
165 bp 900 / 300 64
◦
C
TNFRSF1B 5'-GTA GCC TTG CCC GGA TTC TGG-3'
5'-ACC CTG CCC CTG CTC TGC TA-3'
118 bp 300 / 300 58
◦
C
TRAF1 5'-GGG GCA TAA ACT TTC CTC TCC C-3'
5'-TTT GGG GTT ATA CAT TGC TCA GTG-3'
144 bp 300 / 50 58
◦
C
LGALS3 5'-CCT TTG CCT GGG GGA GTG GTG-3'
5'-TGA AGC GTG GGT TAA AGTGGA AGG-3'
130 bp 300 / 300 58
◦
C
RPS9 5'-CGC AGG CGC AGA CGG TGG AAG C-3'
5'-CGA AGG GTC TCC GCG GGG TCA CAT-3'
92 bp 50 / 50 54-64
◦
C
Table 2: Primer harateristis.
2.2.4 In vitro ativation
For the in vitro ativation assay, 24-well plates were oated with anti-CD3 (TR66)
in a nal onentration of 1 µg/ml in PBS ontaining 50 µg/ml Gentamiin (PAA
Laboratories) over night at 4
◦
C. Afterwards this solution was removed and plates were
one washed with ulture medium. 6.5·105 MACS separated T
Reg
and 10
6
naive T ells
eah were inubated in appropriate ulture medium supplemented with or without
100 U reombinant human IL2 (Proleukin; provided by P Wagner, Ciron Corporation,
CA, USA) at 37
◦
C and 5% CO
2
. After three and ve days, ativation status of the
ultured ells was onrmed and ells were harvested for real-time RT-PCR or FACS
analyses.
2.2.5 Proliferation and suppression assay
T ell proliferation was assessed by stimulating 3·104 T ells in tripliate with irradiated
allogenei LG2-EBV B ells or 1µg/ml plate-bound anti-CD3 (TR66) with or without
100 U reombinant human IL2 (Proleukin; provided by P Wagner, Ciron Corporation,
CA, USA) in 96-well at bottom mirotiter plates (Nun). To determine their sup-
pressive ativity, CD4
+
CD25
+
T
Reg
ells and CD4
+
CD25
-
naive T ells were ultured
under the same onditions but in additional presene of equal numbers of indiated
responder T ells. Cells were pulsed with 1µCi/well of 3[H℄thymidine after 72 hours for
the nal 16 hours. Statistial analysis was performed using two-sided Student's t-test.
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2.3 Methods of moleular biology
2.3.1 Isolation of total-RNA
For ell lysis, human CD4
+
CD25
+
T
Reg
and CD4
+
CD25
-
naive T ells were divided into
aliquots of maximum 5·106 ells, entrifuged for ten minutes at 300 g and 4◦C, freed
from the supernatant and resuspended in 350 µl RLT-buer (Qiagen) ontaining 1% of
β-meraptoethanol (Sigma Aldrih). RNA was extrated from both T ell populations
applying the RNeasy kit following the manufaturer's instrutions (Qiagen, Germany).
2.3.2 Enzymati DNA digestion
As DNA ontaminating the total-RNA was demonstrated to interfere with subsequent
DNA and RNA synthesis, a DNA digestion step was added. Therefore, the RNase-
free DNase set (Qiagen, Germany) was applied aording to the proposed protool,
where the DNA is digested during RNA isolation diretly after binding of the sample
to the RNeasy olumn using DNase I.
2.3.3 Photometri determination of nulei aid onentration and purity
Conentration and purity of the obtained total-RNA, DNA and RNA was deter-
mined photometrially. Therefore, samples were diluted using TE (10/1) and their
optial density (OD) was assessed at a wavelength of 260 nm, whih is the absorbane
maximum of nulei aids. An OD
260nm
= 1 orresponds to approximately 40 µg/ml
RNA and 50 µg/ml DNA for a uvette with 1 m edge length. Measuring the sam-
ple's OD at 280 nm gives information about protein ontaminations, as the ratio of
OD
260nm
/OD
280nm
should lie between 1.8 and 2.0 for protein-free nulei aid prepara-
tions [252℄.
• photometer: BioPhotometer, Eppendorf
• TE (10/1): 10mM Tris-HCl (pH 7.4), 1mM EDTA (pH 8.0)
2.3.4 RNA probe synthesis for miroarray analysis
After extration of total RNA from human CD4
+
CD25
+
T
Reg
and CD4
+
CD25
-
naive
T ells, its integrity and quality was ontrolled by running all samples on an Agilent
Tehnologies 2100 Bioanalyzer. Samples were prepared by applying a double-linear
ampliation method in aordane with the Eberwine protool [251℄ and modied by
Aymetrix as desribed briey in the following.
2.3.4.1 First round of DNA synthesis Total RNA extrated from 1-2·105
(≈100-200 ng) human CD4+CD25+ T
Reg
and CD4
+
CD25
-
naive T ells, respetively,
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was transformed into double stranded DNA in the rst step of the ampliation pro-
tool [Figure 4℄. Therefore, T7-oligo(dT
23
)-Primers hybridize to the poly(A)-tail ha-
raterizing eukaryoti mRNAs, thus ensuring that exlusively mRNAs are funtioning
as template for the SuperSript II Reverse Transriptase (Qiagen, Germany). Seond
strand DNA synthesis was performed inluding RNase H, that is partly digesting
mRNA in the mRNA-DNA heteroduplexes formed after rst strand DNA synthesis,
thus providing primers for the DNA polymerase I (Invitrogen). Addition of T4-DNA
polymerase (Invitrogen) to the double-stranded DNA nally blunt their ends. After-
wards, the synthesized DNA was puried by phenol-hloroform-isoamylalohol extra-
tion using PhaseLok Gel Tubes (Eppendorf) to failitate phase separation. Addition
of NaA and absolute EtOH preipitated the DNA, that was subsequently washed
twie and resuspended in DEPC-water after drying.
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T T T T T T T T T 5 3 
T T T T T T T T T
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A A A A A A A A A
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T T T T T T T T T 5 3 
A A A A A A
A
A
A
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T T T T T T T T T
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T 7 d T - P r i m e r
2 3
A A A A A A A A A
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m R N A
F i r s t  s t r a n d  s y n t h e s i s
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w i t h  r e m a i n i n g  R N A  a s  p r i m e r s
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Figure 4: Sheme of the rst round of DNA synthesis.
A. The oligo(dT)-primers seletively anneal to the poly(A)-tail of eukaryoti mRNA.
B. First strand DNA synthesis: A RNA-DNA-hybrid is formed by reverse transrip-
tion. C. Seond strand DNA symnthesis: The RNA is partly digested by RNase
H, thus providing the primers for the DNA synthesis by DNA polymerase I. The lig-
ase is linking the synthesized piees of DNA. D. Blunt end generation by T4-DNA
polymerase. Adapted from [253℄.
2.3.4.2 In vitro transription (rst round) As all DNA moleules provide a
T7-promotor after DNA synthesis, they an be transribed into RNA by a T7-RNA
polymerase [Figure 5℄. Therefore, we used the Ribomax
TM
Large Sale RNA Produ-
tion System T7 Kit (Promega) enabling the rst round of linear RNA ampliation
without biotinylated nuleotides as eah DNA an repeatedly funtion as template for
the T7-RNA polymerase. The synthesized RNA moleules are antisense orientated
ompared to the primary mRNA and lak the T7-promoter, as it is omitted from trans-
ription. The RNA was extrated from the reation bath applying the RNeasy kit
and its purity and onentration was determined photometrially and by running on
the Bioanalyzer.
28 2 Materials and methods
A A A A A A A A A
5  3 
T T T T T T T T T 5 3 
i n  v i t r o  d o u b l e - s t r a n d e d  c D N A              
t r a n s c r i p t i o n  b y  T 7 - R N A  p o l y m e r a s e
U U U U U U U U U
3  5 
c R N A  ( a n t i s e n s e )
E
F
R N A T 7 - R N A -
P o l
T 7 - P r o m o t e rD N A
Figure 5: Sheme of the rst in vitro transription.
E. The T7-RNA polymerase reognizes the T7-promoter and transribes the previously
synthesized double-stranded DNA. During this step, the rst linear ampliation of
the starting mRNA takes plae. F. The resulting RNA is antisense orientated om-
pared to the primary mRNA. Adapted from [253℄.
2.3.4.3 Seond round of DNA synthesis For the seond linear ampliation,
the rst RNA was subjeted to a seond round of DNA synthesis resembling the
rst round, but instead of using oligo-dT-Primers, random hexamers were added to
the reation [Figure 6℄.
A A A A A A A A A
5  3 
U U U U U
5 3 
D i g e s t i o n  o f  R N A  
b y  R N a s e  H  
U U U U U U U U U
3 
N N N N N N N N N N N N
5  5 3  3 
5 
c R N A  ( a n t i s e n s e )
r a n d o m  h e x a m e r s
( N  =  A ,  C ,  G ,  o d e r  T )
I
G
U U U U U U U U U3  5 
J A A A A A A A A A5  3 
T T T T T T T T T
5 3 
S e c o n d  s t r a n d  s y n t h e s i s
w i t h  T 7 d T - P r i m e r
2 3
R N A
R e v e r s e  
T r a n s c r i p t a s e
R N a s e  H D N A - P o l  I L i g a s eT 7 - P r o m o t e rD N A
F i r s t  s t r a n d  s y n t h e s i s
( r e v e r s e  t r a n s c r i p t i o n )
N N N N N N N N N N N N
5  3 H
Figure 6: Sheme of the seond round of DNA synthesis.
G and H. Random hexamers anneal to the rst RNA and serve as primers for the
Reverse Transriptase during the rst strand DNA synthesis. I. Total digestion of the
RNA strand of the resulting DNA-RNA heteroduplex to allow hybridization of the
T7dT
23
-Primers. J. Seond strand DNA synthesis by DNA polymerase I. [253℄.
After rst strand DNA synthesis, RNase H funtions to digest the whole RNA
strand, enabling annealing of the T7-oligo(dT
23
)-Primer to the poly(A)-tail of the new
DNA strand for seond strand DNA synthesis. Commitment of DNA polymerase I
and T4-DNA polymerase resulted in the synthesis of blunt end, double-stranded seond
DNA, that was puried and preipitated as desribed for rst round.
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2.3.4.4 In vitro transription (seond round) inluding labelling reation
The seond round of linear RNA ampliation was performed as an in vitro transrip-
tion (IVT) assay in the presene of biotinylated UTP using the GeneChip
R
Expression
3'-Ampliation Reagents Kit for IVT Labelling (Aymetrix). Similar to the rst
ampliation round, a T7-RNA polymerase (MEGAsript, Aymetrix) used the T7-
promoter provided by the T7-oligo(dT
23
)-Primer for RNA synthesis, but inorporated
biotinylated UTP enabling parallel RNA labelling and later detetion [Figure 7℄. The
synthesized seond RNA was puried and preipitated as desribed before. The on-
entration of the biotinylated RNA was determined by UV absorbane and its quality
as means of produt length distribution was again heked using the Bioanalyzer.
A A A A A A A A A
5  3 
T T T T T T T T T 5 3 
i n  v i t r o  t r a n s c r i p t i o n
b y  T 7 - R N A  p o l y m e r a s e
U U U U U U UU UU U U U U3  5 
c R N A  h y b r i d i z a t i o n  
p r o b e  ( a n t i s e n s e )
K
L
T 7 - R N A  
p o l y m e r a s e
T 7 - P r o m o t e rD N AR N A B i o t i n
U
P s e u d o -
u r i d i n
U
Figure 7: Sheme of the seond in vitro transription.
K. T7-RNA polymerase synthesizes antisense RNA starting from the T7-promoter
provided by the DNA. During this step, the seond linear ampliation of the starting
mRNA take plae. L. Inooperation of biotinylated pseudo-uridine results in synthesis
of biotin labelled RNA enabling easy detetion upon hybridization to the miroarray.
Adapted from [253℄.
2.3.4.5 Fragmentation Eah miroarray experiment ruially depends on the e-
ieny, with whih the biotin-labelled RNA sample moleules bind to their immobilized
targets. Due to hybridization kinetis, this eieny improves with dereasing sample
length. For similar hybridization eienies of all sample moleules, a narrow length
distribution needs to be ahieved. This was done by fragmentation of the RNA using
a buer ontaining high potassium- and magnesium-ion onentrations at high temper-
atures. Per miroarray, 15 µg of biotinylated RNA were subjeted to fragmentation
at 94
◦
C for 35 minutes.
• fragmentation buer (5x): 4ml 1M Tris-aetate (pH 8.1), 0.98g K-aetate,
0.64g Mg-aetate, add to 20ml of Milli-Q water, sterile ltered
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2.3.5 real-time RT-PCR
To verify auray of the obtained miroarray expression data, real-time RT-PCR of se-
leted genes was performed. Therefore, CD4
+
CD25
+
regulatory and CD4
+
CD25
-
naive
T ells were isolated by MACS tehnology as desribed below. After ell lysis, RNA
was extrated from both ell populations applying the RNeasy kit (Qiagen, Hilden,
Germany). DNA was synthesized using oligo(dT) primers and random hexamers by
SuperSript II Reverse Transriptase (Invitrogen, Karlsruhe, Germany). Quantita-
tive real-time RT-PCR was performed in an ABI PRISM yler (Applied Biosystems)
applying a SYBR green PCR kit from Stratagene and spei primers optimized to
amplify 90-230 bp fragments from the dierent genes analysed. A threshold was set in
the linear part of the ampliation urve, and the number of yles needed to reah
it was alulated for every gene. Relative mRNA levels were determined by using in-
luded standard urves for eah individual gene and further normalization to RPS9
as a housekeeping gene. Melting urves established the purity of the amplied band.
Primer sequenes and their harateristis are summarized in Table 2.
2.3.5.1 Primermatries To prevent ampliation of unspei produts and ge-
neration of primer dimers, the onentrations of the 5'- and 3'-primers used for the
real-time RT-PCR had to be optimized. Therefore, onentrations ranging from 50 nM
to 900 nM for eah primer were tested and the optimal primer ombination resulted
from the maximal dierene of the C
t
-values obtained for the spei amplion and
the negative ontrol [Table 2, olumn 5':3' primer℄.
2.4 Immunologial methods
2.4.1 Isolation of peripheral blood mononulear ells (PBMCs)
Peripheral blood mononulear ells (PBMCs) were isolated from freshly drawn blood
by Fioll (Biohrom, Berlin, Germany) density gradient entrifugation as desribed
previously [120℄. First, the blood samples were diluted 2-4 times with rinsing buer,
arefully applied onto the Fioll and subsequently entrifuged for 30-40 minutes at
room temperature and 400 g without brake. Thereby, mononulear ells, onsisting
mainly of lymphoytes and monoytes, are enrihed in the interphase. These ells
have been suked o, transferred into a new tube and washed with FACS buer for ten
minutes at 4
◦
C and 300 g. Afterwards, pelleted ells were freed from the supernatant,
resuspended in FACS buer again and entrifuged at 200 g and 4
◦
C for another 10
minutes to remove the thromboytes. The reeived ell pellet is mainly omposed of
PBMCs and was resuspended in 90 µl ie old FACS buer per 107 ells.
• rinsing buer: PBS, 2mM EDTA
• FACS buer: PBS, 2mM EDTA, 2% FCS
• Fioll: Biooll Separating Solution, density = 1.077 g/ml, Biohrom AG
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2.4.2 Magneti ell separation (MACS)
For isolation of human CD4
+
CD25
+
regulatory and CD4
+
CD25
-
naive T ells, PBMCs
were further separated using the Regulatory Human T ell Isolation Kit and an Au-
toMACS separation unit (Miltenyi Biote, Bergish Gladbah, Germany) following the
manufaturer's instrutions. In the rst step, non-CD4
+
T ells were depleted by in-
diret magneti labelling with a biotin-antibody oktail and anti-biotin MiroBeads
[Figure 8A℄.
m
a
gn
et
anti-CD25PE
anti-CD25 MicroBead
anti-CD4 FITC
CD25 antigen
CD4 antigen
CD4 CD25
+ +
CD4 CD25
+ -
m
a
gn
et
CD4 CD25
CD4 CD25
+ -
+ +
X antigens:
CD8
CD14
CD16
CD19
CD36
CD56
CD123
TCR
Glycophorin A
Anti-X iotinylated
anti-Biotin MicroBead
CD25 antigen
CD4 antigen
X antigens
A
B
Figure 8: MACS separation strategy [253℄.
A. Enrihment of CD4
+
T ells from PBMCs. Cells expressing one of the "X" surfae
antigens are speially labelled by biotinylated antibodies. Binding of anti-Biotin
MiroBeads to these antibodies result in retention of labelled ells in a magneti eld
provided by the AutoMACS unit, while unlabelled ells - ontaining the CD4
+
T ell
fration - ow through. B. Separation of CD4
+
CD25
+
regulatory and CD4
+
CD25
-
naive T ells. CD4
+
CD25
+
T ells are diretly labelled with anti-CD25 MiroBeads
and are thus retained in the magneti eld, whereas the unlabelled CD4
+
CD25
-
ells
an pass through. After removal of the magneti eld, the CD4
+
CD25
+
T ells an be
eluted from the olumns. The indiated CD4-FITC and CD25-PE antibodies enable
subsequent analyses of the obtained purities of both T ell subpopulations by FACS.
In the seond step, CD4
+
CD25
+
T ells were diretly labelled with CD25 Mi-
roBeads and isolated by positive seletion from the pre-enrihed CD4
+
T ells [Fi-
gure 8B℄. The magnetially labelled CD4
+
CD25
+
T ells were retained on the olumn,
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whereas the CD4
+
CD25
-
T ells owed through. After removal of the magneti eld,
CD4
+
CD25
+
T ells ould be eluted after separation over two olumns. To inrease pu-
rity of the CD4
+
CD25
-
T ell fration an additional separation step depleting remaining
CD4
+
CD25
+
T ells was added, if neessary. Purity of the enrihed ell frations was
>90% as determined by ow ytometry.
2.4.3 Flow ytometri analysis
To onrm purity of the separated ell frations, to determine T
Reg
ell frequeny and to
verify gene expression data on protein level, PBMCs or separated CD4
+
CD25
+
regula-
tory and CD4
+
CD25
-
naive T ells were analysed by multiolour uoresene-ativated
ell sorting (FACS) using the antibodies listed below. Flow ytometry was done on a
FACS Calibur applying CellQuest software (BD Biosienes). For immunostaining of
surfae proteins, ells were inubated in FACS buer ontaining appropriate onentra-
tions of the partiular antibody at 4-8
◦
C. Intraellular FOXP3 staining was performed
as reommended by the manufaturer applying the delivered xation and permeabi-
lization buers. Intraellular LGALS3 detetion was done after xation of ells in 4%
para-formaldehyde and permeabilization in 0.5% saponin, both in PBS/EDTA. Apop-
toti ells were stained with Annexin V and PI aording to the protool provided in
the Annexin V-FITC apoptosis detetion kit.
• anti-CD4-FITC and -APC (M-T466), anti-CD25-PE (4E3): Miltenyi Biote
• anti-FOXP3-APC (PCH101) staining set: eBiosiene
• monolonal anti-TNFRSF1B-FITC (22235.311): R&D Systems
• monolonal anti-LGALS3-FITC and -PE (B2C10): BD Pharmingen
• isotype ontrol antibody (MOPC-21): mouse IgG
1
, κ, FITC or PE onjugate:
BD Pharmingen
• polylonal antibody to human CCR10 from goat: Alexis Biohemials
• rabbit anti-goat IgG seondary antibody, Alexa Fluor 647: Moleular Probes
• Annexin V-FITC apoptosis detetion kit: BD Pharmingen
• propidium iodide (PI): 1mg/ml PI in PBS, diluted 1:1000 before use
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2.5 Methods of miroarray tehnology
2.5.1 Manufaturing the Human T
Reg
Chip
395 dierent oligonuleotides were deposited onto CodeLink ativated slides (Amer-
sham Biosienes) at a onentration of 25 µM in 1.5 x sodium phosphate buer in a
ontat-dependent manner using a MiroGrid TAS II spotter (BioRobotis, Freiburg,
Germany). All these 50mers were amino-modied at the 5'-end enabling ovalent lin-
kage to reative ester groups provided by the glass surfae. Coupling of DNA was
ensured by over night inubation in a saturated sodium hloride hamber and bloking
of residual reative groups was done as reommended by the manufaturer [118℄. Until
used, slides were maintained in a desiated environment. To ensure omplete spotting,
SYBR green staining of three randomly seleted Human T
Reg
Chips of eah printing
bath was performed as previously desribed [119℄.
2.5.2 Design of the Human T
Reg
Chip
Eah probe of our miroarray onsists of a single 50mer oligonuleotide, as utility and
performane of 50mer oligonuleotide miroarrays were proved before [117℄. The Hu-
man T
Reg
Chip is omposed of 350 oligonuleotides probing genes assoiated with T
Reg
ells and 31 oligonuleotides representing housekeeping genes onsulted for normaliza-
tion. Furthermore, lots of ontrol oligonuleotides are inluded: two 5'-3'-ontrols to
ensure RNA integrity, four baterial hybridization ontrols to examine a linear hy-
bridization proess, ve spike-in ontrols to hek sample preparation, one positive
ontrol (Arabidopsis thaliana) for simpler grid nding and nally 32 negative ontrols
to alulate the bakground level. Altogether, we immobilized eight repliates per
oligonuleotide, splitted in two separated arrays per slide, eah ontaining 1600 spots.
Genes probed on the Human T
Reg
Chip were seleted by extensive analyses of literature
and previously performed Aymetrix miroarray experiments [196℄. Design and syn-
thesis of the oligonuleotides was performed by MWG using the Aymetrix probe sets
as referene. The Human T
Reg
Chip will be freely available to the sienti ommunity.
2.5.3 Hybridization
In all ases, 15 µg of eah biotin-labelled RNA preparation was fragmented and plaed
in a hybridization oktail (Amersham Biosienes) ontaining four biotinylated hy-
bridization ontrols (BioB, BioC, BioD, Cre). This hybridization solution buered
the pH, dereased surfae tension to failitate moistening of the miroarray slide and
ontained auxiliary omponents allowing low hybridization temperatures in order to
prevent thermi degradation of RNAs. Samples were hybidized to individual Human
T
Reg
Chips for 16 hours using a Luidea Slidepro (Amersham Biosienes).
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2.5.4 Posthybridization and Cy5-streptavidin staining
Unbound RNA and the omponents of the hybridization oktails have to be strin-
gently washed o after hybridization in order to ensure low bakground noise. Thus,
slides were washed in 0.75 x TNT at 46
◦
C for one hour. Afterwards, they were stained
for 30 minutes at room temperature with Cy5-streptavidin working solution. Strep-
tavidin is a 60 kDa extraellular protein of Streptomyes avidinii possessing four high
anity biotin binding sites, thus speially interating with the biotinylated UTP
of the hybridized RNA. Exessive Cy5-streptavidin was washed o in four steps by
inubation in 1 x TNT for ve minutes. Afterwards, slides were dipped into 0.05%
Tween for 10 seondes and entrifuged to dry.
• 1 x TNT: 200 ml 1M Tris-HCl (pH 7.6), 60 ml 5M NaCl, 1 ml Tween20, add to
2000 ml Milli-Q water, sterile ltered
• TNB buer: 522 ml Milli-Q water, 60 ml 1M Tris-HCl (pH 7.6), 18 ml 5M NaCl;
heat to 60
◦
C, add 3g of NEN Bloking Reagent (Amersham) in 0.5g inrements
and let dissolve, stir 30 minutes at 60
◦
C, sterile lter, aliquot and freeze at -20
◦
C;
thaw over night at 4
◦
C prior use
• Cy5-streptavidin stok solution: 1 mg Cy5-streptavidin (Amersham Bio-
sienes), 1 ml DEPC water; slowly vortex three times, keep on ie for ve mi-
nutes, freeze aliquots at -20
◦
C
• Cy5-streptavidin working solution: prepare 3.4 ml per slide, resuspend 6.8 µl
of the Cy5-streptavidin stok solution in TNB buer
2.5.5 Sanning and signal quantiation
Using a laser-uoresene sanner (arrayWorX
e
, Applied Preision) and an exitation
wavelength of 694 nm the stained miroarrays were read at a solution of 10 µm and
an exposure time of one seond. Obtained uoresene signals for all 3200 spots were
expressed and saved as image data, that were onverted into numerial values using
ImaGene software (version 5.5, BioDisovery). Correlation of the partiular spots to the
assoiated oligonuleotide was performed with the aid of an alloation le generated by
the spotter. The provided grid and the image are overlayed and the software alulates a
signal intensity and a loal bakground intensity for eah spot. The dierene between
the rst and the latter yields the eetive signal strength of the spot. During this
alulation, additional quality ags are assigned to the spots: Good or unagged spots
are indiated zero, signal intensities near the bakground level are agged as empty or
two, and spots of poor quality (due to e.g. strange morphology or dust on the slide) are
tagged with three. During alulation of the array raw data, spots agged with 3 due
to poor quality and spots with signal intensities smaller than the mean signal intensity
of the negative ontrols were exluded from further analysis.
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2.5.6 Normalization strategy
Normalization adjusts for dierenes in labelling and detetion eienies for the uo-
resent labels and for dierenes in the quantity of initial RNA from the samples
examined in one assay. Countless normalization strategies exist. To adjust arrays from
dierent experiments, we nally deided to normalize our data based on median signal
intensities of the housekeeping genes as previously proposed [164℄ and desribed in
hapter 3.2.6 using the following formula:
SI
norm
=
In −Bn
e<ln(house)>
Where SI
norm
is the normalized signal intensity, I
n
is the signal intensity of gene n,
B
n
is the bakground intensity of gene n, and <ln house> is the median logarithmi
signal intensity of all housekeeping genes.
2.5.7 Signiane Analysis of Miroarrays and hierarhial lustering
To asertain gene expression hanges between human CD4
+
CD25
+
T
Reg
and CD4
+
CD25
-
naive T ells dierenes in gene expression were determined statistially by
orreted t-test analysis using the SAM tool [5℄. For two-dimensional hierarhial
lustering analysis Genesis software v1.4.0 was applied [254℄.
2.5.8 Pathway analysis
Genes that were signiantly up- or down-regulated in human CD4
+
CD25
+
T
Reg
ver-
sus CD4
+
CD25
-
naive T ells from healthy donors were imported into PathwayAssist
3.0.8 (Ariadne Genomis, Rokville, MD). The pathway was built using the "nd di-
ret interations" algorithm based on the embedded ResNet 3.0 database ontaining
500,000 links for approximately 50,000 proteins, extrated from 4.5 million MEDLINE
publiations (as of February 26, 2005).
2.5.9 Aession numbers
The entire data set for healthy donors was deposited in a MIAME ompliant for-
mat at Gene Expression Omnibus (GEO). Data derived from the Human T
Reg
Chip
are available under the series aession number GSE3882 (platform ID, GPL 3110).
Data derived from the Aymetrix GeneChips used as referene and seletion data sets
were published at GEO under series aession number GSE4527 (FOXP3 and GFP
transdued CD4
+
T
H
ells) and GSE4571 (representing data from CD4
+
CD25
+
and
CD4
+
CD25
-
T ells isolated by ell sorting from human peripheral blood and from
spleen of BALB/C mie).
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2.6 Aymetrix GeneChip experiments
Prior to this study, Aymetrix GeneChip experiments were performed by hybridiza-
tion of RNA derived from regulatory and naive T ells of mouse or human origin,
from FOXP3 and ontrol vetor transfeted human CD4
+
T
H
ell lines and a human
CD4
+
CD25
+
derived T
Reg
ell line (kindly provided by W.Hansen and M.Probst-
Kepper, GBF Braunshweig, Germany, [197℄). Samples were amplied aording to the
reommended protools of the manufaturer and desribed above. In all ases, 10 µg of
eah biotinylated RNA was fragmented and plaed in a hybridization oktail ontai-
ning four biotinylated hybridization ontrols (BioB, BioC, BioD, Cre). Samples were
hybridized to an idential lot of Aymetrix GeneChips for 16 hours. After hybridiza-
tion the GeneChips were washed, stained with SAPE, and read using an Aymetrix
GeneChip uidi station and sanner. Data derived from these Aymetrix GeneChip
experiments were used as referene and seletion data sets in this projet.
2.6.1 Puriation of human and murine CD4
+
T ells
Human CD4
+
T ells were prepared from peripheral blood of healthy donors by en-
trifugation over Fioll-Hypaque gradients (Biohrom AG, Berlin, Germany) and MACS
isolation using the CD4
+
T ell isolation kit and an AutoMACS unit (Miltenyi Biote,
Bergish Gladbah, Germany). Subsequently, ells were separated into CD4
+
CD25
+
and CD4
+
CD25
−
T ells by sorting on a MoFlo (DakoCytomation, CO, USA) to a
purity in exess of 98%. Red blood ell depleted splenoytes from BALB/ mie were
labelled with anti-CD4 and anti-CD25 antibodies and also separated with a MoFlo in
omparable purities.
2.6.2 Retroviral transdution of human eetor CD4
+
T ells
The DNA enoding human FOXP3 was amplied from DNA of T
Reg
ells using high
delity PFU polymerase (Promega) and spei primers (FOXP3: 5'-GAC AAG GAC
CCG ATG CCC A-3' and 5'-TCA GGG GCC AGG TGT AGG TG-3'). The PCR
produt was loned into pCR4.1 TOPO (Invitrogen, CA, USA), sequened, and inserted
into a pMSCV-based retroviral vetor enoding an enhaned GFP under the ontrol
of an IRES sequene. The amphotropi PT67 pakage ell line (kindly provided by
M.Wirth, GBF Braunshweig, Germany) was used for transfetion. Filtrated (0.45 µm)
virus-ontaining supernatant supplemented with 8 mg/ml sequabrene (Sigma Aldrih,
Munih, Germany) was applied to T
H
ells at day two after allogenei stimulation by
entrifugation at 5000 x g for 60 minutes at room temperature. Cells were expanded
thereafter with 50 U/ml IL2 and GFP-expressing ells were sorted 1-2 weeks later using
a FACS-Vantage (BD Biosiene).
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2.6.3 Criteria for Human T
Reg
Chip gene seletion
Dierentially expressed genes between CD4
+
CD25
+
and CD4
+
CD25
−
T ells of either
mouse or human origin measured on Aymetrix GeneChips were seleted aording to
predened ategories dedued from three parameters alulated by MAS 5 software:
fold hange (FC), hange p value (pValue), and signal intensity dierene (SID). Ca-
tegory A is dened as a FC above 2, pValue < 0.001 (for inreased) or pValue >
0.999 (for dereased), and SID above 200. Category B is dened as a FC above 2,
pValue < 0.01 (for inreased) or pValue > 0.99 (for dereased), and SID above 100.
Category C is dened as a FC above 1.5, pValue < 0.001 (for inreased) or pValue
> 0.999 (for dereased), and SID above 40. The likelihood of a signiant regulation
dereases from ategory A to C. Thus, most of the genes seleted for the Human T
Reg
Chip were ategorized as A. Seletion was performed by olleting genes that were
signiantly regulated in human ells, genes that were similarly regulated between
mouse and human, genes that were found to be regulated only in mouse ells and
referened in the literature, and genes that were signiantly aeted by FOXP3 over-
expression in ultured T
H
ell lines. Genes known for their impat in mouse and human
regulatory T ell development were also onsidered [196, additional data les 1-4℄.
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3.1 Development and design of the Human T
Reg
Chip
To improve moleular haraterization of human T
Reg
ells, a unique miroarray has
been ompiled, the Human T
Reg
Chip, onsisting of 350 T
Reg
ell assoiated genes. The
oligonuleotides probed on the Human T
Reg
Chip were seleted on the basis of whole
genome transription data obtained from human and mouse CD4
+
CD25
+
and CD4
+
CD25
-
T ells measured on Aymetrix GeneChips [196, additional data le 1℄. CD4
+
T ell subsets were isolated from either human peripheral blood or murine splenoytes
and separated using FACS-based ell sorting at purities onstantly greater than 98%.
Dierential gene expression was determined using statistial parameters, as desribed
in Material and methods (see hapter 2.6.3). This primary data set was extended
to genes that were aeted by FOXP3 over-expression in ultured human CD4
+
T
H
ell lines. Therefore, CD4
+
CD25
-
derived T
H
ell lines were infeted with retroviruses
enoding for FOXP3 and GFP (green uoresent protein) under the ontrol of an inter-
nal ribosomal entry site (IRES) or with an empty ontrol vetor ontaining only GFP
(kindly provided by M.Probst-Kepper, [197℄). FOXP3 ould partially indue a regula-
tory phenotype in these transfeted ells in vitro (data not shown). Using Aymetrix
GeneChips, these genetially engineered ells were ompared to those infeted with
the GFP ontrol vetor only. Furthermore, a human T
Reg
ell line was analysed that
was derived from human CD4
+
CD25
+
T ells, maintained its regulatory phenotype in
vitro and ompared its gene expression prole to the ontrol CD4
+
T
H
ell line (kindly
provided by M.Probst-Kepper, [197℄). For the development of the Human T
Reg
Chip
those genes were added to the primary data set that were dierentially expressed in
both experiments by more than twofold [196, additional data les 2 and 4℄. Moreover,
T
Reg
ell assoiated genes identied by extensive literature searh were inluded [196,
additional data le 3℄. In summary, this proess resulted in the seletion of 350 T
Reg
ell relevant genes that were arranged on an oligonuleotide miroarray. Furthermore,
45 ontrol genes were inluded in the primary miroarray design. Eah probe of the
miroarray onsists of a single 50mer oligonuleotide, as utility and performane of
50mer oligonuleotide miroarrays were proved before [117℄. Design and synthesis of
the oligonuleotides was performed by MWG using the Aymetrix probe sets as ref-
erene. Altogether, eight repliates per oligonuleotide were immobilized, splitted in
two separated arrays per slide, eah ontaining 1600 spots [Figure 9B℄. Applying the
MiroGrid TAS II spotter, 25µM of eah oligonuleotide were deposited in a ontat-
dependent manner onto CodeLink ativated slides (Amersham Biosienes) providing
reative ester groups to ovalently link the aminomodied oligonuleotides to the glass
surfae. Quality ontrol of three randomly seleted slides of eah hip bath was ar-
ried out by SYBR green staining, to ensure omplete spotting and that signal values
near the bakground intensity are really due to low transript levels in the sample
[Figure 9A℄.
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A B
Figure 9: The Human T
Reg
Chip.
A: SYBR green staining as quality ontrol of the spotting proess. As SYBR green is
interating unspeially with the immobilized oligonuleotides, the applied spotting
pattern an be demonstrated. A 4 x 4 pin onguration was used, with eah pin
printing a square of 10 x 10 spots, resulting in 1600 spots per array. Two of these
arrays were repliated per slide of the Human T
Reg
Chip. Missing spots in this image
are due to negative ontrols. Furthermore, a homogeneous spot morphology, similar
signal intensities (due to the same onentration of all printed oligonuleotides) and
low bakground levels are illustrated. B: Representative Human T
Reg
Chip hybridized
with RNA derived from regulatory T ells isolated from a healthy donor. In ontrast
to the SYBR green staining in A, variation in spot signal intensity an be observed,
diretly reeting the dierent expression levels of the 395 test genes. Additionally, a
high intra-array reproduibility is demonstrated, as both repliates show very similar
signal intensity patterns.
3.2 Performane and evaluation
Important fators for seleting an appropriate miroarray format inlude ross-platform
omparison, sensitivity, speiity and both intra- and inter-assay reproduibility [106℄.
To ensure measurement of aurate and reliable transription proles, all these quality
parameters have been validated for the 59 Human T
Reg
Chips ontributing to the
expression prole that disriminates CD4
+
CD25
+
regulatory from CD4
+
CD25
-
naive
T ells isolated from healthy donors.
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3.2.1 Comparability to Aymetrix
To evaluate the performane of the Human T
Reg
Chip its omparability to Aymetrix
as the market leader of miroarray tehnology was rst examined. Therefore, relative
expression data gained from experiments investigating FOXP3 aeted gene expression
on Aymetrix GeneChips were used as referene data in a ross-platform omparison.
Idential samples, obtained either from FOXP3 transfeted CD4
+
CD25
-
T ells or GFP
transfeted ontrols, were hybridized to Aymetrix HG_U133A GeneChips
R
and Hu-
man T
Reg
Chips, respetively. As demonstrated, onordane of signiantly regulated
genes on both platforms was 81% [29/36; Figure 10℄. Opposite regulation was only
observed for few marginally regulated genes (7/36).
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Figure 10: Comparability to Aymetrix.
Splitted samples (FOXP3 or GFP transfeted T ells) were hybridized to Aymetrix
HG_U133A GeneChips
R
and Human T
Reg
Chips, respetively. Aymetrix genes show-
ing a regulation of at least 1.5fold (exluding signals labelled as absent on both mi-
roarrays) were ompared to those fold hanges arising from the Human T
Reg
Chip
platform (inluding noisy fold ratios generated from low intensity genes). As depited,
29 out of 36 genes demonstrated similar regulation on the Human T
Reg
Chip ompared
to Aymetrix, resulting in a orrelation of 81%.
3.2.2 Reproduibility of the Human T
Reg
Chip
A basi property of a good miroarray platform is high reproduibility in repeated
experiments [108℄. That is why stability of signal intensities arising from the same
sample hybridized to several Human T
Reg
Chips was assessed. Figure 11 illustrates a
satterplot of normalized signal intensities of two exemplarily seleted slides, showing
that almost all signals were loated along the biseting line within the two-fold range,
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reeting the relatively low measurement noise in the data. Linear regression for 52
repliated miroarray experiments applying the Human T
Reg
Chip yielded a median
orrelation oeient of 0.98, demonstrating high reproduibility in measurement, even
for low signal intensities.
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Figure 11: Reproduibility of the Human T
Reg
Chip.
The same sample was hybridized to several Human T
Reg
Chips. A log-log-plot of
normalized signal intensities of two exemplarily seleted slides is illustrated, showing
that 99.7% of all signals are loated within the two-fold range.
3.2.3 Coeient of variane
As written above, eah oligonuleotide is repliated eight times per miroarray, en-
abling the alulation of variane oeients (CV) for eah probed gene as another
performane riterion of the Human T
Reg
Chip. The CV is dened as the standard
deviation divided by the mean [113℄. The pie hart in Figure 12 summarizes mean
CV values obtained from the 59 Human T
Reg
Chips onstituting the expression prole
of T
Reg
ells isolated from healthy donors. It is depited that the vast majority of
signal intensities (74%) have a CV < 0.3, meaning that their values vary less than
30% aross the entire data set, whih is a threshold used for industrially manufatured
miroarrays.
3.2.4 Quality ags
Other performane parameters onsulted for the evaluation of the Human T
Reg
Chip are
the so alled quality ags. After hybridization the slides are sanned and the resulting
images are analysed by ImaGene
R© (Biodisovery, El Segundo, CA), a software whih
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Figure 12: Coeients of variation (CV).
The ratios of standard deviation and mean were alulated for eah gene probed in
eight repliates per miroarray. CVs of all 59 experiments applying the Human T
Reg
Chip ontributing to the expression prole of human T
Reg
ells from healthy donors
are presented as means. As demonstrated, 74% of all signals have a CV < 0.3.
quanties and qualies eah spot on the array. During this alulation it assigns quality
ags to the spots: Good or unagged spots are indiated zero, signal intensities near
the bakground level are agged as empty or two, and spots of poor quality (due to
e.g. strange morphology or dust on the slide) are tagged with three.
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Figure 13: Quality ags.
Quality ags are displayed as assigned by ImaGene
R
software (v5.5.2). Values represent
means of all 59 miroarray experiments applying the Human T
Reg
Chip that onstitute
the expression prole of healthy human T
Reg
ells. As depited, almost two third of
all spots were left unagged, 32% have signal intensities near the bakground level and
less than 3% were agged due to poor spot quality.
In Figure 13, quality ags of the 59 Human T
Reg
Chips onstituting the expression
pattern of human T
Reg
ells isolated from healthy volunteers, are displayed as means
alulated aross the entire data set. It is demonstrated, that normally 65.4% of all
spots are unagged, 31.6% are agged as empty (inluding 2% due to negative ontrols)
and 2.9% are of poor quality.
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3.2.5 Linearity of hybridization proess
To monitor the hybridization proess regarding its linear run and to determine mi-
roarray system sensitivity, baterial hybridization ontrols were reorded at dierent
onentrations as another performane riterion of the Human T
Reg
Chip. Therefore,
normalized signal intensities versus onentrations of the used hybridization ontrols
were plotted as means of 59 experiments [Figure 14℄. Linear regression yielded a orre-
lation oeient of > 0.96, demonstrating that a linear hybridization proess overing
more than three orders of magnitude of onentrations is ensured. Furthermore, this
plot reveals a nal detetable onentration of 0.3 pM.
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Figure 14: Hybridization ontrols.
Normalized signal intensities versus onentration of used hybridization ontrols are
plotted as means of 10 (1.5 pM, 25 pM, 100 pM) and 59 experiments applying the
Human T
Reg
Chip. Standard deviations are visualized by error bars. Linear regression
yielded a orrelation oeient of > 0.96, demonstrating a linear hybridization proess
overing more than three orders of magnitude of onentrations.
3.2.6 Normalization strategy
The Human T
Reg
Chip provides rapid, parallel surveys of gene-expression patterns for
hundreds of genes in a single assay. To analyse and handle the huge amount of gen-
erated data, an appropriate omputational strategy had to be found. Software tools
are rapidly evolving but no lear onsensus exists about the "best" approah for gene
expression data analyses. Indeed, it beomes inreasingly lear that appliation of
dierent tehniques will allow dierent aspets of the data to be explored [6℄. Conse-
quently, hoosing an appropriate algorithm for analysis was a ruial element of the
experimental design.
To nd this optimal normalization strategy, global approahes were tried as well
as methods relying on housekeeping genes only, linear versus logarithmi and saling
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versus non-saling algorithms were applied to the data set and normalization by mean
and median values was ompared. During this proess, it beame obvious that global
normalization methods are not appropiate for the data, as they require equal overall
signal intensities for all miroarrays independently from the hybridized sample mate-
rial. Thus, global normalization strategies an only be applied when the number of
dierentially expressed genes an be negleted ompared to the total number of test
genes of the miroarray. This requirement annot be fullled for ustomized approahes
inluding the Human T
Reg
Chip that was designed to point out dierential gene ex-
pression between CD4
+
CD25
+
and CD4
+
CD25
-
T ells. Furthermore, only analyses
of at least 20% of the whole transriptome an guarantee equal signal intensity levels
[188℄. That is why normalization was performed by inluding just the housekeeping
genes that are equally expressed by both analysed T ell subpopulations.
Boxplots are a good tool to illustrate how dierent normalization proedures aet
data distribution. Figure 15 summarizes boxplots for all done RCC miroarrays before
and after data normalization. As demonstrated, the majority of values is loated in
a raw signal intensity range between 1 and 10
4
before normalization. Strikingly, raw
data of the various miroarrays learly dier in their distribution pattern, espeially in
their median and mean values. Thereby, the mean is always higher than the median
resulting from an overestimation of extremely big signal intensities when alulating
the mean. That is why the median is more robust to outliers. To ompensate for all
these varianes, normalization of raw data is indispensably required. Finally, the data
was normalized similar to a proposal of MWG (for details see Materials and methods)
by the following formula:
SI
norm
=
In − Bn
e<ln(house)>
Where SI
norm
is the normalized signal intensity, I
n
is the signal intensity of gene
n, B
n
is the bakground intensity of gene n, and <ln house> is the median logarith-
mi signal intensity of all housekeeping genes. MWG's algorithm was improved by
using the median instead of the mean to make the approah less suseptible to pos-
sible outliers. This data normalization proedure led to the most homogeneous data
distribution pattern. As shown in Figure 15, most of the values are now loated in a
signal intensity range between 10
-2
and 10
2
and additionally the medians beame more
similar. Extremely low values are evened out as demonstrated by the 1st perentile
and the minimum, while dierenes of the maximum values seem to get a little big-
ger. Thus, the applied normalization strategy results in a transformation to smaller
values, ompensates for dierenes in data distribution parameters and symmetrially
arranges the data around an arithmeti mean of the distribution loated at 10
0
= 1.
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Figure 15: Boxplots of raw and normalized signal intensities of all test genes.
Distribution of signal intensities for all done RCC miroarray experiments before and
after normalization is depited. Vertial boxes ontain 50% of all values falling between
25th and 75th perentile. The horizontal lines within the bars illustrate the median
of the distribution and blak squares () show its arithmeti mean. Horizontal lines
extending from the boxes inlude 98% of all values (1st to 99th perentile), minimum
and maximum value are represented by a ross (×) and outliers are depited as blak
points (•). Adapted from [253℄
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3.3 Human regulatory T ells in health
3.3.1 Purity and phenotype of isolated T ell frations
In order to obtain reliable and signiant transription proles of human CD4
+
CD25
+
regulatory and CD4
+
CD25
-
naive T ells, isolation of highly pure T ell subpopulations
was indispensably required. Both T ell frations were separated from PBMCs using
MACS tehnology as desribed above. To assess purity of the isolated regulatory and
naive T ell populations, ells were stained with CD4-FITC and CD25-PE antibodies
and subsequently analysed by FACS. Thereby, expression of the surfae moleules CD4
and CD25 was determined for living lymphoytes, as exemplied in Figure 16.
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Figure 16: FACS strategy to assess purity of MACS separated human
CD4
+
CD25
+
regulatory and CD4
+
CD25
-
naive T ell frations.
A) Lymphoyte population in gate R1. B) Living PI
-
lymphoytes (FL3 = PI =
propidiumiodide) of gate R1 in gate R2. C) Isolated CD4
+
CD25
+
T
Reg
ells gated
for R1 and R2. D) Separated CD4
+
CD25
-
naive T ells gated for R1 and R2. Purity
of the obtained T ell frations were given as perentages of vital CD4
+
CD25
+
and
CD4
+
CD25
-
T ells, respetively, based on the partiular total ell fration. Quadrants
in C and D were set aording to the unstained PBMCs.
To get a more omprehensive overview of the ahieved purity of both separated T
ell frations, results of the FACS analyses for all donors are summarized in Table 1,
while means for the dierent donor groups are shown in a bar hart in Figure 17. As
demonstrated, the isolated human CD4
+
CD25
+
T
Reg
ells were normally learly more
than 90% pure, while the CD4
+
CD25
-
naive T ell fration ahieved purities of more
than 80% in average. Furthermore, it beomes obvious, that the obtained purities for
both T ell subpopulations are similar between the dierent donor groups whih is an
essential requirement for the future intended omparison of T
Reg
ells in health and
disease.
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Figure 17: Mean purity of MACS separated T ell subpopulations.
Human T
Reg
and naive T ells were isolated from PBMCs using MACS tehnology.
Their purity was assessed by the FACS strategy explained in Figure 16 and expressed
as means for either the CD4
+
CD25
+
regulatory (red bars) or the CD4
+
CD25
-
naive
(green bars) T ell fration, depited separately for healthy donors, renal ell arinoma
(RCC) and inammatory bowel disease (IBD) patients as well as for all groups together.
Error bars indiate standard deviations.
Additionally, the phenotype of ontaminating ells within the MACS puried CD4
+
CD25
+
T
Reg
and CD4
+
CD25
-
naive T ells was analysed by FACS. As depited in Fi-
gure 18, remaining ells in both T ell subpopulations mainly represented CD16
+
/CD56
+
natural killer ells and, at lower levels, CD8
+
T ells, CD19
+
B ells and CD14
+
mono-
ytes.
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Figure 18: Phenotype of ontaminating ells within MACS separated CD4
+
CD25
+
and CD4
+
CD25
-
T ells.
Data was obtained from three healthy donors and re-analysed by FACS. The absolute
number of ontaminating ells was set to 100% and mean perentages of surfae marker
expression ± standard deviation are shown.
To onrm the regulatory phenotype of MACS puried CD4
+
CD25
+
T ells, the
fration of FOXP3 expressing ells was estimated by intraellular FACS staining.
Thereby, more than 80% of the isolated CD4
+
CD25
+
T ells turned out to be FOXP3
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positive [Figure 19A℄. Additionally, suppressor funtion of MACS separated CD4
+
CD25
+
T ells was assessed in proliferation assays that ould onrm exhibition of regulatory
T ell funtion in vitro [Figure 19℄. As demonstrated, CD4
+
CD25
+
T ells did almost
not proliferate in response to allogenei stimulation, while their naive ounterparts
showed strong proliferation under the same experimental onditions. Adding equal
numbers of CD4
+
CD25
+
T ells to the autologous CD4
+
CD25
-
fration resulted in a
lear inhibition of their proliferation rate due to T
Reg
ell suppressive ativity.
Taken together, these results demonstrate that the applied separation strategy is
able to enrih funtional and phenotypi human CD4
+
CD25
+
T
Reg
ells.
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Figure 19: Regulatory phenotype and suppressor funtion of MACS puried
human CD4
+
CD25
+
T ells.
A MACS separated CD4
+
CD25
+
T ells were analysed for ell surfae CD4 and CD25
expression as well as intraellular FOXP3 expression. Perent of positive ells is indi-
ated. Data shown is representative for three independent experiments. B To assess
T
Reg
ell proliferation and suppressive apaity, CD4
+
CD25
+
and CD4
+
CD25
-
derived
T ells were stimulated with allogenei EBV B ells alone or in the presene of equal
numbers of indiated T ells. Proliferation was assessed at day 3, bakground prolifer-
ation was 891.3 ± 376.2 pm.
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3.3.2 Frequeny of T
Reg
ells in peripheral blood of healthy donors
In order to estimate prevalene of the isolated human CD4
+
CD25
+
T
Reg
ells, their
frequenies in peripheral blood of 17 healthy donors was determined. Therefore,
PBMCs were isolated, stained for CD4 and CD25 and subsequently analysed by FACS.
CD4
+
CD25
high
T ell numbers were evaluated as a perentage of total CD4
+
T ell
population and resulted in an average frequeny of 3.7% ± 1.9% in healthy volunteers
[Figure 30℄.
3.3.3 Gene expression signatures of CD4
+
CD25
+
T
Reg
ells
One reason for the development of the Human T
Reg
Chip was to provide a tool enabling
improved moleular haraterization of human T
Reg
ells not by a single marker but by
expression proling. To obtain aurate and reliable individual transription proles,
highly pure CD4
+
CD25
+
regulatory and CD4
+
CD25
-
naive T ells from peripheral
blood of 11 healthy donors were isolated using MACS tehnology [Table 1℄. Eah
sample was measured in at least two independent miroarray experiments. Following
SAM analysis to identify genes with statistially signiant hanges in expression, 62
genes were found to be dierentially expressed in regulatory ompared to naive T ells in
all healthy volunteers. Based on Gene Ontology and referenes in literature, genes were
lassied into funtional ategories, suh as ytokines/hemokines and their reeptors
(12 genes), ell yle and proliferation (11), apoptosis (7), signal transdution (9) and
transriptional regulation (10). A detailed desription of these genes is summarized in
Table 3. Among them, LGALS3, CCR7, IL2RA (CD25), CTLA4, TRAF1, SATB1 and
GZMK were additionally found to be diretly aeted upon retroviral over-expression
of FOXP3 in CD4
+
T
H
ells [Figure 10℄.
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Table 3: Genes dierentially expressed between human CD4
+
CD25
+
T
Reg
and CD4
+
CD25
-
naive T ells from healthy donors.
JIA = juvenile idiopathi arthritis,RA = rheumatoid arthritis, CIA = ollagen-indued arthritis, SLE = systemi lupus erythematosus,
CHA = autoimmune hroni ative hepatitis, UC = ulerative olitis, MC = Morbus Crohn, COPD = hroni obstrutive pulmonary
disease, T2D = type II diabetes, T1D = type I diabetes, AS = atheroslerosis, LAD-1 = leukoyte adhesion deieny-1, ALPS =
autoimmune lymphoproliferative syndrome, IBD = inammatory bowel disease, XLP = X-linked lymphoproliferative syndrome, MS
= multiple slerosis, ITP = idiopathi thromboytopeni purpurea, SCID = severe ombined immunodeeny, HIGM1 = hyper-IgM
immunodeeny syndrome type I, ITP = immune thromboytopeni purpura, EAT = experimental autoimmune thyroiditis, IPEX =
immunodysregulation, polyendorinopathy, and entheropathy, X-linked, EAE = experimental autoimmune enephalomyelitis, HCC =
hepatoellular arinoma, NSCLC = nonsmall lung ell aner, AML = aute myeloyti leukaemia, CML = hroni myeloid leukaemia,
(B)-CLL = (B-ell) hroni lymphati leukaemia, ESCC = esophageal squamous ell arinoma, APL = aute promyeloyti leukaemia,
RCC = renal ell arinoma, T-LGLL = T-ell large granular lymphoyti leukaemia, CTCL = utaneous T-ell lymphoma, PCNSL =
primary entral nervous system lymphoma. HNSCC = head and nek squamous ell arinoma, (a/)GvHD = (aute/hroni) graft-
versus-host disease, Sl-GvHD = slerodermatous graft-versus-host disease, HSCT = hematopoieti stem ell transplantation, CD =
elia disease, CMSE = ows milk protein sensitive entheropathy, HP = hypersensitivity pneumotitis, HDM = house dust mite, TF =
typhoid fever. *Genes that were additionally found to be dierentially expressed upon retroviral over-expression of FOXP3 in CD4
+
CD25
-
T ells. red = up-regulated, green = down-regulated genes
3 Results 51
3.3.3.1 Hierarhial lustering analysis An unsupervised, two-dimensional hie-
rarhial lustering analysis was performed by entering the generated data set into
Genesis software, revealing the displayed gene expression prole of regulatory T ells
[Figure 20℄. Thereby, oexpressed genes and repliated experiments were arranged next
to eah other. Furthermore, the transriptional pattern learly separated CD4
+
CD25
+
regulatory from CD4
+
CD25
-
naive T ells and distinguished between 32 up- and 30
down-regulated genes.
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Figure 20: Transriptional proling of CD4
+
CD25
+
T
Reg
and CD4
+
CD25
−
naive T ells.
To reveal moleular dierenes between regulatory and naive human T ells, dierential
expression of 350 genes was investigated by appliation of the Human T
Reg
Chip. Fol-
lowing data normalization, Statistial Analysis of Miroarrays (SAM) was applied as a
data mining tool to asertain gene expression hanges, dislosing 62 signiantly altered
genes between both T ell subpopulations (delta = 2.46, median FDR = 0.48). After
entering the generated data set into Genesis software a two-dimensional hierarhial
lustering analysis unovered the displayed transriptional pattern disriminating hu-
man regulatory from naive T ells onsisting of 32 up-regulated and 30 down-regulated
genes. Eah row represents a gene probed on the Human T
Reg
Chip; eah olumn shows
expression of the 62 genes measured for eah individual in the study. Red indiates
genes that are expressed at higher levels ompared to the mean signal intensities of
all experiments, while down-regulated genes are oloured in green, and blak indiates
signal intensities near the mean expression level.
52 3 Results
3.3.3.2 Old friends and new players 21 out of these 62 genes have already been
desribed in the literature as being assoiated with T
Reg
ells of both mouse and hu-
man origin, e.g. FOXP3, CTLA4, IL2RA (CD25) and ITGB2 [Figure 21℄. Reovery of
these "old friends" onrmed the applied non-redundant miroarray approah inlu-
ding the ell separation strategy. Among the 62 genes, eight that were previously only
impliated in murine T
Reg
ell biology, ould also be deteted to be dierentially ex-
pressed in human T
Reg
ells (LGALS1, IL7R, GATA3, SATB1, TNFRSF1B, TNFSF5,
DGKA, CCR5). Altogether, 15 genes were identied that were similarly regulated
in mouse and human. Those genes at the intersetion of both organisms reet high
levels of interspeies onservation during the evolutionary proess, thereby lending
redibility to their important role in T
Reg
ell development and funtion. In addition
to FOXP3, CTLA4 and IL2RA, the hemokine reeptor 7 (CCR7), the transferring re-
eptor (TFRC) and integrin beta 2 (ITGB2) were also found in this intersetion group
between mouse and men. Furthermore, six genes previously assoiated with human
T
Reg
ells ould be onrmed by these miroarray experiments. Apart from the "old
friends", 41 "new players" were identied that have not previously been mentioned in
the ontext of human T
Reg
ells at all.
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Figure 21: Old friends and new players.
Genes dierentially expressed in regulatory and naive T ells as revealed by appliation
of the Human T
Reg
Chip. The upper half of the Venn diagram summarizes "old friends",
i.e. T
Reg
ell assoiated genes that have previously been desribed in literature for
either mouse or human. The lower half of the hart illustrates the new situation
by displaying all the "new players" of the T
Reg
ell ngerprint. As demonstrated
by the extended intersetion, eight genes, formerly only reported to be impliated in
mouse T
Reg
ell immunology, were revealed to play an additional role in human T
Reg
ell ativity (red arrow). Furthermore, the obtained results broadened the knowledge
about the transriptional pattern haraterizing human T
Reg
ells by adding 41 new
andidate genes (indiated by the red +).
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3.3.3.3 Signaling modules in T
Reg
ells revealed by pathway analysis To
eluidate potential pathway modules impliated in T
Reg
ell biology, PathwayAssist
software was applied to the unique expression data set of human T
Reg
ells from indi-
vidual healthy donors. Mapping the 62 T
Reg
ell spei genes yielded a network of 31
genes diretly interating with eah other [Figure 22℄. These 31 genes provided a om-
prehensive framework for further dissetion into funtional modules. These modules
point to mehanisms ontrolling diverse ellular proesses like survival/apoptosis, T ell
reeptor signaling/ativation/proliferation and dierentiation/maintenane of human
T
Reg
ells and are disussed in detail in hapter 4.2.2.2.
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Figure 22: Pathway analysis of the 62 genes onstituting the T
Reg
nger-
print.
Genes signiantly dierentially expressed in regulatory versus naive human T ells
were imported into PathwayAssist software and grouped aording to the diret in-
teration algorithm of the pathway building tool. Unlinked nodes were exluded from
this shemati representation, whereas the remaining 31 omponents were additionally
assigned to their ommon ellular loalization using the partiular integrated layout
option. Genes found to be up-regulated are shown in red, down-regulated nodes are
oloured in green.
3.3.3.4 Impliations in T
Reg
ell mediated diseases Apart from the "old
friends", the obtained T
Reg
ell signature omprises 41 "new players" that have not
54 3 Results
yet been desribed in T
Reg
ells at all. As T
Reg
ells have a far-reahing eet on our
health by inuening the outome of infetion, autoimmunity, transplantation, aner,
and even allergy, it was studied whether these new andidates have been reported to
partiipate in these proesses. Interestingly, the vast majority of the genes identied in
this study (51 out of 62) were impliated in at least one of these disease senarios [Table
3℄. To summarize, 32 genes were found to be involved in autoimmune disorders, 44
andidates to partiipate in tumor development, 20 genes inuening graft survival and
19 andidates to ontribute to allergi disease pathogenesis. Chapter 4.2.2.3 provides
a detailed disussion of the genes in these T
Reg
ell mediated diseases.
3.3.4 More news about the phenotype of human T
Reg
ells
3.3.4.1 Conrmation of miroarray gene expression data To verify au-
ray of the obtained miroarray data in more detail, quantitative real-time RT-PCR
was performed using the original samples. Referring to well-haraterized T
Reg
ell
genes (FOXP3, CTLA4 and CCR7) the hosen approah ould be onrmed [Figure
23A-C℄. This gave greater redene and reliability to the numerous additional genes
that have not yet been reported in (human) T
Reg
ells. Five of these "new players"
(LGALS3, CCR10, TNFRSF1B, CCR5, TRAF1) were seleted and their T
Reg
ell spe-
i expression was approved by quantitative real-time RT-PCR [Figure 23D-H℄. As
depited, PCR results generally orrelated well with the dierential gene expression
data obtained by appliation of the Human T
Reg
Chip. For a few donors variability
in gene expression was observed between miroarray and quantitative RT-PCR data,
but the diretion of hange was onsistent, lending ondene to the reliability of the
Human T
Reg
Chip results and the hosen ell separation strategy.
3.3.4.2 Protein expression by FACS analysis As post-transriptional meha-
nisms an modify mRNA stability, it was assessed whether gene expression orrelated
on mRNA and protein level. Therefore, four interesting target proteins were seleted,
two of them are expressed at the surfae (TNFRSF1B, CCR10) and two intraellu-
larly (FOXP3, LGALS3). Expression of these proteins was determined by three-olour
staining of isolated PBMCs and subsequent FACS analyses.
As shown in Figure 24, FOXP3 antibody staining revealed that almost all CD4
+
CD25
high
T
Reg
ells (84.3%± 3.5%) but only very few CD4+CD25- naive T ells (3.7%±
0.8%) expressed this protein intraellularly. This nding is thereby onrming the ap-
plied gating strategy as FOXP3 is generally aepted as the best marker for regulatory
T ells available to date. Furthermore, it ould be demonstrate that CD4
+
CD25
high
T
Reg
ells expressed signiantly higher amounts of TNFRSF1B and LGALS3 protein
than their naive ounterparts as shown by the shifts in the histogram overlays [Figure
24A℄. An average of 64.4% ± 4.9% T
Reg
ells versus 13.8% ± 3.4% of CD4+CD25- T
ells showed TNFRSF1B protein expression on their surfae, while 23.5% ± 7.0% T
Reg
ells ompared to only 0.5% ± 0.06% of CD4+CD25- T ells expressed intraellular
LGALS3 protein [Figure 24B℄.
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Figure 23: Old friends and new players: Conrmation of miroarray results.
Real-time RT-PCR was performed for FOXP3 (A), CTLA4 (B), CCR7 (C), LGALS3
(D), CCR10 (E), TNFRSF1B (F), CCR5 (G), TRAF1 (H) and RPS9 (data not shown)
expression in MACS separated human CD4
+
CD25
+
T
Reg
and CD4
+
CD25
-
naive T
ells. Following normalization to RPS9, relative mRNA amounts in CD4
+
CD25
+
T
Reg
ells were adjusted to orresponding expression levels in CD4
+
CD25
-
naive T ells and
expressed as fold hanges. Real-time RT-PCR results, indiated by blak bars, were
ompared to fold hanges arising from the Human T
Reg
Chip (represented by grey
bars). The partiular healthy donors were speied by letters aording to Table 1.
Furthermore, mean and median fold hanges for all indiated volunteers were given for
eah gene.
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Figure 24: Protein expression by human CD4
+
CD25
high
regulatory and
CD4
+
CD25
-
naive T ells.
PBMCs of healthy donors were isolated, stained for CD4, CD25 and a third protein-
of-interest. A Gated CD4
+
CD25
high
T
Reg
(upper red panel) and CD4
+
CD25
-
naive
(lower green panel) T ells were analysed for either FOXP3, LGALS3, TNFRSF1B or
CCR10 protein expression by FACS. Representative overlays for the partiular protein
expression in regulatory (red histograms) and naive (green histograms) T ells are
shown. B Perentages of ells expressing the protein-of-interest in the dierent T ell
subpopulations (red and green bars) as well as fration of ells that were positive for
CD4 and the target protein (brown bars) were summarized for all analysed donors as
means ± standard deviation (n = number of healthy volunteers, *P < 7·10-6).
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In ontrast to that, just a very low over-expression of CCR10 protein was found
in CD4
+
CD25
high
T
Reg
ells reeted in the smallest shift in the histogram overlays
among all andidate proteins. Furthermore, only a marginal fration of T
Reg
ells at all
(2.8% ± 1.1%) expressed CCR10 at their surfae. Taken together, signiantly higher
amounts of FOXP3, LGALS3 and TNFRSF1B protein expression ould be onrmed
in human CD4
+
CD25
high
T
Reg
ells ompared to CD4
+
CD25
-
T ells of healthy donors.
To get a better impression of the frequeny of positive ells within the total lym-
phoyte population, the perentages of CD4
+
T ells expressing the partiular protein-
of-interest were additionally assessed. In average, 1.7% CD4
+
FOXP3
+
, 2.4% CD4
+
LGALS3
+
, 2.9% CD4
+
TNFRSF1B
+
and only 0.8% CD4
+
CCR10
+
T ells were found
in the living lymphoyte population [Figure 24B, brown bars℄. These results reet
similar protein expression ranges of LGALS3 and TNFRSF1B, respetively, ompared
to FOXP3.
Comparing gene expression data obtained by miroarray analyses and real-time
RT-PCR to protein synthesis measured by FACS, ould learly demonstrate a strong
orrelation between mRNA and protein levels for FOXP3, LGALS3, TNFRSF1B and
even CCR10 expressed as fold hanges between CD4
+
CD25
+
and CD4
+
CD25
−
T ells
[Figure 25℄. Thereby, these ndings again lend ondene to the miroarray results.
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Figure 25: Correlation of gene and protein expression data.
Gene expression data obtained by Human T
Reg
Chip analyses (n = 11) and real-time
RT-PCR (n = 8) as well as protein expression data (number of analysed healthy donors
as given in Figure 24B) revealed by FACS analyses are presented as logarithmi fold
hanges in MACS separated healthy human CD4
+
CD25
+
versus CD4
+
CD25
−
T ells.
Values are given as means of all analysed donors, error bars indiate standard deviation.
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Taken together, signiantly higher gene and protein expression of FOXP3 ould
be onrmed in CD4
+
CD25
high
T
Reg
ells ompared to CD4
+
CD25
−
T ells. Further-
more, orrelating up-regulation of LGALS3 and TNFRSF1B expression on gene and
protein level by healthy human T
Reg
ells has been proven. Both new andidate marker
moleules were demonstrated to be expressed in similar amounts as FOXP3.
3.3.4.3 Coexpression of LGALS3, TNFRSF1B and FOXP3 protein To
date, FOXP3 is widely aepted as the most suitable human T
Reg
ell marker available.
To further examine qualiation of LGALS3 and TNFRSF1B as possible new andi-
date markers, oexpression of both proteins with FOXP3 was assessed. Three-olour
staining with subsequent FACS analysis of isolated PBMCs from healthy donors re-
vealed that double positive CD4
+
T ell frations indeed exist. As illustrated in Figure
26, approximately 1.5% of gated CD4
+
T ells oexpress LGALS3 and FOXP3 intra-
ellularly, while 0.5% oexpress TNFRSF1B on the surfae and intraellular FOXP3.
Furthermore, it beomes obvious, that there is an even more extended population of
CD4
+
T ells expressing just the protein-of-interest, but not FOXP3. In average, 7.5%
of analysed ells are CD4
+
LGALS3
+
and 5.8% are CD4
+
TNFRSF1B
+
, respetively,
but show no detetable FOXP3 protein expression. Conversely, a onsiderable part
of the CD4
+
FOXP3
+
T ell population is negative for LGALS3 (2.4% ± 0.3%) or
TNFRSF1B (4.8% ± 0.9%) protein expression. Whether these dierent T ell subpo-
pulations dier in their regulatory phenotype and suppressive apaity remains to be
eluidated.
Figure 26: LGALS3 as well as TNFRSF1B are oexpressed with FOXP3
protein.
PBMCs were isolated by MACS from nine healthy volunteers, stained with CD4-PE,
FOXP3-APC and either LGALS3-FITC or TNFRSF1B-FITC. For FACS analyses ells
were gated for living CD4
+
lymphoytes. The depited dot plots are representative for
all nine donors analysed. Indiated perentages represent positive ells in the partiular
quadrant and are given as means ± standard deviation.
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3.3.4.4 Putative new marker moleules Charaterization, enumeration and
manipulation of human T
Reg
ells would be greatly failitated by the identiation
of a spei marker moleule apable to distinguish them from naive and reently a-
tivated T ells. Optimally this marker should be a ell surfae reeptor that is highly
expressed exlusively in T
Reg
ells independently from their ativation status. In on-
trast to CD25, CTLA4 and GITR (whih are examples of surfae proteins ommonly
used to identify T
Reg
ells), putative new markers should additionally not be indued
upon ativation of CD4
+
CD25
-
T ells [15℄.
Comparative gene expression analyses of human ex vivo CD4
+
CD25
+
and CD4
+
CD25
-
T ells applying the Human T
Reg
Chip revealed several new andidate genes that
ould potentially funtion as marker moleules [Figure 21℄. Dierential gene expression
of seleted andidates, namely of LGALS3, CCR10, CCR5, TNFRSF1B and TRAF1
was onrmed by real-time RT-PCR [Figure 23℄. Finally, FACS analyses veried up-
regulation of LGALS3, TNFRSF1B and - to a lesser extent - CCR10 proteins in these
ex vivo human T
Reg
ells ompared to their naive ounterpart [Figure 24℄.
Next, the question was addressed whether these genes/proteins are onstitutively
expressed on CD4
+
CD25
+
T ells even after in vitro ativation. Furthermore, their
expression status in reently ativated CD4
+
CD25
-
T ells was of speial interest. To
larify these points, human CD4
+
CD25
+
T
Reg
and CD4
+
CD25
-
T ells were isolated
from the peripheral blood of healthy donors using MACS. Purity of both ell frations
was ensured by FACS analysis as desribed before. Afterwards, both T ell subpopu-
lations were ultured independently from eah other in appropriate medium and were
ativated by plate-bound anti-CD3 in a nal onentration of 1 µg/ml and 100 U IL2.
As muh more CD4
+
CD25
-
T ells than T
Reg
ells an be isolated, ontrols of naive T
ells ativated with anti-CD3 only (1 µg/ml) and suh stimulated just with IL2 (100 U)
were added to the experiment. Some of the ells were harvested at day 0 and day 3 for
subsequent real-time RT-PCR, while the rest of the ells was analysed for their protein
expression by FACS at day 0 and 5.
Figure 27 summarizes results of the real-time RT-PCR analyses omparing gene
expression of LGALS3, FOXP3, TNFRSF1B, TRAF1, CCR10 and CCR5 in ex vivo
isolated to reently in vitro ativated CD4
+
CD25
+
and CD4
+
CD25
-
T ells. As illus-
trated, LGALS3, TNFRSF1B, TRAF1 and CCR10 are onstitutively over-expressed
by T
Reg
ells independently from their ativation status as the fold hanges to their
naive ounterparts remain onstantly high after in vitro stimulation with anti-CD3 and
IL2. Expression status of these four andidates thereby follows the expression pattern
of FOXP3, whih is generally aepted as the most suitable T
Reg
marker urrently avai-
lable. In ontrast to that, CCR5 expression learly dereases after in vitro ativation
of human T
Reg
ells, but is still higher than in ex vivo CD4
+
CD25
-
T ells. Exten-
ding these analyses to ativated CD4
+
CD25
-
T ells revealed that CCR10 and CCR5
expression is strongly down-regulated. TNFRSF1B expression is slightly higher than
in non-ativated ex vivo CD4
+
CD25
-
T ells, but still lower than in ativated and ex
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Figure 27: Gene expression of LGALS3, FOXP3, TNFRSF1B, TRAF1,
CCR10 and CCR5 in naive, ativated and regulatory human T ells as
assessed by real-time RT-PCR.
PBMCs were isolated from peripheral blood of healthy human donors and separated
by MACS into CD4
+
CD25
+
T
Reg
and CD4
+
CD25
-
T ells. A part of these ells were
ativated with 1 µg/ml anti-CD3 and 100 U IL2 in vitro. As ontrols, CD4+CD25-
T ells stimulated either with anti-CD3 or IL2 alone were inluded. Total RNA was
prepared after three days, reverse transribed and relative mRNA expression levels
of LGALS3, FOXP3, TNFRSF1B, TRAF1, CCR10, CCR5 and RPS9 (as an internal
ontrol) were analysed in dupliate real-time RT-PCR assays. Relative mRNA amounts
were normalized to expression levels in CD4
+
CD25
-
T ells (fold hange = 1). Mean
fold hanges (n = 3) are illustrated.
vivo T
Reg
ells, thereby following expression behaviour of FOXP3. LGALS3 expression
is learly up-regulated upon ativation, thereby even exeeding expression levels in ex
vivo T
Reg
ells, but is still signiantly lower than in ativated T
Reg
ells. In ontrast
to that, TRAF1 expression is strongly up-regulated in ativated CD4
+
CD25
-
T ells
exeeding expression levels in all other ell populations analysed. This expression sta-
tus learly disqualies TRAF1 from being a putative new marker of human T
Reg
ells
as a disrimination to reently ativated T ells is not possible. Altogether, the same
trends in results were obtained when stimulating the CD4
+
CD25
-
T ells with either
anti-CD3 or IL2 only.
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Finally, orrelation of gene and protein expression was veried for TNFRSF1B,
LGALS3 and CCR10 in ex vivo ompared to in vitro ativated (5 days) CD4
+
CD25
+
and CD4
+
CD25
-
T ells by FACS analysis. As illustrated in Figure 28, TNFRSF1B
expression remained learly up-regulated on CD4
+
CD25
+
T
Reg
ells upon 5 days of
ativation ompared to in vitro ativated CD4
+
CD25
-
T ells.
Figure 28: TNFRSF1B, LGALS3 and CCR10 expression in ex vivo and
ativated CD4
+
CD25
+
T
Reg
versus CD4
+
CD25
-
T ells.
PBMCs were isolated from peripheral blood of healthy human donors and separated
by MACS into CD4
+
CD25
+
T
Reg
(red histograms) and CD4
+
CD25
-
T ells (green
histograms). A part of these ells were ativated with anti-CD3 (1µg/ml) plus IL2
(100 U) in vitro. As a ontrol, some CD4
+
CD25
-
T ells were stimulated with anti-
CD3 only (blue histograms). After 5 days ells were harvested, stained for CD4, CD25
as well as for TNFRSF1B, LGALS3 and CCR10, respetively, and were subsequently
analysed by FACS.
97% of ativated T
Reg
but only 16% and 12%, respetively, of anti-CD3 and anti-
CD3 + IL2 ativated CD4
+
CD25
-
T ells were revealed to express TNFRSF1B at
their surfae. Similarly, high sustained levels of LGALS3 protein expression were only
deteted in ativated T
Reg
(93.2%) and almost no indution ould be observed in ati-
vated CD4
+
CD25
-
(6.4%) T ells. So, the shift in TNFRSF1B and LGALS3 expression
between the subpopulations is even higher than that observed for freshly isolated (ex
vivo) ells. Taken together, the gene and protein expression data for TNFRSF1B and
LGALS3 on ex vivo and reently ativated CD4
+
CD25
+
T
Reg
and CD4
+
CD25
-
T ells,
respetively, support the role of both moleules as new putative human T
Reg
ell marker
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moleules. In ontrast to that, the shift for CCR10 protein expression after ativation
is still as small as for the freshly isolated T
Reg
versus naive T ells not reeting the
gene expression data obtained by real-time RT-PCR. Sine only a very small fration
expressed CCR10 at the surfae and the over-expression after ativation stayed low,
CCR10 annot further be onsidered as a marker moleule for human T
Reg
ells.
3.3.4.5 Suseptibility to apoptosis As disussed later in more detail in hapter
4.2.2.2.1, the performed miroarray analyses revealed several genes partiipating in
apoptosis ontrol. Using real-time RT-PCR [Figure 23℄ as well as ow ytometry
[Figure 24℄, up-regulation of two anti-apoptoti genes / proteins, namely LGALS3 and
TNFRSF1B, ould be onrmed in human CD4
+
CD25
high
T
Reg
ompared to naive
CD4
+
CD25
−
T ells. To eluidate whether both T ell subpopulations onsequently
dier in their apoptoti suseptibility, a ombined Annexin V and propidium iodide
(PI) staining of isolated PBMCs with subsequent FACS analysis was arried out [Figure
29℄. Annexin V is a 35-36 kDa Ca
2+
dependent phospholipid-binding protein with a
high anity for phosphatidylserine, a membrane phospholipid that is transloated from
the inner to the outer leaet in early stages of apoptosis. As PI enables staining of
dead ells, Annexin V
-
PI
-
viable ells an be easily distinguished from Annexin V
+
PI
-
apoptoti and Annexin V
+
PI
+
dead ells. Gating for CD4
+
CD25
high
T
Reg
and
naive CD4
+
CD25
−
T ells indeed revealed that regulatory T ells are less suseptible
to apoptosis than their naive ounterparts. As illustrated, a fration of 2.6% ± 1.1%
T
Reg
versus 5.9% ± 1.0% naive T ells was demonstrated to undergo apoptosis. This
dierene in apoptoti behaviour was found to be highly signiant (P < 10
-4
).
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Figure 29: Human CD4
+
CD25
high
T
Reg
ells are less suseptible to apop-
tosis than CD4
+
CD25
−
T ells.
PBMCs from seven healthy donors were isolated and stained for CD4, CD25 as well as
with Annexin V and propidium iodide (PI). These ells were analysed by FACS, gated
for lymphoyte population rst (left panel) and afterwards for regulatory and naive T
ells, respetively (middle panel). Perentages of apoptoti ells, whih are Annexin
V
+
but PI
-
are given as means ± standard deviation (right panels).
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3.4 Human regulatory T ells in RCC
3.4.1 Frequeny of T
Reg
ells in peripheral blood of RCC patients
As inreased populations of T
Reg
ells are thought to ontribute to impaired anti-
tumor immune responses in various human malignanies, T
Reg
ell frequenies were
investigated in peripheral blood of RCC patients and healthy donors. Therefore,
CD4
+
CD25
high
T ell numbers were evaluated by FACS as a perentage of the total
CD4
+
T ell population using the gating strategy shown in Figure 30A. Representative
dot plots of RCC patients and healthy volunteers are depited there, while umulative
data are presented in a bar hart in Figure 30B.
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Figure 30: T
Reg
ell frequeny in health and RCC.
A Flow ytometri analysis of CD4
+
CD25
high
T
Reg
and CD4
+
CD25
-
naive T ells in
healthy donors and RCC patients. PBMCs were stained with anti-CD4-FITC and anti-
CD25-PE. T
Reg
ell frequeny was determined as the perentage of brighter CD25
+
ells
on gated CD4
+
T ell population. Representative FACS results of a healthy donor and
an RCC patient are shown. B Comparison of CD4
+
CD25
high
T
Reg
and CD4
+
CD25
+
T ells between healthy individuals and RCC patients. Perentages of CD4
+
CD25
high
and CD4
+
CD25
+
T ells in the peripheral blood of 17 healthy donors () and 12 RCC
patients () are shown. Values are given as means ± standard deviation. * P < 0.004
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As demonstrated, the prevalene of CD4
+
CD25
high
T ells in RCC patients (8.0%
± 4.1%, n = 12) was signiantly higher than that in healthy individuals (3.7% ±
1.9%, n = 17, P < 0.004). Furthermore, elevated frequenies of CD4
+
CD25
high
T ells
in RCC patients were aompanied by an inrease of total CD4
+
CD25
+
T ell popu-
lation, inorporating CD25
low
to CD25
dim
T ells. In RCC patients, 50.7% ± 14.6%
of CD4
+
CD25
+
T ells ompared to 32.5% ± 8.8% in healthy individuals (P < 0.002,
Figure 30B) were observed. In ontrast to that, no signiant dierenes in frequenies
of CD4
+
CD25
high
and CD4
+
CD25
+
populations ould be deteted between loalized
(n = 7) and metastati (n = 5) RCC (data not shown).
3.4.2 Gene expression signatures of CD4
+
CD25
+
T
Reg
ells in RCC
Apart from elevated T
Reg
ell frequenies, exaggerated suppressive ativity or inreased
homing to tumor sites an be supposed to ontribute to tumor immune esape. To iden-
tify genes able to indue these harateristis in T
Reg
ells from RCC patients, miroar-
ray analyses were performed applying the Human T
Reg
Chip. Therefore, CD4
+
CD25
+
T
Reg
and CD4
+
CD25
-
T ells were separated by MACS from six patients with loalized
and ve patients with metastati growth of RCC and proessed as desribed before. All
RCC patients' harateristis were summarized in Table 1. Altogether, 62 miroarray
experiments were arried out; 31 slides were hybridized with CD4
+
CD25
+
and another
31 with CD4
+
CD25
-
T ell-derived RNA, respetively.
3.4.2.1 Regulatory versus naive T ells in RCC To identify genes signi-
antly dierentially expressed between CD4
+
CD25
+
T
Reg
and CD4
+
CD25
-
T ells in
RCC, miroarray data was normalized and subjeted to SAM and luster analysis as
previously desribed. The revealed transriptional pattern arranged oexpressed genes
and repliated experiments next to eah other and learly separated CD4
+
CD25
+
T
Reg
from CD4
+
CD25
-
T ells. The gene expression signature of regulatory and naive T
ells in RCC turned out to onsist of 81 altered genes, whih were omposed of 49
up-regulated and 32 down-regulated andidates [Figure 31℄. Expetedly, prominent
ones were found among them, suh as FOXP3, CTLA4 and IL2RA, but also numerous
genes not previously assoiated with T
Reg
ells at all were inluded (e.g. CCR8, CEB1,
CDC25B).
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Figure 31: Transriptional proling of CD4
+
CD25
+
T
Reg
and CD4
+
CD25
−
naive
T ells from RCC patients.
To reveal moleular dierenes between regulatory and naive human T ells in RCC pa-
tients, dierential expression of 350 genes was investigated by appliation of the Human T
Reg
Chip. Following data normalization, SAM was applied as a data mining tool to asertain
gene expression hanges, dislosing 81 signiantly altered genes between both T ell sub-
populations (delta = 2.83, median FDR = 0.53). After entering the generated data set into
Genesis software, a two-dimensional hierarhial lustering analysis unovered the displayed
transriptional pattern disriminating human regulatory from naive T ells in RCC onsisting
of 49 up-regulated and 32 down-regulated genes. Eah row represents a gene probed on the
Human T
Reg
Chip; eah olumn shows expression of the 81 genes measured for eah individual
in the study. Red indiates genes that are expressed at higher levels ompared to the mean
signal intensities of all experiments, while down-regulated genes are oloured in green and
blak indiates signal intensities near the mean expression level.
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3.4.2.2 Comparison to healthy donors As enhaned survival and potentially
inreased regulatory properties of T
Reg
ells in RCC would be reeted in the revealed
gene expression prole, it was ompared to the transriptional pattern obtained from
T
Reg
and naive T ells of healthy donors [Figure 20℄ whih an be interpreted as a
referene ngerprint. Although no genes with opposed regulations ould be revealed
between both donor groups, numerous genes ould be deteted that were just dieren-
tially expressed between T
Reg
and naive T ells of either healthy donors (n = 27) or
RCC patients (n = 46, [Figure 32℄). Additional 35 genes were inluded in the expres-
sion proles from T
Reg
and naive T ells of both donor groups, but generally showed
stronger regulation in RCC.
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Figure 32: Similarities and dierenes in the gene expression signatures of
T
Reg
ells in RCC and health.
Genes signiantly dierentially expressed between CD4
+
CD25
+
T
Reg
and CD4
+
CD25
-
T ells from 11 RCC patients and 11 healthy volunteers, respetively, were summarized
in a Venn diagram. As depited by the intersetion, 35 genes were ontained in the
expression proles of both donor groups, but generally showed stronger regulation in
RCC. Additional 27 and 46 genes, respetively, were found to be just dierentially
expressed between T
Reg
and naive T ells of either healthy donors or RCC patients.
Genes were arranged aording to their dereasing fold hange between CD4
+
CD25
+
T
Reg
and CD4
+
CD25
-
T ells.
To reveal signiant dierenes in the gene expression proles of CD4
+
CD25
+
T
Reg
from healthy volunteers and RCC patients, miroarray data of the same ell type but
of dierent donor origin had to be ompared. As illustrated in Figure 33, SAM and
hierarhial lustering analysis identied 121 genes dierentially expressed in T
Reg
ells
of both donor groups, omposed of 71 up-regulated and 64 down-regulated genes when
omparing RCC to health.
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Figure 33: Expression proling of CD4
+
CD25
+
T
Reg
from RCC patients and
healthy donors.
To reveal moleular dierenes between regulatory T ells in RCC patients ompared to
healthy donors, dierential expression of 350 genes was investigated by appliation of the
Human T
Reg
Chip. Following data normalization, SAM was applied as a data mining tool to
asertain gene expression hanges, dislosing 121 signiantly altered genes between both T
ell subpopulations (delta = 2.15, median FDR = 0.18). After entering the generated data
set into Genesis software, a two-dimensional hierarhial lustering analysis unovered the
displayed transriptional pattern disriminating human regulatory T ells in RCC patients
from those of healthy donors. It onsists of 71 up-regulated and 64 down-regulated genes.
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3.4.2.3 Metastati versus loalized RCC Miroarray analyses of T
Reg
and
naive T ells obtained from seven and ve RCC patients with loalized and metastati
RCC growth, respetively, allowed diret omparison of resulting gene expression pro-
les depending on stage of disease. As depited in Figure 34, 72 and 85 genes were
revealed to be signiantly dierentially expressed between CD4
+
CD25
+
T
Reg
and
CD4
+
CD25
-
T ells in loalized and metastati RCC, respetively. Among them,
FOXP3, IL2RA and CTLA4 ould be again onrmed as "old friends" in T
Reg
ell
immunology, but various "new players" - suh as BCL2, CCR6 and ITGB5 - were
additionally deteted that have not been desribed in T
Reg
ell ontext before.
Figure 34: Gene expression proling of CD4
+
CD25
+
T
Reg
and CD4
+
CD25
−
naive T ells from RCC patients with loalized (A) and metastati (B) tumor
growth.
To reveal moleular dierenes between regulatory and naive human T ells in RCC patients
with loalized (A) and metastati (B) tumor growth, dierential expression of 350 genes was
investigated by appliation of the Human T
Reg
Chip. Following data normalization, SAM was
applied as a data mining tool to asertain gene expression hanges, dislosing 72 (A) and 85
(B) signiantly altered genes between both T ell subpopulations (A: delta = 1.38, median
FDR = 0.8; B: delta = 2.1, median FDR = 0.5). After entering the generated data set into
Genesis software a two-dimensional hierarhial lustering analysis unovered the displayed
transriptional pattern disriminating human regulatory from naive T ells in loalized (A)
or metastati (B) RCC onsisting of 43 (A) or 63 (B) up-regulated and 29 (A) or 22 (B)
down-regulated genes.
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The Venn diagram in Figure 35 summarizes the results of a omparison of both
transriptional patterns. As depited by the intersetion, 51 genes were unovered
to be dierentially expressed between T
Reg
and T
naiv
ells in loalized as well as in
metastati RCC. Similarly to observations made between healthy donors and RCC
patients, most of these genes were stronger regulated in metasti than loalized tumor
growth and opposite diretions of regulation were not disovered. Additional 21 and
34 genes, respetively, were found to be an exlusive part of the expression prole from
either loalized or metastati RCC.
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Figure 35: Similarities and dierenes in the gene expression signatures of
T
Reg
ells in loalized and metastati RCC.
Genes signiantly dierentially expressed between CD4
+
CD25
+
T
Reg
and CD4
+
CD25
-
T ells from seven and ve RCC patients suering from loalized and metastati tumor
growth, respetively, were summarized in a Venn diagram. As depited by the inter-
setion, 51 genes were ontained in the expression proles of both donor groups, but
generally showed stronger regulation in metastati RCC. Additional 21 and 34 genes,
respetively, were found to be just dierentially expressed between T
Reg
and naive T
ells of either loalized or metastati RCC. Genes were arranged aording to their
dereasing fold hange between CD4
+
CD25
+
T
Reg
and CD4
+
CD25
-
T ells.
3.4.3 More news about the phenotype of human T
Reg
ells in RCC
3.4.3.1 Conrmation of miroarray data Quantitative real-time RT-PCR was
performed using the original RCC samples to verify the obtained miroarray data. Re-
ferring to FOXP3 as a well-haraterized T
Reg
ell gene, the applied approah ould
be onrmed [Figure 36A℄. This gave greater redene and reliability to the numerous
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additional genes that have not yet been reported in (human) T
Reg
ells. Four of the
"new players" were seleted that have also been identied as dierentially expressed
in CD4
+
CD25
+
T
Reg
versus CD4
+
CD25
-
T ells of healthy donors (LGALS3, CCR10,
TNFRSF1B, TRAF1) and their T
Reg
ell spei expression was approved by quantita-
tive real-time RT-PCR [Figure 36B-E℄. As depited and shown for the healthy donors
before, PCR results generally orrelated well with the dierential gene expression data
obtained by appliation of the Human T
Reg
Chip. For a few donors variability in gene
expression was observed between miroarray and quantitative RT-PCR data, but the
diretion of hange was onsistent, lending ondene to the reliability of the Human
T
Reg
Chip results and the applied ell separation strategy. While similar fold hanges
in mRNA expression were observed for FOXP3, CCR10, TNFRSF1B and TRAF1 in
T
Reg
versus naive T ells omparing healthy to RCC donors, a signiant derease was
deteted in the fold hange of LGALS3 expression in RCC patients [Figure 36F℄. In
healthy donors, LGALS3 was 7.6 ± 3.4 times over-expressed in T
Reg
versus naive T
ells, whereas this fold hange delined to 2.9 ± 1.0 in RCC patients when omparing
the same T ell subsets. These results diretly reeted the miroarray data whih
revealed fold hanges of 3.9 ± 1.5 for healthy donors and 2.9 ± 1.0 for RCC patients.
For all the genes analysed by real-time RT-PCR, no signiant dierenes in expression
levels ould be observed between loalized and metastati RCC tumor growth.
3.4.3.2 Protein expression of human T
Reg
ells in RCC Next, orrelation of
FOXP3, LGALS3 and TNFRSF1B mRNA and protein expression was examined be-
ause post-transriptional gene regulation mehanisms may inuene mRNA stability.
Therefore, three-olour staining with subsequent FACS analysis was applied to PBMCs
isolated from seven RCC patients that were additionally gated for CD4
+
CD25
high
T
Reg
and CD4
+
CD25
-
naive T ells. Obtained results were diretly ompared to aordant
ndings derived from previous analyses of nine healthy donors [hapter 3.3.4.2 and
3.3.4.3℄. As illustrated in Figure 37A and omparable to healthy donors, FOXP3 and
LGALS3 protein expression levels were signiantly elevated in RCC T
Reg
versus naive
T ells. Furthermore, very similar levels of FOXP3 protein expression were observed in
CD4
+
CD25
high
T
Reg
ells of healthy (84.3% ±3.5%) and RCC (84.9% ± 5.7%) donors
[Figure 37B℄. In ontrast to that, signiant elevated frations of LGALS3 expressing
ells were deteted within the T
Reg
subpopulation in RCC patients ompared to healthy
volunteers. In average, 23.5% ± 7.0% of CD4+CD25high T
Reg
ells isolated from healthy
donors were LGALS3 positive, whereas this perentage rose to 37.6% ± 8.3% in RCC
patients (P < 0.004). This is well in line with the obtained Human T
Reg
Chip ex-
pression prole omparing healthy and RCC T
Reg
ells whih also reported a 2.2 times
higher LGALS3 expression in T
Reg
ells isolated from RCC patients [Figure 33℄. Next,
the extent of oexpression of FOXP3 and either LGALS3 or TNFRSF1B was investi-
gated. Comparing healthy donors to RCC patients again, signiant larger CD4
+
T ell
subpopulations were revealed oexpressing LGALS3 and FOXP3 as well as TNFRSF1B
and FOXP3 in the RCC donor group [Figure 37℄. While only 1.5% ± 0.4% of healthy
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Figure 36: Conrmation of miroarray results in RCC.
Real-time RT-PCR was performed for FOXP3 (A), TNFRSF1B (B), CCR10 (C),
TRAF1 (D), LGALS3 (E), and RPS9 (data not shown) expression in MACS sepa-
rated human CD4
+
CD25
+
T
Reg
and CD4
+
CD25
-
naive T ells isolated from RCC
patients. Following normalization to RPS9, relative mRNA amounts in CD4
+
CD25
+
T
Reg
ells were adjusted to orresponding expression levels in CD4
+
CD25
-
naive T
ells and expressed as fold hanges. Real-time RT-PCR results, indiated by blak
bars, were ompared to fold hanges arising from the Human T
Reg
Chip (represented
by white bars). The partiular RCC patients are speied by letters aording to Table
1. Furthermore, mean and median fold hanges for all indiated volunteers are given
for eah gene. (F) illustrates the signiant derease in the fold hange of LGALS3
expression in CD4
+
CD25
+
T
Reg
versus CD4
+
CD25
-
naive T ells from RCC patients
ompared to healthy donors (*P = 0.006).
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CD4
+
T ells oexpressed LGALS3 and FOXP3, this fration inreased to 2.5% ± 0.9%
in RCC patients (P = 0.03). Similarly, 0.5% ± 0.2% of CD4+ T ells isolated from
healthy donors showed oexpression of TNFRSF1B and FOXP3, whereas this popu-
lation omprises 1.2% ± 0.7% CD4+ T ells in RCC patients (P = 0.04). The latter
inrease was aompanied by a signiant rise in the fration of CD4
+
TNFRSF1B
+
T
ells laking FOXP3 expression in RCC patients (10.9% ± 3.7%) ompared to healthy
ontrols (5.8% ± 2.3%; P = 0.01).
F O X P 3 L G A L S 3 L G A L S 3
 F O X P 3
T N F R S F 1 B T N F R S F 1 B
    F O X P 3
w i t h i n  C D 4 + C D 2 5 h i g h w i t h i n  C D 4 +  T  c e l l s
*
*
*
*
*
R C C  p a t i e n t s R C C  p a t i e n t sh e a l t h y  d o n o r s h e a l t h y  d o n o r s
F O X P 3 L G A L S 3
*
*
*A
B
0 . 1
1
1 0
1 0 0
%
 
p
o
s
i
t
i
v
e
 
c
e
l
l
s
 
(
l
o
g
 
s
c
a
l
e
)
0 . 1
1
1 0
1 0 0
%
 
p
o
s
i
t
i
v
e
 
c
e
l
l
s
 
(
l
o
g
 
s
c
a
l
e
)
Figure 37: Protein expression of human T
Reg
ells in health and RCC.
PBMCs of nine healthy and seven RCC donors were isolated, stained for CD4, CD25, FOXP3,
TNFRSF1B and LGALS3. A Elevated expression of FOXP3 and LGALS3 proteins in RCC
T
Reg
(red bars) versus naive (green bars) T ells, omparable to that observed in healthy
donors. (*P < 2.1·10-5). B Gated CD4+CD25high T
Reg
were analysed for either FOXP3 or
LGALS3 protein expression by FACS. Alternatively, PBMCs were gated for total CD4
+
T ells
and fration of ells oexpressing TNFRSF1B and FOXP3 as well as FOXP3 and LGALS3
were determined. Perentages of ells expressing the proteins-of-interest in the dierent T ell
subpopulations were ompared between healthy donors (white bars) and RCC patients (blak
bars; *P < 0.04). Values are represented in logarithmi sale as means ± standard deviation.
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3.4.3.3 Suseptibility to apoptosis As disussed in more detail in hapter 4.3.2,
the performed miroarray analyses revealed several genes partiipating in apoptosis
ontrol. Using real-time RT-PCR [Figure 36℄ as well as ow ytometry [Figure 37℄,
up-regulation of two anti-apoptoti genes/proteins, namely LGALS3 and TNFRSF1B,
ould be onrmed on human CD4
+
CD25
high
T
Reg
ompared to naive CD4
+
CD25
−
T ells isolated from RCC patients. To eluidate whether both T ell subpopulations
onsequently dier in their apoptoti suseptibility, a ombined Annexin V and pro-
pidium iodide staining of isolated PBMCs with subsequent FACS analysis was arried
out and results obtained were diretly ompared to those reeived from healthy donors.
Gating for CD4
+
CD25
high
T
Reg
and naive CD4
+
CD25
−
T ells indeed revealed that
regulatory T ells are less suseptible to apoptosis than their naive ounterparts, in fat
independent from their donor origin [Figure 38℄. As illustrated, a fration of 2.6% ±
1.1% T
Reg
versus 5.9% ± 1.0% naive T ells for healthy donors and 2.9 ± 1.4% T
Reg
versus 9.2% ± 3.4% naive T ells from RCC patients were demonstrated to undergo
apoptosis. These dierenes in apoptoti behaviour were found to be highly signiant
(healthy: P < 10
-4
; RCC: P < 0.005). Nevertheless, the number of apoptoti ells did
not vary signiantly when omparing T
Reg
ells isolated either from healthy or RCC
donors. Instead, naive T ells showed learly higher apoptoti rates in RCC patients
than in healthy donors. This result bordered on signiane (P = 0.06) sine it was
found to be variable among RCC donors, but should be further analysed by inreasing
the numbers of RCC patients in this study.
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Figure 38: Similar to human CD4
+
CD25
high
T
Reg
ells from healthy donors,
RCC patient derived T
Reg
ells are less suseptible to apoptosis than their
naive ounterparts.
PBMCs from seven healthy and six RCC donors were isolated and stained for CD4,
CD25 as well as with Annexin V and propidium iodide (PI). These ells were analysed
by FACS, gated for lymphoyte population rst and afterwards for CD4
+
CD25
high
T
Reg
(red bars) and CD4
+
CD25
-
naive (green bars) T ells, respetively. Perentages
of apoptoti ells, whih are Annexin V
+
but PI
-
are given as means ± standard
deviation (*P < 0.005).
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3.5 Human regulatory T ells in IBD
Inammatory bowel disease (IBD) is a hroni relapsing and remitting inammatory
ondition of the gastrointestinal trat that manifests at two distint but sometimes
overlapping linial entities, known as Crohn's disease (CD) and ulerative olitis (UC).
T
Reg
ells have been proven eetive in the prevention and down-regulation of IBD in
animal models, thus abnormalities in their suppressor funtion, frequeny or distribu-
tion in the intestinal muosa are supposed to ontribute to IBD pathogenesis [235℄.
These fats led us to have a loser look on T
Reg
ells isolated from IBD patients,
suering either from UC or CD and presenting ative or inative state of disease.
3.5.1 Frequeny of T
Reg
ells in IBD patients
In a ooperation projet with Dr. Johen Maul under the diretion of Prof.Duhmann
at the Charite´-University Mediine Berlin, T
Reg
ells isolated from PB of 36 patients
with ative and 34 patients with inative CD or UC have been investigated. As pub-
lished during this work, hanges in T
Reg
ell frequeny were revealed in IBD that
additionally orrelated with disease ativity [235℄. Maul et al. showed dereased PB
T
Reg
ell numbers in ative IBD, while T
Reg
ells were enrihed in the PB of IBD
patients in remission (inative state). Although, T
Reg
ell frequeny was enhaned in
inamed ative IBD lesions versus noninamed areas within the intestinal muosa,
their number remained signiantly lower ompared to divertiulitis, an inammatory
ontrol expeted to exhibit undisturbed immunoregulatory funtions. Thus, ative IBD
seems to be haraterized by an insuient ounterregulation, i.e. ontration of the
peripheral CD4
+
CD25
+
T
Reg
ell pool and an insuient inrease of their frequeny
in intestinal lesions [235℄.
3.5.2 Gene expression prole by appliation of the Human T
Reg
Chip
To deipher gene regulation events and to identify novel genes that might be involved
in IBD pathogenesis, maintenane and progression, omparative miroarray analyses
were performed. As desribed previously, CD4
+
CD25
+
T
Reg
and CD4
+
CD25
-
naive T
ells were therefore isolated from PB of IBD patients suering from ative CD, inative
CD or inative UC (n = 3 eah). IBD patients' harateristis were summarized in
Table 1. Total RNA was extrated and reverse transribed into DNA. In subsequent
IVT reations using T7 RNA polymerase, RNA ould be amplied and hybridized
to the Human T
Reg
Chip. Altogether, 18 miroarray experiments were arried out; 9
slides were hybridized with CD4
+
CD25
+
and another 9 with CD4
+
CD25
-
T ell-derived
RNA, respetively.
3.5.2.1 Regulatory versus naive T ells in IBD To identify genes signiantly
dierentially expressed between CD4
+
CD25
+
T
Reg
and CD4
+
CD25
-
T ells in IBD, mi-
roarray data was normalized and subjeted to SAM and luster analysis as previously
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desribed. The revealed transriptional pattern arranged oexpressed genes and repli-
ated experiments next to eah other and learly separated CD4
+
CD25
+
T
Reg
from
CD4
+
CD25
-
T ells. The gene expression signature of regulatory and naive T ells in
IBD turned out to onsist of 64 altered genes, whih were omposed of 40 up-regulated
and 24 down-regulated andidates [Figure 39℄. Among them, prominent ones were
expetedly found, suh as FOXP3, CTLA4 and IL2RA, but also numerous genes not
previously assoiated with T
Reg
ells at all (e.g. PECAM1, CCR8, CCL5).
Figure 39: Transriptional proling of CD4
+
CD25
+
T
Reg
and CD4
+
CD25
−
naive
T ells from IBD patients.
To reveal moleular dierenes between regulatory and naive human T ells in IBD patients
dierential expression of 350 genes was investigated by appliation of the Human T
Reg
Chip.
Following data normalization, SAM was applied as a data mining tool to asertain gene ex-
pression hanges, dislosing 64 signiantly altered genes between both T ell subpopulations
(delta = 1.57, median FDR = 0.99). After entering the generated data set into Genesis
software, a two-dimensional hierarhial lustering analysis unovered the displayed tran-
sriptional pattern disriminating human regulatory from naive T ells in IBD onsisting of
40 up-regulated and 24 down-regulated genes. (MCa = Crohn's disease ative state, MCi =
Crohn's disease inative state, UCi = ulerative olitis inative state)
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3.5.2.2 Comparison to healthy donors and RCC patients As hanges in
frequeny and insuient regulatory ativity of T
Reg
ells in IBD would be reeted
in the revealed gene expression prole, it was ompared to the transriptional pattern
obtained from T
Reg
and naive T ells of healthy donors [Figure 20℄ funtioning as a
referene ngerprint. Although no genes with opposed regulations ould be revealed
between both donor groups, numerous genes were deteted that were just dierentially
expressed between T
Reg
and naive T ells of either healthy donors (n = 30) or IBD
patients (n = 32, [Figure 40℄).
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Figure 40: Similarities and dierenes in the gene expression signatures of
T
Reg
ells in IBD and health.
Genes signiantly dierentially expressed between CD4
+
CD25
+
T
Reg
and CD4
+
CD25
-
T ells from 9 IBD patients and 11 healthy volunteers, respetively, were summarized
in a Venn diagram. As depited by the intersetion, 32 genes were ontained in the
expression proles of both donor groups, but generally showed stronger regulation in
IBD. Additional 30 and 32 genes, respetively, were found to be just dierentially
expressed between T
Reg
and naive T ells of either healthy donors or IBD patients.
Genes were arranged aording to their dereasing fold hange between CD4
+
CD25
+
T
Reg
and CD4
+
CD25
-
T ells.
Additional 32 genes were inluded in the expression proles from T
Reg
and naive
T ells of both donor groups, but generally showed stronger regulation in IBD. Inter-
estingly, a omparison of this Venn diagram to the one obtained by analysis of RCC
patients [ompare Figure 32℄ revealed that the omposition of genes exlusively altered
between T
Reg
and naive T ells in healthy donors remained almost unhanged, thus
indiating their importane for the maintenane of a healthy T
Reg
ell phenotype. In
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ontrast to that, genes uniquely hanged between T
Reg
and naive T ells in disease
diered onsiderably between RCC and IBD patients, underlining distint dierenes
in T
Reg
ell gene expression for both disorders.
To reveal signiant dierenes in the gene expression proles of CD4
+
CD25
+
T
Reg
between healthy volunteers and IBD patients, miroarray data of the same ell type
but of dierent donor origin had to be ompared. As illustrated in Figure 41, SAM
and hierarhial lustering analysis identied 109 genes dierentially expressed in T
Reg
ells of both donor groups, omposed of 35 up-regulated and 74 down-regulated genes
when omparing IBD to health. In ontrast to previously shown expression proles,
the separation of healthy from IBD T
Reg
ells was not omparably lear as illustrated
by the hosen lustering behaviour. This result is probably aused by the patients
presenting with inative state of IBD. As they are in remission, this ould reet
an inreasing rapprohement of T
Reg
ell gene expression to healthy standard thus
hampering proper lassiation. Comparison of this IBD T
Reg
ell ngerprint to the
one obtained by analysis of RCC patients [see Figure 31℄ revealed a signiantly lower
number of up-regulated genes in IBD versus RCC patients that additionally showed
weaker over-expression. In exhange, more genes were deteted to be down-regulated
in a stronger manner in IBD patients, although the total number of altered genes was
higher in RCC ompared to IBD. These ndings support ideas of a gain-of-funtion
in T
Reg
ells from RCC patients that may mediate enhaned suppressive apaities
enabling tumor immune esape, whereas inreased down-regulation of T
Reg
ell genes
ould point to loss-of-funtions ontributing to insuient regulatory features and thus
to IBD pathogenesis.
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Figure 41: Expression proling of CD4
+
CD25
+
T
Reg
from IBD patients and
healthy donors.
To reveal moleular dierenes between regulatory T ells in IBD patients ompared
to healthy donors dierential expression of 350 genes was investigated by appliation
of the Human T
Reg
Chip. Following data normalization, SAM was applied as a data
mining tool to asertain gene expression hanges, dislosing 68 signiantly altered
genes between both T ell subpopulations (delta = 1.41, median FDR = 0.2). After
entering the generated data set into Genesis software a two-dimensional hierarhial
lustering analysis unovered the displayed transriptional pattern disriminating hu-
man regulatory T ells in IBD patients from those of healthy donors. It onsists of 35
up-regulated and 74 down-regulated genes.
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3.5.2.3 Ative versus inative state of disease and CD versus UC Next,
separate omparison of T
Reg
versus naive T ells from (in)ative CD and inative UC
patients enabled denition of dierenes and similarities in T
Reg
ell gene expression
depending on IBD stage. As illustrated in Figure 42, the number of dierentially
expressed genes between both T ell subpopulations diered onsiderably between pa-
tient ohorts dependent on disease stage: Whereas 58 altered genes (41↑, 17↓) were
revealed in patients suering from ative CD, this number dereased via 42 (28↑, 14↓)
for inative UC to only 34 (17↑, 17↓) in inative CD.
i n a c t i v e  C D  ( C D i ) i n a c t i v e  U C  ( U C i )a c t i v e  C D  ( C D a )
Figure 42: Gene expression proling of CD4
+
CD25
+
T
Reg
versus CD4
+
CD25
−
naive T ells from IBD patients with ative CD (left), inative CD (middle) and
inative UC (right).
To reveal moleular dierenes between regulatory and naive human T ells in distint IBD
states dierential expression of 350 genes was investigated by appliation of the Human T
Reg
Chip. Following data normalization, SAM was applied as a data mining tool to asertain
gene expression hanges, dislosing 58 (CDa), 37 (CDi) and 42 (UCi) signiantly altered
genes between both T ell subpopulations (CDa: delta = 1.08, median FDR = 1.53; CDi:
delta = 1.35, median FDR = 1.09; UCi: delta = 0.65, median FDR 1.52). After entering the
generated data set into Genesis software, a two-dimensional hierarhial lustering analysis
unovered the displayed transriptional pattern disriminating human regulatory from naive
T ells in the investigated IBD stages. Grey ells indiate missing signal intensity values.
80 3 Results
The Venn diagram in Figure 43 summarizes the results of a omparison of the three
transriptional patterns. As depited by the intersetion, only 7 genes were unovered
to be dierentially expressed between T
Reg
and T
naiv
ells in CD versus UC and in-
ative versus ative state of disease. Similarly to observations made between healthy
donors and IBD patients, six of these genes showed strongest regulation in ative CD,
with dereasing fold hanges via inative CD to inative UC, supporting the idea of
a rapprohment of T
Reg
ell gene expression to healthy values. Opposite diretions of
regulation were not disovered. Furthermore, the depited Venn diagram allows identi-
ation of T
Reg
ell genes that either distinguish or unite (inative) CD from (inative)
UC, ative from inative CD and ative CD from inative UC. Expetedly, ative IBD
is haraterized by the highest number of genes dierentially expressed between T
Reg
and naive T ells in the dierene setion (29), whereas the number of regulated genes
in the partiular setion dereased via inative UC (19) to only 9 in inative CD.
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Figure 43: Similarities and dierenes in the gene expression signatures of
T
Reg
ells in ative CD, inative CD and inative UC.
Genes signiantly dierentially expressed between CD4
+
CD25
+
T
Reg
and CD4
+
CD25
-
T ells from IBD patients suering ative CD, inative CD and inative UC, respe-
tively, were summarized in a Venn diagram. As depited by the intersetion, 7 genes
were ontained in the expression proles of all three patient ohorts, but generally
showed strongest regulation in ative CD. Genes were arranged aording to their de-
reasing fold hange between CD4
+
CD25
+
T
Reg
and CD4
+
CD25
-
T ells; red indiates
up-regulated, green means down-regulated genes.
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3.5.3 Conrmation of miroarray data by quantitative real-time RT-PCR
As done before for healthy donors and RCC patients, quantitative real-time RT-PCR
was performed using the original IBD samples to verify the obtained miroarray data.
Referring to FOXP3 as a well-haraterized T
Reg
ell gene, the approah ould be ad-
ditionally onrmed for LGALS3, CCR10, TNFRSF1B and TRAF1 gene expression
[Figure 44A-E℄. Although LGALS3 was exluded by SAM algorithm to be signiantly
dierentially expressed between CD4
+
CD25
+
T
Reg
and CD4
+
CD25
-
T ells in IBD
patients, omparison of fold hanges between healthy donors and IBD patients as ob-
tained by real-time RT-PCR revealed a signiant down-regulation in IBD (healthy:
7.6 ± 3.4 versus IBD: 1.4 ± 0.8, P = 9.9 · 10-4, Figure 44F). Similarly, a signiant
derease in the fold hange of TNFRSF1B gene expression was observed in IBD pa-
tients (healthy: 4.8 ± 1.7 versus IBD: 2.9 ± 1.8, P = 0.04), whereas FOXP3 mRNA
levels expressed as fold hanges showed a signiant inrease in IBD patients (healthy:
11.5 ± 8.7 versus IBD: 29.9 ± 17.2, P = 0.02). Comparing these real-time RT-PCR
results between RCC and IBD patients as well as between ative and inative state of
IBD did not reveal signiant dierenes between patient groups.
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Figure 44: Conrmation of miroarray results in IBD.
Real-time RT-PCR was performed for FOXP3 (A), TNFRSF1B (B), CCR10 (C),
TRAF1 (D), LGALS3 (E), and RPS9 (data not shown) expression in MACS sep-
arated human CD4
+
CD25
+
T
Reg
and CD4
+
CD25
-
naive T ells isolated from IBD
patients. Following normalization to RPS9, relative mRNA amounts in CD4
+
CD25
+
T
Reg
ells were adjusted to orresponding expression levels in CD4
+
CD25
-
naive T
ells and expressed as fold hanges. Real-time RT-PCR results, indiated by blak
bars, were ompared to fold hanges arising from the Human T
Reg
Chip (represented
by white bars). The partiular IBD patients are speied by letters aording to Table
1. Furthermore, mean and median fold hanges for all indiated volunteers are given
for eah gene. (F) illustrates the signiant hanges in the fold hange of LGALS3,
FOXP3 and TNFRSF1B expression in CD4
+
CD25
+
T
Reg
versus CD4
+
CD25
-
naive T
ells from IBD patients () ompared to healthy donors (, *P < 0.04).
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4 Disussion
4.1 Performane of the Human T
Reg
Chip
To ensure measurement of aurate and reliable transription proles, the Human T
Reg
Chip has been validated in terms of ross-platform omparison, sensitivity and re-
produibility. First, a onordane of 81% ould be demonstrated for the detetion
of signiantly regulated genes generated with the Human T
Reg
Chip and Aymetrix
GeneChips, respetively. The question of ross-platform agreement for gene expression
studies has been previously addressed by several investigators, but without lear on-
sensus [107℄. Some groups laimed a signiant divergene omparing spotted oligonu-
leotide arrays (30- to 80-mers) and Aymetrix GeneChips
R© by reporting orrelation
oeients of < 0.6 [108, 109℄ or even only 0.21 [106℄, while others desribed aeptable
onordane levels of 80-90% for suh a platform omparison [110, 111℄. Furthermore,
it was observed that sequene-mathed probes inrease ross-platform onsisteny re-
sulting in a orrelation oeient of ∼ 0.7 for a omparison between Aymetrix and
Agilent 60mer oligonuleotide miroarrays [112℄. Thereby, appliation of dierent tar-
get preparation methods and array surfae hemistries, may in part be responsible
for disrepanies in gene expression measurements aross miroarray platforms. Taken
together, the developed Human T
Reg
Chip demonstrated high omparability to the
Aymetrix approah, showing a orrelation oeient at the upper range of those
desribed in literature. Next, reproduibility of measurements as another quality para-
meter of the Human T
Reg
Chip was assessed. Therefore, idential samples were applied
to dierent Human T
Reg
Chips and signal intensities were ompared to eah other.
The median orrelation oeient yielded from 52 log-log-plots was 0.98, emphasizing
a high degree of internal onsisteny and reliability of the applied miroarray system
[113℄. Customized oligonuleotide miroarrays have been reported to show average or-
relation oeients for repeated experiments of ∼ 0.9 [108℄, while signiantly lower
reliability was obtained for pin-spotted arrays [114℄. Aymetrix' reproduibility has
been desribed as highly reliable, expressed in pairwise orrelation oeients ranging
from 0.96 to almost 1 [115, 116℄. To summarize, the Human T
Reg
Chip provides re-
liability similar to Aymetrix and previously published oligonuleotide miroarrays.
Furthermore, the auray of measurements was determined expressed as oeient of
variane alulated aross eight repliates per gene. It ould be demonstrated, that the
vast majority of signal intensities (74%) alulated for the entire data set varied less
than 30% reeting the robustness of the applied miroarray approah. Finally, bate-
rial ontrol genes at dierent onentrations were used to monitor miroarray system
sensitivity and the spetrum of linear signal measurement. A nal onentration of 0.3
pM was reliably detetable orresponding to one transript in 500,000 or approximately
one opy per ell. Furthermore, a linear regression ould be demonstrated between sig-
nal intensity and onentration overing more than three orders of magnitude. By
onsidering all these results of the evaluation proess, the Human T
Reg
Chip seems to
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represent a reliable and suitable tool failitating researh of human regulatory T ells.
Furthermore, it merges several advantages. Due to its inexpensive prodution osts
it enables extensive miroarray analyses, like e.g. investigation of samples from indivi-
dual donors, thereby avoiding sometimes misleading probe pools and delivering data
reeting similarities as well as individual dierenes. Additionally, experiments an
be repeated in more repliates, allowing alulation of statistial parameters leading to
inreased reliability of the obtained data. Moreover, ustomized miroarrays, suh as
the Human T
Reg
Chip, provide a more foussed view at the partiular question under
examination, thereby preventing unmanageably huge oods of data. To summarize,
the Human T
Reg
Chip enables broad miroarrays analyses at a higher resolution and
lower osts.
4.2 Regulatory T ells in health
4.2.1 Purity of isolated ell frations and frequeny of T
Reg
ells
Reliable and signiant transription proles of human CD4
+
CD25
+
regulatory and
CD4
+
CD25
-
naive T ells an only be obtained if isolation of highly pure T ell subpo-
pulations an be assured. Both T ell frations were separated from peripheral blood
of healthy donors by MACS at purities onsistently greater than 90% for T
Reg
and
more than 85% for naive T ells, respetively. Although, onstitutive expression of
CD25 is a primary harateristi of human T
Reg
ells that allows onsistent isolation
of funtionally suppressive ells from human peripheral blood, CD25 alone is not a
reliable marker for T
Reg
ells in humans [55℄. While mouse T
Reg
ells appear as a dis-
tint CD4
+
CD25
+
T ell population that an easily be distinguished from their naive
ounterparts, human CD4
+
T ells exhibit a more ontinuous and primarily low ex-
pression of CD25. Only 2-4% of human CD4
+
T ells express high levels of CD25,
while up to 30% are CD25
low
or CD25
int
. This staining ontinuum ompliates reliable
disrimination between human regulatory and non-regulatory T ells and requires addi-
tional analysis of more spei markers [56℄. As FOXP3 is the most suitable human
T
Reg
ell marker urrently available, its protein expression was examined in MACS
separated T
Reg
ells by FACS during this study. Thereby, learly more than 80% of
the ells were found to express FOXP3 intraellularly. Ronador et al.were the rst
to demonstrate that the majority of human CD4
+
CD25
+
T ells express FOXP3 and
that the frequeny of FOXP3
+
ells strongly orrelates with their CD25 expression
level. They found almost 96% of CD4
+
CD25
high
T
Reg
ells to express FOXP3, while
only 35% of the CD25
int
ells were FOXP3
+
, indiating that human regulatory T ell
ativity is mainly enrihed within the CD4
+
CD25
high
pool [71℄. Compared to these
ndings, slightly lower FOXP3 frequenies were obtained within the T
Reg
ell fration
in this work, probably due to staining with a dierent antibody and to ontaminating
ells. Sine CD25 is urrently the most useful marker for identiation and isolation,
it is more or less impossible to avoid ontamination with eetor ells [190℄. There-
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fore, phenotype of these remaining ells was determined and demonstrated to represent
mainly natural killer ells and to a lower level, CD8
+
T ells, B ells and monoytes.
Nevertheless, the isolated CD4
+
CD25
+
regulatory T ells showed anergi behaviour
in vitro and well onrmed their suppressive apaity in proliferation assays. These
ndings indiate that the MACS separated CD4
+
CD25
+
T ell population was mainly
assembled by human CD4
+
CD25
high
T
Reg
ells. Enrihment of funtional and phe-
notypi human T
Reg
ells by MACS was further onrmed by the expression prole
obtained by appliation of the Human T
Reg
Chip [Figure 20℄. It diretly reeted
previously desribed T
Reg
ell surfae markers, suh as elevated expression of IL2RA,
TFRC, CTLA4 and HLA-DR in the MACS separated CD4
+
CD25
+
T ells ompared
to their naive ounterparts [Figure 21℄.
4.2.2 Gene expression signatures of CD4
+
CD25
+
T
Reg
ells
RNA was synthesized from CD4
+
CD25
+
regulatory and CD4
+
CD25
-
naive T ells
isolated from peripheral blood of 11 healthy donors and hybridized to the Human T
Reg
Chip in order to obtain aurate and reliable individual transription proles improving
moleular haraterization of these T ell frations. Altogether, 62 genes were identied
to be signiantly dierentially expressed in regulatory ompared to naive T ells.
4.2.2.1 FOXP3 aeted gene expression Among them, nine genes were re-
vealed that have also been demonstrated to be aeted by retroviral over-expression
of FOXP3 in CD4
+
T
H
ells: LGALS3, CCR7, IL2RA (CD25), TNFRSF1B, CTLA4
and TRAF1 were found to be up-regulated in T
Reg
versus naive T ells as well as in
FOXP3 transdued CD4
+
T
H
ells ompared to their ontrol ells. In ontrast to that,
SATB1, GZMK and IL7R gene expression was redued when omparing the partiular
ell types in both experiments. Regarding their gene expression proles, these ndings
indiate that CD4
+
T
H
ells infeted with the FOXP3 enoding retrovirus do at least
partially resemble ex vivo isolated T
Reg
ells. Similarly, a reent miroarray study
also examined Foxp3-dependent and -independent moleules spei for CD4
+
CD25
+
naturally ourring T
Reg
ells, but in the mouse [189℄. They ould also demonstrate
up-regulation of IL2RA and down-regulation of SATB1 in ex vivo T
Reg
versus naive T
ells as well as in Foxp3 versus mok transdued murine T ells thereby onrming the
ndings of this study and adding data about similarities between mouse and human
T
Reg
ells.
4.2.2.2 Signaling modules in T
Reg
ells Pathway analysis allowed objetive
examination of the presented experimental miroarray data in the ontext of known
genome-wide interations by providing more insights into the biologial proesses and
omplex signaling networks underlying human T
Reg
ell immunology. Appliation
of PathwayAssist software to the unique gene expression data set of human regula-
tory and naive T ells revealed funtional modules pointing to mehanisms ontrolling
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survival/apoptosis, T ell reeptor signaling/ativation/proliferation and dierentia-
tion/maintenane of human T
Reg
ells.
4.2.2.2.1 Genes ontrolling survival/apoptosis of T
Reg
ells Naturally
ourring T
Reg
ells survive lonal deletion during their development in the thymus by
esape from ativation-indued ell death (AICD). This protetive mehanism seems to
be maintained in T
Reg
ells enountered in the periphery as a signaling module ould
be identied that ounterats apoptosis and mediates the release of survival fators
[Figure 45℄.
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Figure 45: Funtional dissetion of signaling modules in human T
Reg
ells.
Shemati representation of potential signaling pathways involving genes that ontrol
survival/apoptosis of human regulatory T ells thereby mediating T
Reg
ell funtio-
nality. Transriptional up-regulation of genes in T
Reg
versus naive T ells is marked
by red symbols, whereas green symbols represent down-regulated genes. Symbols lled
with grey depit unaeted genes or summarize pathway modules.
During this analysis, FOXP3 induible up-regulation of tumor nerosis fator re-
eptor superfamily member 1B (TNFRSF1B, TNF-RII) was found upon retroviral
over-expression in CD4
+
CD25
-
T ells [Figure 10℄. TNFRSF1B was also up-regulated
in the ex vivo isolated CD4
+
CD25
+
T
Reg
ells from individual healthy donors (Fi-
gure 20). TNFRSF1B belongs to a group of trans-membrane TNF reeptor moleules
haraterized by TNF reeptor-assoiated fator (TRAF)-interating motifs (TIMs).
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Ativation of TIM ontaining TNF reeptors leads to the reruitment of TRAF fami-
ly members, subsequent ativation of signal transdution pathways like NF-κB, JNK,
p38, ERK (extraellular signal-related kinase) or PI3K (phosphoinositide 3-kinase),
that in turn inuene immune responses and inrease the expression of survival fators
[122, 123℄. Well in line, a signiant up-regulation of TRAF1 was also revealed in this
study in both, FOXP3 transfeted CD4
+
CD25
-
T ells and ex vivo isolated human
T
Reg
ells.
This mehanism is linked to additional moleules ontrolling the nulear translo-
ation and onsequently ativity of TP53 (tumor protein p53), a tumor suppressor
gene induing ell growth arrest or apoptosis [124℄. While TIAF1 (TGFB-1 indued
anti-apoptoti fator 1) interats with TP53 in the ytosol and may partiipate in
its nulear transloation, TP53INP1 (TP53 induible nulear protein 1) is engaged in
the regulation of TP53 ativity in the nuleus [125, 126℄. Both genes, TP53INP1 and
TIAF1 were found to be over-expressed in the naturally ourring T
Reg
ells in the
presented study. Apart from this, TIAF1 is known to be up-regulated in T
H
2 versus
T
H
1 lymphoytes and its funtional role as an apoptosis protetor is disussed [127℄.
S100A4 was also identied as up-regulated in the naturally ourring T
Reg
ells
from the analysed individual healthy donors. S100A4 is a member of the S100 fami-
ly of proteins ontaining 2 EF hand alium binding motifs. Its expression is TP53
dependent and S100A4 is involved in the regulation of ell yle progression and dif-
ferentiation. Together with S100B, S100A4 is hypothesized to ontrol tetramerization
of TP53 leading to its nulear transloation [128, 129℄. TP53 an ativate the ex-
trinsi apoptoti pathway through the indution of TNF reeptor family members,
like FAS and TNFRSF10B [124, 130℄. Both TNF reeptors are haraterized by their
ytoplasmi death domain whih is responsible for transmission of apoptoti signals.
Ativation of these reeptors leads to the reruitment of intraellular death domain on-
taining adaptors suh as FAS-assoiated death domain (FADD) or TNFR assoiated
death domain (TRADD). These moleules ativate the aspase asade and subse-
quently indue apoptosis. The death domain learly separates these TNF reeptors
from TNFRSF1B [122℄. As a potential onsequene of the assumed TP53 inativation
in T
Reg
ells TNFRSF10B expression ould be impaired.
Further evidene supporting this assumption was provided by another diret tar-
get of TP53. PTTG1 expression (pituitary tumor-transforming 1), that was revealed
to be up-regulated in the naturally ourring T
Reg
ells during this study, an be
diretly repressed by ativated TP53 in oloretal aner ells. RNAi mediated knok-
down of PTTG1 was suient to indue apoptosis suggesting that repression of novel
anti-apoptoti genes by ative TP53 an signiantly ontribute to apoptosis [130℄.
Controversially, it was reported that PTTG1 an ativate TP53 and BAX to inrease
apoptoti funtion, but this seems to be rather an indiret eet of PTTG1 and is addi-
tionally dependent on other fators, suh as MYC, whih was found down-regulated in
the naturally ourring human T
Reg
ells [131℄. Interestingly, -MYC is a diret down-
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stream target of PTTG1, whih is part of the DNA binding omplex formed near the
transription initiation site of the -MYC promoter [132℄.
During this work, additional genes were deteted to be down-regulated in human
T
Reg
ells aeting the ativation status of TP53. In lung aner ells, it was shown that
FHIT (fragile histidine triad gene) mediates MDM2 inativation. The anti-apoptoti
moleule MDM2 is ativated through the PI3K-AKT pathway leading to inativation
of TP53 [133℄. Thus, down-regulation of FHIT also ontributes to the inative status
of TP53.
Based on this data, destabilization and thereby inativation of TP53 may be sug-
gested to provoke a shift in T
Reg
ells from apoptoti sensitivity to protetion and sur-
vival. It is tempting to speulate that this mehanism allows T
Reg
ells to survive upon
re-ativation, whereas eetor T ells underlie ativation-indued ell death (AICD).
This apoptoti proess eliminates the expanded pool of eetor lymphoytes during
the ontration phase of the immune response and maintains lymphoyte homeostasis.
In line with the presented ndings, murine T
Reg
ells were reported to be more re-
sistant to apoptosis when treated with dexamethasone or anti-CD95 Ab than CD4
+
total or CD4
+
CD25
-
eetor T ells [134, 135℄. Moreover, Fritzshing et al. and Wang
et al.demonstrated that human T
Reg
ells are less sensitive to ativation-indued ell
death than their naïve ounterparts [136, 104℄.
Galetin-3 (LGALS3) is one of the best haraterized members of the evolutio-
nary onserved family of galetins and was found to be strongly up-regulated in the
ex vivo isolated T
Reg
ells [Figure 20℄. In addition, LGALS3 was also indued upon
FOXP3 over-expression in CD4
+
CD25
-
T ells [Figure 10℄. This is of speial interest
as LGALS3 is known to partiipate in apoptosis ontrol. Whereas its seretion triggers
apoptoti signal asades on T ells [137℄, intraellular expressed LGALS3 ats as an
anti-apoptoti moleule [138, 139, 140℄. The underlying mehanism was revealed in
marophages, suggesting that LGALS3 may prevent alterations of the mitohondrial
membrane and formation of reative oxygen speies. Moreover, it has been reported
that LGALS3 phosphorylation is neessary for its anti-apoptoti ativity. Taken to-
gether, the inreased expression level of LGALS3 further supports the idea of a shifted
balane towards survival and tness of T
Reg
ells.
4.2.2.2.2 Genes ontrolling TCR signaling, ativation and proliferation
of T
Reg
ells The seond module that was revealed in this study involves genes
ontrolling T ell reeptor (TCR) signaling, ativation and proliferation of human T
Reg
ells [Figure 46℄.
Galetin-1 (LGALS1) antagonizes T-ell ativation by partial phosphorylation of
the TCR-ζ hain [141℄, an blok seretion of pro-inammatory ytokines suh as IL2
and skews the balane towards a T
H
2-type ytokine prole [142, 143℄. Dimeri LGALS1
triggers immunosuppressive IL10 prodution in T ells ontributing to their immune
regulatory funtion [144℄. LGALS3 an potentially form omplexes on the TCR with
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Figure 46: Funtional dissetion of signaling modules in human T
Reg
ells.
Shemati representation of potential signaling pathways involving genes that on-
trol TCR signaling/ativation/proliferation and dierentiation/maintenane of human
regulatory T ells thereby mediating T
Reg
ell funtionality. Transriptional up-
regulation of genes in T
Reg
versus naive T ells is marked by red symbols, whereas
green symbols represent down-regulated genes. Symbols lled with grey depit unaf-
feted genes or summarize pathway modules.
N-glyans thereby limiting its lateral mobility resulting in restrited TCR-mediated
signaling on T ells [137℄. Hene, it may be suggested that up-regulation of both
galetins in T
Reg
ells results in a modulation of their ytokine prole thereby allowing
appropriate regulation of eetor ells and immune ell homeostasis.
This module also identied a set of genes like CTLA4, TNFRSF1B and PIM1
that ontrols proliferation within the ell [Figure 46℄. CTLA4 plays a major role in
inhibiting proliferation of T
Reg
ells. It is an ativation-indued homo-dimeri glyo-
protein reeptor on T ells interating with the B7 ligands on the surfae of antigen
presenting ells (APC). The mehanism of T ell inativation involves antagonism
of CD28-dependent o-stimulation and diret negative signaling through its ytoplas-
mi tail. When engaged by B7, CTLA4 plays a key role as a negative regulator of
T ell ativation through down-regulation of ytokine prodution by preventing the
aumulation of AP-1, NF-κB and NFAT in the nuleus. CTLA4 was found to be
up-regulated in the human T
Reg
ells analysed during this work. Its expression has
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been linked to enhaned suppressor ativity and higher expression of FOXP3 in human
T
Reg
ells. However, the blokade of CTLA4 resulted in a signiant but inomplete
loss of suppressor ativity [145℄. In addition to CTLA4, TNFRSF1B was also found to
be up-regulated in the isolated human T
Reg
ells in the presented study. TNFRSF1B
is known to be diretly o-stimulatory to TCR-mediated ativation in human T ells
thereby induing ativation markers, like CD25. In ontrast to CD28 o-stimulation,
ross-linking of TNFRSF1B shows signiant dierenes and triggers dierent signa-
ling pathways resulting in a modied ytokine prole. TNFRSF1B has the apaity
to down-regulate early TCR/CD28 indued Ca
2+
mobilization and to inhibit T-ell
funtions suh as IL2 and IL10 prodution [146℄. In omparison to ativated naïve T
ells the proliferation of T
Reg
ells in response to IL2 is quite low, although the reeptor
for this ytokine is signiantly up-regulated. A serine/threonine kinase alled PIM1
ould be identied during this projet that diretly trans-ativates NFAT at the end
of the Ras signaling asade to failitate IL2 dependent proliferation and/or survival
of lymphoid ells. Furthermore, PIM1 enhanes NFAT-dependent trans-ativation and
IL2 prodution in Jurkat T ells [147℄. As PIM1 is down-regulated in T
Reg
ells from
individual healthy donors, a redued signal transmission to NFAT ould be proposed
mediating less responsiveness to IL2 resulting in lower proliferation of T
Reg
ells.
4.2.2.2.3 Genes ontrolling dierentiation and maintenane of T
Reg
ells
A third module extrated by the performed pathway analysis involves genes ontrol-
ling T
Reg
ell dierentiation and maintenane upon maturation in the thymus [Figure
46℄. The dierentiation of naïve T ells is indued by TCR ativation and either
IL12/STAT4 or IL4/STAT6 signaling pathways leading to a T
H
1/T
H
2 lineage spei-
ation that is further direted by the transription fators T-bet and GATA3, re-
spetively. STAT4 and STAT6 were both down-regulated in the peripheral T
Reg
ells
analysed in the presented study indiating a potential inability to be transformed into
T
H
ells upon re-stimulation via their TCR [Figure 20℄. Coexpression of GATA3 and
FOXP3, but the lak of T-bet, may point to similarities in the gene expression proles
of T
H
2 and T
Reg
ells in humans.
In a reent study, transription proles of T
H
1 and T
H
2 ells isolated from human
ord blood were analysed [150℄. Although the overall onordane to the presented
T
Reg
ell data set is quite low, some genes ould be deteted to be similarly regulated in
T
H
2 and T
Reg
versus naïve T ells (TCF7, GZMA, S100 family members). However,
a few genes showed opposite expression behavior in T
H
2 ells ompared to the T
Reg
ells (SATB1 and ACTN1 were up-regulated in T
H
2 and down-regulated in T
Reg
ells).
SATB1 and TCF7 are transription fators funtionally similar to GATA3 that have
important funtions in early thymoyte development [148, 149℄. For genes that were
dierentially expressed in T
H
1 versus naïve T ells no similarities to the obtained
T
Reg
ell data set ould be observed. In summary, these data underline the idea that
like their murine homologues, human T
Reg
ells represent a separate lineage. They
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are undergoing a unique dierentiation pathway distint from those ommitting T
H
1
or T
H
2 ells and are therefore equipped with a tightly regulated set of transription
fators ating in addition to FOXP3.
Another important question is how T
Reg
ell populations are regulated and main-
tained in the periphery. There is growing evidene favoring IL7 as a master regulator of
T ell homeostasis, based upon its essential role in the homeostati expansion of naïve
T ells in response to low anity antigens and its apaity to dramatially enhane
expansion of peripheral T ells in response to high anity antigens [151℄. Analyzing
a lonal population of mouse CD4
+
CD25
+
T
Reg
ells, it was demonstrated that these
ells do not proliferate in response to lymphopenia in the absene of the seleting self-
peptide. This was in ontrast to the naïve T ell proliferation behavior reeting the
lower IL7 reeptor (IL7R) expression levels in regulatory ompared to naïve T ells
[152℄, whih was also supported by the data presented in this study. Additionally, it
was shown that GATA3 bloks IL7R expression in early stages of T ell development
[153℄. As self-antigen presentation in ombination with IL7 expression promotes T
Reg
ell proliferation, it ould be assumed that this mehanism ontributes to the spei
aumulation of T
Reg
ells at sites where their self-antigen is presented.
4.2.2.3 Impliations in T
Reg
ell mediated diseases Regulatory T ells play
a fundamental role in the balane of more or less all immune responses. Thus, develop-
mental or funtional deienies in T
Reg
ells ould favor disease pathogenesis. Not only
modied T
Reg
ell frequenies, but also gaps in their TCR immune repertoire or geneti
polymorphisms leading to aberrant ativation, funtion, survival or homing properties
of T
Reg
ells ould be oneivable mehanisms [190℄. The vast majority of genes iden-
tied as dierentially expressed in CD4
+
CD25
+
regulatory versus CD4
+
CD25
-
naïve
T ells onstituting the presented ngerprint of human T
Reg
ells has not yet been
desribed in the ontext of T
Reg
ells. As T
Reg
ells have a far-reahing eet on our
health it was investigated, whether these genes have been reported to ontribute to
pathogenesis in autoimmunity, transplantation tolerane, aner and even allergy [Ta-
ble 3℄. Strikingly, most of the genes (51 out of 62) were revealed to be impliated in at
least one of these disease senarios underlining their possible importane in funtion
and development of T
Reg
ells.
4.2.2.3.1 Seleted genes involved in autoimmune diseases Autoimmu-
nity ours as a onsequene of self-tolerane break-down presumably resulting from a
ombination of inherited polymorphisms (or DNA variations), aquired environmental
triggers and stohasti events [154℄. Analyzing the transriptional pattern of human
T
Reg
ells isolated from individual healthy donors, 32 genes were revealed to be in-
volved in the pathogenesis of diverse autoimmune diseases [Table 3℄. The following
disussion will fous only on a few aeted genes that are entral of the funtional
modules desribed above and that might therefore inuene disease pathogenesis.
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For example, TNFRSF1B was shown to be 2.5-fold over-expressed in the natu-
rally ourring T
Reg
ells ompared to their naïve ounterparts. A single nuleotide
polymorphism (SNP) in this gene was reported to inuene suseptibility to multiple
slerosis, a severe inammatory autoimmune disorder of the entral nervous system
[81℄. In addition, Sashio et al. linked two other polymorphisms to the TNFRSF1B
gene lous that inrease suseptibility to Crohn's disease and ulerative olitis, whih
are both hroni inammatory diseases of the gastrointestinal trat [82℄. In Japanese
patients, Morita et al. identied another SNP in the TNFRSF1B gene assoiated with
systemi lupus erythematosus (SLE) , a hroni, relapsing, inammatory and often
febrile multisystemi disorder of autoimmune origin [155℄.
Type I diabetes is a T-ell mediated inammatory autoimmune disease of the en-
dorine panreas, resulting in lak of insulin aused by beta ell destrution. Alto-
gether, 18 genes were inluded in the presented human T
Reg
ell signature that have
been reported to ontribute to pathogenesis of this disease, e.g. granzyme A (GZMA)
[156℄, the CD40 ligand (TNFSF5) [157, 158℄, CTLA4 [83℄ and the T-ell spei trans-
ription fator 7 (TCF7) [159℄. Furthermore, two polymorphisms in the HLA-DRB1
gene, whih was found over-expressed in T
Reg
ells, have been desribed to onfer
high-risk suseptibility [160℄.
Rheumatoid arthritis (RA) is a hroni inammatory disorder aeting the joints
probably aused by autoimmune mehanisms. 21 T
Reg
ell spei genes revealed in
this study have been desribed as suseptibility genes for RA. For example, LGALS3
[161, 162℄, GZMA [163℄ and the S100 alium binding protein A4 (S100A4) [164℄ were
desribed as highly expressed in the synovial tissue and at sites of joint destrution
ontributing to the inammatory proess. The omplex geneti omponent of RA
etiology was further demonstrated by the disovery of multiple polymorphisms, for
example in genes of the hemokine reeptor 5 (CCR5) [84℄ and of HLA-DRB1 [165℄,
onferring high risk suseptibility.
In mie deient for signal transduer and ativator of transription 4 (STAT4), a
gene also found to be down-regulated in the analysed human T
Reg
ells, RA is sup-
pressed due to redued levels of IL12 and INF-γ [166℄. Interestingly, STAT4-/- mie
were additionally almost ompletely proteted from diabetes [167℄ and the indution
of experimental allergi enephalomyelitis [168℄ underlining the importane of STAT4
down-regulation in T
Reg
ells for their proper immune regulatory funtion.
As T
Reg
ells are essential for the maintenane of self-tolerane, SNPs or mutations
aeting genes expressed in T
Reg
ells may result in the synthesis of aberrant mRNAs
and proteins whih in turn ould impair T
Reg
ell funtion and/or development leading
to higher risks for autoimmunity. Additionally, failures in gene regulation resulting in
inadequate protein amounts ould disturb appropriate T
Reg
ell ativity thereby most
likely ontributing to the pathogenesis of autoimmune disorders.
As most of the genes disussed here, are entral omponents of the funtional mo-
dules disussed in hapter 4.2.2.2, it is oneivable that the dys-regulation of one or
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more of these genes aet T
Reg
ell ation in terms of survival/apoptosis, dierentiation,
proliferation and suppressor funtion thereby promoting break-down of self-tolerane
eventually leading to autoimmunity. However, further researh is needed in order to
better understand the omplex mehanisms of geneti bakground and environmental
fators that ontrol the development of autoimmunity.
4.2.2.3.2 Seleted genes involved in aner T
Reg
ells are haraterized
by their ability to suppress host immune responses and to indue self-tolerane. At
tumor sites, antigen-spei T
Reg
ells are supposed to attenuate anti-tumor immunity
[169, 170, 171, 172℄. Elevated frequenies of CD4
+
CD25
+
T
Reg
ells with funtional
suppressive ativity were reently reported in tumors and blood of patients suering
from dierent human aners, among them lung, breast and ovarian tumors [86, 90, 91℄,
hepatoellular [40℄ and squamous ell head and nek arinoma [39℄ as well as in hroni
lymphoyti leukemia [41℄. Furthermore, elimination of T
Reg
ells in mouse models
enhaned anti-tumor responses [173, 174, 170℄. In addition to the T
Reg
ell media-
ted immunosuppressive miroenvironment, the tumor itself an esape from immune
surveillane by ounterating apoptoti signals delivered by ativated immune ells.
Strikingly, a high degree of onordane in gene expression ould be observed during
data analysis ontributing to both T
Reg
ell ativity and tumor survival.
44 out of the 62 spei T
Reg
ell genes reported in this study are also expressed
by tumor ells thereby partiipating in aner development and progression [Table
3℄. Among them, one an nd several tumor suppressors (like STAT4, FHIT and
TNFRSF10B) as well as proto-onogenes (e.g. PIM1, MYC, XBP1 and PTTG1): For
example, aberrant transripts or omplete lak of the fragile histidine triad gene FHIT
were observed in esophageal, stomah, olon [175℄ and lear ell renal arinomas [176℄
as well as in lung [177℄, head and nek [178℄ and ervial aner [179℄. Furthermore,
inativation of one or both Fhit alleles in mie dramatially inreased development of
multiple tumors, underlining the importane of FHIT as a tumor suppressor gene [180℄.
Down-regulated FHIT expression was found in human T
Reg
ells in this study, while
the pituitary tumor-transforming 1 gene (PTTG1) was revealed to be over-expressed
in T
Reg
ells [Figure 20℄. High PTTG1 expression levels have been reported in various
human tumors, inluding pituitary, adrenal, kidney, liver and ovarian aner resulting
from enhaned ell proliferation and ellular transformation [181℄.
Furthermore, it ould be demonstrated that LGALS3, whih is a member of the
β-galatoside-binding gene family, was highly up-regulated in regulatory versus naïve
T ells and was indued upon retroviral over-expression of FOXP3 in CD4
+
CD25
-
T
ells. This multifuntional protein has been impliated in tumor ell adhesion, pro-
liferation, dierentiation, angiogenesis, aner progression and metastasis [138℄. In-
traellular LGALS3 exhibits anti-apoptoti ativity thus ontributing to ell survival
[139, 140℄. Conversely, extraellular LGALS3 was additionally shown to be sereted by
tumor ells themselves in order to indue apoptosis of aner-inltrating ells thereby
supporting tumor immune esape [137℄.
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As reeted by their o-regulated gene repertoire, both T
Reg
and tumor ells may
employ similar mehanisms to mediate immune suppression in their partiular miroen-
vironment. Ativated T ells direted against the tumor or against self-antigens are
ontrolled by both ell types either to esape from immune surveillane or to protet
from autoimmunity. Furthermore, inreasing evidene argues that up-regulation of
T
Reg
ell frequenies observed in aner patients is tumor driven [172℄. This supports
the idea of partly onordant pathways leading to the indution of tolerane towards
antigens enountered under diverse linial onditions ranging from autoimmunity to
aner.
4.2.2.3.3 Seleted genes involved in transplantation tolerane As part
of their immune suppressive funtion, T
Reg
ells are able to indue transplantation
tolerane thereby ontributing to graft survival [44, 42℄. Out of the 62 T
Reg
ell spei
genes, 20 andidates have been desribed to inuene graft fate [Table 3℄. CCR5 up-
regulation was shown in T
Reg
ells in the presented work, whih is onordant with
reent results demonstrating that CCR5 is essential for preventing graft-versus-host
disease (GvHD) in murine models. In their study, Wysoki et. al demonstrated that
CCR5 is not only guiding T
Reg
ells to lymphoid tissues in order to down-regulate
eetor ell populations, but also allows their migration to GvHD target tissues to
improve graft survival [96℄. Another gene found over-expressed in the analysed T
Reg
ells is the TGFB1-indued anti-apoptoti fator 1 (TIAF1). It was reported that
TIAF1 expression in lymphoytes during hroni kidney and liver allograft rejetion
may protet these ells from apoptosis [127℄. Furthermore, down-regulated expression
of interleukin 7 reeptor (IL7R) and hemokine (C-C motif) reeptor 7 (CCR7) ould
be demonstrated in this study. CCR7 is a lymphoid-spei member of the G protein-
oupled reeptor family that together with its ligands regulates T ell migration to
seondary lymphoid organs [182℄. CCR7
-/-
mie ompletely failed to rejet MHC lass I
mismathed grafts impliating its entral role in transplant rejetion [183℄. Antagonists
of CCR7 ligands were additionally demonstrated to provide beneial eets for the
prevention of hroni GvHD in mie by bloking the homing of donor CCR7-expressing
T ells into the reipients lymphoid organs [184℄. Furthermore, it was shown, that
binding of IL7 to its reeptor enhanes peripheral T ell reonstitution after allogenei
hematopoieti stem ell transplantation by seletively mediating proliferation and anti-
apoptoti eets to non-alloreative and de novo-generated T ells [185℄.
Taken together, the genes reported here to aet transplantation tolerane are
important mediators of a balaned immune response by ontrolling migration, apoptosis
and survival of T ells.
4.2.2.3.4 Seleted genes impliated in allergy Allergi hyper-reativity is
haraterized by an exaggerated immune response towards harmless antigens aused
by dysregulated responsiveness of T
H
2 ells [99℄. During the allergi immune response
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high levels of the T
H
2 ytokines IL4, IL5 and IL15 are produed, leading to seretion
of allergen-spei IgE and reruitment of eosinophils [190℄. The ability of regulatory
T ells to suppress T
H
2 ytokine prodution suggests that T
Reg
ells play an important
part in the development of tolerane to allergens [100℄. Out of the 62 genes onsti-
tuting the presented T
Reg
ell expression prole, 19 andidates have been desribed
to be impliated in allergi disease pathogenesis, inluding suh diverse disorders like
e.g. asthma, psoriasis or elia disease [Table 3℄.
For example, the G protein-oupled reeptor 2 (GPR2 or CCR10) is known as
a skin-homing reeptor and its up-regulation and interation with its ligand CCL27
was demonstrated in skin lesions of atopi dermatitis, ontat dermatitis and psoriasis
patients [186℄. CCR10 was found to be over-expressed in human T
Reg
ells ompared
to their naive ounterparts isolated from healthy donors during this work.
The hemokine (C-C motif) ligand 5 (CCL5, also known as RANTES), whih was
revealed to be down-regulated in regulatory versus naïve human T ells, was shown to
play a ruial role as a mediator in the immuno-pathogenesis of house dust mite-indued
hroni bronhitis. Inreasing CCL5 serum levels orrelated with disease progression
from stable via hroni bronhitis to asthma [187℄. Furthermore a polymorphism in the
RANTES promoter was assoiated with sensitization to at and mold allergens [250℄,
underlining the importane of CCL5 for adequate T
Reg
ell funtion.
4.2.3 More news about the phenotype of human regulatory T ells
Quantitative real-time RT-PCR on seleted transripts was performed as a sensitive
independent veriation method of the presented miroarray results. Therefore, well-
aepted T
Reg
ell spei genes have been hosen, suh as FOXP3, CTLA4 and CCR7,
as well as ve newly revealed andidate genes (LGALS3, TNFRSF1B, CCR10, CCR5,
TRAF1). For all these seleted genes a high orrelation between PCR and miroar-
ray results ould be demonstrate thereby lending ondene to the reditability of the
applied miroarray approah and suggesting a possible role of the 41 "new players" in
human T
Reg
ell ativity. Observed quantitative dierenes in the fold hanges have
been desribed before; espeially an underestimation of real expression hanges by mi-
roarray approah versus quantitative RT-PCR has been reported [108, 121℄ and is
thought to result at least partly from the applied normalization proedure. Besides
validating the miroarray data, quantitative RT-PCR also onrmed the applied ell
separation strategy yielding highly pure regulatory as well as naive T ells. As des-
ribed above, FOXP3 is ruial for development and funtion of CD4
+
CD25
+
T
Reg
ells and is generally aepted as their most spei moleular marker available to
date [52℄. FOXP3 was found to be up-regulated 2.5fold by miroarray and 11.6fold
by qRT-PCR in regulatory ompared to naive T ells, thereby underlining the regula-
tory phenotype of the isolated CD4
+
CD25
+
T
Reg
ells. The observed fold hanges for
FOXP3 expression are similar to those desribed previously for CD4
+
CD25
high
T
Reg
ells versus CD4
+
CD25
−
naive T ells isolated by MACS tehnology from peripheral
blood of healthy donors [41, 234℄.
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After onrming elevated gene expression of LGALS3, CCR10, CCR5, TRAF1 and
TNFRSF1B on mRNA level in human CD4
+
CD25
high
T
Reg
versus CD4
+
CD25
−
naive
T ells, three andidates were seleted to verify their up-regulation on protein level.
LGALS3 was hosen beause it showed highest over-expression in T
Reg
ells among
the 41 new andidate genes revealed by miroarray analyses. TNFRSF1B and CCR10
were seleted for their possible qualiation as onvenient T
Reg
ell markers as both
proteins are expressed at the ell surfae. Applying FACS analysis, statistially sig-
niant higher amounts of LGALS3 and TNFRSF1B protein expression ould be on-
rmed in human CD4
+
CD25
high
T
Reg
ells ompared to CD4
+
CD25
-
T ells of healthy
donors. Compared to FOXP3 as the urrently most aepted T
Reg
ell marker, both
proteins were expressed by a similar fration of CD4
+
T ells. To our knowledge, this
is the rst study demonstrating LGALS3 and TNFRSF1B up-regulation on mRNA
and protein level in human peripheral blood CD4
+
CD25
high
T
Reg
ells ompared to
their naive ounterparts [196, 197℄. Only one study investigating human CD4
+
CD25
+
T ells puried from postnatal thymuses assessed TNFRSF1B gene and protein ex-
pression. They found that almost all of these CD4
+
CD25
+
thymoytes onstitutively
over-expressed TNFRSF1B mRNA and protein ompared to CD4
+
CD25
-
T ells. They
explain dierenes in gene/protein expression between peripheral blood and thymus-
derived human T
Reg
ells by the fat that CD4
+
CD25
+
thymoytes represent a more
homogenous population [194℄. Again onsistent with the ndings presented here, an-
other study on mouse T
Reg
ells reported TNFRSF1B up-regulation on mRNA level in
regulatory versus naive T ells.
It is now widely aepted, that natural T
Reg
ells are positively seleted in the
thymi ortex through their TCR interations with self-peptides presented by thymi
stromal ells. Probably during this high-anity reognition T
Reg
ells reeive signals
rendering them anergi and able to produe anti-apoptoti moleules whih protet
them from apoptosis [194℄. The results presented here in this study may suggest that
TNFRSF1B is one of these protetive moleules as signals derived from this reeptor
inhibit TCR-indued apoptosis and prolong survival [122℄. Furthermore, TNFRSF1B
indution seems to be an important proess in thymi T
Reg
ell maturation as its over-
expression is maintained in mouse and human T
Reg
ells entering the periphery. This
hypothesis is further supported by the shown up-regulation of LGALS3 gene and pro-
tein expression in human peripheral blood T
Reg
ells. Galetin-3 is the only member
in its galetin family that possesses anti-apoptoti abilities when expressed intrael-
lularly [139, 138℄. LGALS3 was shown to protet T ells, marophages and various
arinoma ells from ell death triggered by a variety of agents [195℄. As disussed
in more detail before (hapter 4.2.2.2.1), the performed analyses revealed even more
moleules involved in apoptosis ontrol whih were summarized in a funtional module
ounterating apoptosis. Combined Annexin and PI staining followed by subsequent
FACS analysis indeed onrmed that human T
Reg
ells are less suseptible towards
apoptoti ell death than their naive ounterparts thereby supporting the idea of a
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shifted balane towards survival and tness of T
Reg
ells. Well in line with these n-
dings is a mouse study investigating the thymi seletion of CD25
+
T
Reg
ells. It points
out that regulatory T ells seem to be more resistant to lonal deletion than their naive
ounterparts resulting in seletive survival [191℄.
Next, oexpression of LGALS3 and TNFRSF1B, respetively, with FOXP3 protein
was onrmed on a small fration of CD4
+
T ells and revealed an even more ex-
tended population that was just single positive for either LGALS3 or TNFRSF1B but
expressed no FOXP3 protein. Furthermore, a fration of CD4
+
ells ould be inden-
tied expressing FOXP3 protein but laking expression of LGALS3 and TNFRSF1B,
respetively. Expression of LGALS3 has been observed in dierent ell types and tis-
sues, among them monoytes and marophages, DCs, mast ells, granuloytes and
murine T ells [135℄. Furthermore, TNFRSF1B expression was shown in resting and
ativated human T ells [122℄ thereby also supporting the obtained ndings. Whether
the various subpopulations identied dier in their suppressive ativity remains to be
eluidated. For example, it has been reported that among CD4
+
CD25
+
T ells those
expressing CD103 (ITGAE) or CD62L are more potent suppressors than their negative
ounterparts [69℄. Within the CD4
+
CD25
+
T ell subset, CD27, that like TNFRSF1B
belongs to the TNFR family, was demonstrated to disriminate regulatory from a-
tivated eetor T ells. The highest frequeny of FOXP3
+
ells was thereby found
in the CD4
+
CD25
+
CD27
+
subset, but was only 42%. Nevertheless, suppressive a-
tivity was restrited to this CD4
+
CD25
+
CD27
+
subpopulation. In ontrast to that,
CD4
+
CD25
+
CD27
-
T ells still ontained 6.2% FOXP3
+
ells but did not inuene
proliferation of responder ells at all [72℄. Thus, FOXP3 an also be indued in on-
ventional T ells upon ativation showing no suppressive apaity [16, 73℄. Hene, it
is tempting to speulate that apart from FOXP3, other moleules or more probably
ombinations of them might be able to onfer regulatory apaities. In ontrast to
results obtained from mie, human T
Reg
ell biology seems to be still more omplex
and diverse.
As availability of spei marker moleules is still limited, isolation and hene ha-
raterization of human T
Reg
ells remain diult. In the mouse, CD25 is a good marker
for T
Reg
ells, as animals are held under pathogen-free onditions. In ontrast to that,
humans are onstantly exposed to foreign antigens, leading to a signiant fration
of reently ativated non-regulatory CD25
+
eetor T ells. During the searh for
more spei T
Reg
ell markers, FOXP3 has been identied as uniquely expressed in
mouse T
Reg
ells and has emerged as a lineage marker in developing mouse T
Reg
ells.
As expeted and previously reported, ex vivo human CD4
+
CD25
+
T ells isolated in
this study expressed signiantly higher amounts of both FOXP3 mRNA and protein
than did CD4
+
CD25
-
T ells. Furthermore, it was demonstrated that FOXP3 mRNA
was onsistently indued after 3 days of ativation with anti-CD3 ± IL2 even in non-
regulatory CD4
+
CD25
-
T ells, and FOXP3 protein was learly detetable after 5
days. However, FOXP3 mRNA and protein levels never reahed those observed in
CD4
+
CD25
+
T
Reg
ells. The apaity of human CD4
+
CD25
-
T ells to up-regulate
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FOXP3 gene and protein expression following ativation and expansion has reently
been desribed [16, 73℄ thereby supporting the presented results. Allan et al. further
demonstrated that retroviral over-expression of FOXP3 in human CD4
+
CD25
-
T ells
alone is not suient to generate potent suppressor T ells in vitro that are funtionally
equivalent to CD4
+
CD25
+
T
Reg
ells [16℄. Although FOXP3 is learly a link in the
regulatory iruit ontrolling immunologial tolerane, it does not appear to be the sole
master swith. These experiments rather suggest additional fators required during the
proess of ativation and/or dierentiation nally resulting in the development of bona
de human T
Reg
ells [52℄. A number of studies have proposed additional moleules that
are expressed at higher levels on CD4
+
CD25
+
T
Reg
ompared to naive T ells. Among
them, inhibitory ostimulatory reeptors like PD1, GITR, TNFRSF9 and TNFRSF4,
as well as hemokine (CCR4), toll-like (TLR4) or homing reeptors (CD103) have been
desribed. Reently disussed putative marker moleules are LAG-3, Nrp1 and CD27.
However, the majority of surfae proteins are also up-regulated on CD4
+
CD25
-
T ells
upon ativation while several markers were just found to be of importane in mouse
but not human T
Reg
ells [190℄.
To further assess qualiation of LGALS3 and TNFRSF1B as putative new T
Reg
ell markers, in vitro ativation experiments were performed. Thereby, onstitutive
and high expression of both genes ould be onrmed on mRNA and protein level in
ativated human CD4
+
CD25
+
T
Reg
ells. Little indution of TNFRSF1B mRNA was
observed in ativated CD4
+
CD25
-
T ells, but expression levels remained learly lower
than those in ativated and ex vivo T
Reg
ells thereby showing similar expression be-
haviour like FOXP3. The only study omparing TNFRSF1B mRNA levels between
reently ativated and ex vivo isolated CD4
+
CD25
-
T ells was arried out by Gavin and
o-workers in the mouse. In ontrast to results presented here, they reported a slight de-
rease in TNFRSF1B mRNA expression, whih is probably due to a dierent ativation
strategy (ConA instead of anti-CD3; ativation for 46h ompared to 3 days), but may
also point to interesting interspeies dierenes [190℄. LGALS3 mRNA was so strongly
indued in CD4
+
CD25
-
T ells upon ativation that expression levels exeeded that of
ex vivo T
Reg
ells. But LGALS3 mRNA expression in ativated eetor T ells still
remained learly lower than that observed in ativated T
Reg
ells, as LGALS3 mRNA
expression was elevated most of all upon ativation in T
Reg
ells. FACS analysis of
LGALS3 and TNFRSF1B protein levels revealed that expression of both proteins was
highly up-regulated in ativated CD4
+
CD25
+
T
Reg
ells ompared to CD4
+
CD25
-
ee-
tor T ells upon ativation. The shift in LGALS3 and TNFRSF1B expression between
both subpopulation turned out to be even more pronouned than that observed for ex
vivo ells. As LGALS3 protein expression is restrited at low levels to nonativated
human peripheral blood CD4
+
CD25
+
ells, a high level of LGALS3 protein represents
a T
Reg
spei FOXP3-signature of antigen-stimulated human CD4
+
CD25
high
derived
T
Reg
ells [197℄. Taken together, these ndings suggest LGALS3 and TNFRSF1B as
suitable new T
Reg
ell marker moleules in healthy humans that ould failitate T
Reg
ell isolation and thus improve T
Reg
ell haraterization in future.
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4.3 Regulatory T ells in RCC
4.3.1 Elevated T
Reg
ell frequeny
The emergene of a tumor results from the disruption of ell growth regulation as
well as from failure of the host to provoke a suient immunologial anti-tumor re-
sponse. Several tumor-spei immune evasion strategies have been desribed, among
them insuient presentation of T ell ativating epitopes through down-regulation of
MHC lass I expression and other proteins involved in proessing antigeni peptides,
seretion of tumor-derived immunosuppressive and anti-apoptoti moleules or indu-
tion of immunotolerane against tumor-spei antigens [85℄. Aumulation of T
Reg
ells in peripheral blood and tumor environment of aner patients was reported by
numerous investigators and is thought to represent an additional mehanism promo-
ting tumor immune esape [41, 85℄. Based on these observations it was interesting to
examine whether T
Reg
ell frequenies are also inreased in peripheral blood of RCC
patients and, if so, whether T
Reg
ell numbers orrelate with stage of disease. In-
deed, a signiantly elevated presene of CD4
+
CD25
high
T
Reg
ells ould be observed
in peripheral blood of RCC patients ompared to healthy ontrols in this study, whih
was aompanied by a signiant inrease in total numbers of CD4
+
CD25
+
T ells.
Two studies published during this work supported these ndings: Cesana et al. also
reported elevated frequenies of otherwise funtionally suppressive CD4
+
CD25
high
T
ells in PB of metastati RCC patients and even perentages given were very similar to
those observed in the presented work. Furthermore they disovered an inrease in T
Reg
ell numbers following IL2 therapy whih remained elevated in patients with disease
progression, but returned to normal levels in patients with objetive linial response
[198℄. Similarly, Dannull et al.measured higher T
Reg
ell frequenies in peripheral
blood of metastati RCC patients when ompared to healthy ontrols. Furthermore,
they demonstrated that seletive elimination of T
Reg
ells followed by vaination with
tumor RNA-transfeted DCs signiantly improved stimulation of tumor-spei T ell
responses in RCC patients when ompared with vaination alone [95℄. Thus, inreased
frequeny of T
Reg
ells with funtional suppressive ativity may have potential implia-
tions for the treatment of aner patients and might explain the poor linial response
of aner patients undergoing immunotherapy. Depletion of T
Reg
ells in ombination
with tumor immunotherapy or vaination ould have the potential to enhane hanes
of RCC eradiation. Inreasing evidene suggests that elevated T
Reg
ell numbers ould
at least in part be tumor-driven [63℄, as e.g. removal of HCC tumors led to restoration
of normal T
Reg
ell frequenies [40℄. Furthermore, T
Reg
ell frequeny was ompared
between metastati and loalized tumor growth in PB of RCC patients but no statis-
tially signiant dierenes ould be unovered. This is well in line with a previous
study reporting no substantial hange in T
Reg
ell numbers among AML subtypes [104℄.
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4.3.2 Gene expression signatures of CD4
+
CD25
+
T
Reg
ells in RCC
Despite reent advanes in human T
Reg
ell researh, the moleular and ellular meha-
nisms responsible for the inrease and maintenane of elevated levels of T
Reg
ells in
aner remain elusive. Furthermore, little is known about potential hanges in T
Reg
ell development and/or funtion during tumor growth leading to augmented suppres-
sion that may failitate tumor immune esape [63℄. Along with other solid malignan-
ies, RCC ontinues to progress despite signiant numbers of tumor-inltrating lym-
phoytes (TIL), implying potential host immune dysfuntion and poor tumor antigen
reognition and/or presentation [199℄. As miroarrays have demonstrated their poten-
tial to unravel gene expression of various subsets of leukoytes [200℄, this tehnology
was applied in the presented study to reveal gene expression signatures of human re-
gulatory T ells. A omparison between transriptional patterns of T
Reg
ells obtained
either from healthy donors or RCC patients may ontribute to a better understanding
of the moleular mehanisms underlying T
Reg
ell mediated tolerane in health and
aner.
Comparative miroarray analyses of CD4
+
CD25
+
T
Reg
and CD4
+
CD25
-
naive T
ells revealed 81 genes signiantly dierentially expressed between both T ell sub-
population in RCC patients, while only 62 genes were regulated in healthy donors. The
81 andidate genes in RCC were omposed of 49 over-expressed and 32 down-regulated
genes when omparing T
Reg
to naive T ells (healthy: 32↑ versus 30↓). Separated ex-
amination of both T ell subsets in either loalized or metastati RCC still more learly
underlined that the majority of genes identied in RCC showed over-expression in T
Reg
ells (loalized: 43↑ versus 29↓; metastati: 63↑ versus 22↓). Thus, a rising number
of regulated genes was identied omparing healthy donors via loalized to metastati
RCC (n=62, 72, 85) and thereby espeially the fration of andidates over-expressed in
T
Reg
ells inreased dramatially depending on stage of disease (n=32, 43, 63). These
ndings may point to a gain-of-funtion in T
Reg
ells from RCC patients that ould
equip them with additional properties and/or survival strategies (ompared to those
in healthy donors) supporting tumor immune protetion.
Many of the genes identied as dierentially expressed between CD4
+
CD25
+
T
Reg
and CD4
+
CD25
-
naive T ells in loalized and metastati RCC ould be linked to
partiipate in apoptosis ontrol. Among them, one an nd the galetins LGALS1 and
LGALS3 again, whih were already revealed when analysing healthy donors. LGALS1
was demonstrated to be able to indue apoptosis in ativated T ells and was shown
to be expressed by various, espeially aggressive and metastati tumor ells. Thus, se-
retion of LGASL1 by the tumor itself ould indue apoptosis in otherwise anti-tumor
direted, ytotoxi T ells and may be supposed as a possible mehanism of tumor
immune esape [138, 139, 140℄. Bloking of LGALS1 in a tumor mouse model resulted
in an inreased tumor-spei T ell response in vivo and even led to redution in
tumor size [138℄, thereby supporting this idea. As LGALS1 expression was also ele-
vated in T
Reg
ells isolated from RCC patients ompared to healthy ontrols (+3.4),
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an augmented ability of RCC T
Reg
ells to render tumorantigen-spei T eetor ells
apoptoti ould be supposed, hene failitating tumor growth. This hypothesis is sup-
ported by the fat, that RCC ontinues to progress despite the presene of signiant
numbers of tumor-inltrating lymphoytes [199℄, thus proedures (like apoptosis indu-
tion by the tumor itself or by T
Reg
ells) seem to exist, that ounterat tumor ombat.
Furthermore, reent studies have re-examined T
Reg
ell indued apoptosis of eetor T
ells as a potential mehanism for suppression. Grossman et al. reported that human
natural and adaptive T
Reg
ells mediate their suppressive eets by a GZMA/perforin
and ITGB2-dependent pathway to ause autologous target ell death [201℄. Similarly,
Parakishvili et al.demonstrated that CD4
+
/perforin
+
T ells from B-CLL patients are
able to kill autologous B-CLL ells ex vivo via a perforin-mediated mehanism [203℄.
More reent studies have shown that T
Reg
ells even suppress ytokine seretion, pro-
liferation, and ytotoxi ativity of anti-tumor NK ells, whih have been reported to
be important ells for tumor learane [172℄.
LGALS3 over-expression was higher in T
Reg
ells ompared to their naive ounter-
parts in healthy individuals (+3.9, miroarray analysis) versus RCC patients (+1.7)
and showed slightly inreased expression in RCC T
Reg
ells ompared to T
Reg
ells of
healthy volunteers (+2.2). These results are onrmed by a miroarray analysis exa-
mining PBMCs from patients with advaned RCC, that also revealed up-regulation of
LGALS3 ompared to the healthy ontrol group and even inorporated this moleule
in a set of eight preditor genes, denitely distinguishing PBMCs from RCC patients
and healthy donors [202℄. As desribed previously, LGALS3 may play distint roles
in apoptosis ontrol depending on its loalization. Extraellularily sereted LGALS3
is funtioning as a pro-apoptoti protein [138℄, thus elevated levels in RCC T
Reg
ells
may in onert with LGALS1 indue apoptoti ell death in tumor-spei eetor T
ells, hene ontributing to tumor immune esape. In ontrast to that, intraellularly
expressed LGALS3 was reported to trigger anti-apoptoti pathways in T ells [138℄,
thereby promoting T ell survival and providing a possible explanation approah for
the inreased frequeny of T
Reg
ells in RCC.
BAX (BCL2-assoiated X protein) belongs to the BCL2 protein family, representing
a ritial intraellular hekpoint in the apoptoti pathway. BCL2 family members form
hetero- or homodimers and at as pro- or anti-apoptoti regulators. As an apoptoti
ativator, BAX is reported to interat with, and inrease the opening of mitohondrial
anion hannels, whih leads to a loss in membrane potential. Release of ytohrome 
and subsequent aspase ativation nally results in programmed ell death. BAX
forms heterodimers with BCL2, that possesses apoptoti repressor ativity and is thus
funtioning as a BAX antagonist. Expression of both, BAX and BCL2 genes, were
shown to be regulated by the tumor suppressor P53 [205℄. Furthermore, sensitivity of
RCC ell lines to INF-α has been orrelated with p53-indution and involved its down-
stream target BAX [204℄. Interestingly, a marked down-regulation of BAX expression
was identied in T
Reg
ells of RCC patients ompared to healthy donors (-3.4) during
102 4 Disussion
this work whih was aompanied by an up-regulation of its repressor BCL2 (+2.4) in
T
Reg
ells versus naive T ells of metastati RCC patients. Over-expression of the BCL2
onogene has been demonstrated to inrease the resistane of lymphoytes to many
dierent death stimuli, inluding ytokine withdrawal, DNA damage and oxidative
stress [205℄. Thus, the results presented here provide further evidene for a protetion
from apoptosis and thus an enhaned survival of T
Reg
ells in RCC ontributing to
their aumulation.
Interleukin-7 (IL7) plays an important role in the normal development and mainte-
nane of the human immune system. Engagement to the IL7 reeptor (IL7R) initiates
a asade of phosphorylation events triggered by various moleules inluding Janus ki-
nases (JAK1 und JAK3), PI3 kinase and STATs. Ativation of IL7 signalling pathway
nally results in survival, proliferation, dierentiation and maturation of haemato-
poieti ells inluding T lymphoytes. Elevated levels of IL7 and IL7R expression
were orrelated with genesis of espeially aggressive malignanies with poor prognosis,
suh as ertain types of leukemia, lymphomas and breast aner [211℄. Interestingly,
knokout studies in mie suggested that bloking apoptosis is an essential funtion of
IL7R during dierentiation and ativation of T lymphoytes [208℄. Although T ell
development ould be observed in IL7R-deient animals, the number of thymoytes
was signiantly redued, implying a role of IL7R in ontrolling the size of the thymi
T ell ompartment. Inversely, over-expression of IL7R in mie was shown to result
in inreased survival of thymoytes due to dereased apoptosis rates [212℄. Strikingly,
opposite regulation of IL7R was observed in T
Reg
ells from healthy donors and RCC
patients in this study. While T
Reg
ells of healthy volunteers expressed signiantly
lower amounts of IL7R than their naive ounterparts (-2.1), up-regulation of IL7R
expression was deteted in T
Reg
versus naive T ells from metastati RCC patients
(+1.6) and when omparing RCC versus healthy T
Reg
ells (+2.6). A reent publia-
tion onrms these results by reporting inverse orrelation between IL7R and FOXP3
expression as well as between IL7R and suppressive funtion in human T
Reg
ells [213℄.
One more, these ndings support the theory of enhaned survival due to dereased
apoptosis as a mehanism to elevate T
Reg
ell frequenies in RCC.
Members of the TNF-α superfamily are type I membrane-bound ell surfae polypep-
tides that signal to target ells upon ell-ell ontat or after protease-mediated release
to the extraellular spae. Four members of this family - FASL, TNF-α, TL1A and
TRAIL - are able to indue ell death under partiular irumstanes. Binding of li-
gand to the extraellular domain of its reeptor, enhanes the anity of the intraellular
death domain for the ytoplasmi adaptor protein FADD. FADD binding results in a-
tivation of a aspase asade through both mitohondria-dependent and -independent
pathways that nally end up in apoptosis. Several TRAIL reeptors (TRAILR) exist:
TRAILR1 is also alled death reeptor 4 or TNFRSF10A, TRAILR2 is also known
as DR5 or TNFRSF10B. Interestingly, DR4 expression was disovered to be markedly
down-regulated in T
Reg
ells from RCC patients ompared to healthy ontrols (-3.3)
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and expression of TNFRSF10C as a third, but deoy TRAILR was learly dereased
in T
Reg
versus naive T ells from RCC patients (-3.0) with an even more signiant
deline in metastati RCC patients (-4.1). Again, these ndings may point to a de-
reased suseptibility of RCC T
Reg
ells towards apoptosis. Well in line, a reent study
demonstrated seletive resistane of naturally ourring human CD4
+
CD25
+
FOXP3
+
T
Reg
ells to rapamyin-indued apoptosis [206℄. Conordant results were obtained
by a study examining T
Reg
ells in aute myeloid leukemia (AML) patients. It ould
be demonstrated that the fration of apoptoti ells within the CD4
+
CD25
high
T
Reg
ells was the lowest when ompared to the remaining CD4
+
T ell subsets (CD25
low
,
CD25
-
). But ompared to healthy donors, an elevated frequeny of apoptoti ells was
observed within the CD4
+
CD25
high
T
Reg
ell population of AML patients. Authors
ould show, that this eet was ompensated by an inreased proliferation of AML
T
Reg
ells ompared to healthy donors [104℄.
Thus, not only diminished suseptibility towards apoptosis but additionally in-
reased proliferation rates in T
Reg
ells from RCC donors ould be responsible for
higher T
Reg
ell frequenies in RCC patients. Expression proling of T
Reg
and naive T
ells from healthy donors as well as from patients suering from loalized or metastati
RCC indeed identied a group of andidate genes involved in ell yle ontrol and
proliferation. For example, the MYC proto-onogene enodes a transription fator
that plays a ritial role in ellular proliferation. Indued rapidly upon entry into
the ell yle, MYC expression is suient to drive quiesent ells into proliferation.
Additionally, MYC has been shown to be deregulated in a large perentage of human
malignanies, and its over-expression frequently orrelates with aggressive, poorly dif-
ferentiated tumors and poor prognosis [207℄. Interestingly, enhaned MYC expression
was revealed in T
Reg
ells of RCC patients ompared to healthy donors (+2.0) and in
T
Reg
versus naive T ells of metastati RCC (+1.9) in this study, while MYC expres-
sion was down-regulated in T
Reg
ompared to naive T ells of healthy donors (-1.7).
Paradoxially, in addition to promoting ell proliferation, MYC was shown to sensitize
ells to apoptosis under ertain onditions [207℄. Strikingly, MYC over-expression was
thereby inversely orrelated with TRAIL sensitivity, whih is well in line with the data
presented in this work.
CDC25B (ell division yle 25 homolog B) is a member of the CDC25 family of
phosphatases. It ativates the ylin dependent kinase CDC2 (CDK1) by leaving two
phosphate groups and is required for entry into mitosis [208℄. CDC25B expression was
signiantly up-regulated espeially in T
Reg
versus naive T ells from metastati RCC
patients (+2.4) and elevated expression levels were also observed when omparing T
Reg
ells from RCC patients to those from healthy donors (+1.5). CDC25B was not among
the signiantly dierentially expressed andidates disriminating T
Reg
from naive T
ells in healthy donors. Thus, its up-regulation in RCC may ontribute to higher
CD4
+
CD25
high
T
Reg
ell frequeny in RCC due to enhaned proliferation. Further
support for this idea is provided by parallel over-expression of CEB1 (ylin E binding
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protein 1) in T
Reg
ells from RCC patients ompared to healthy donors (+2.1). Inrease
in CEB1 expression was most signiant in T
Reg
versus naive T ells from metastati
RCC patients (+5.2) and CEB1 was not found to be dierentially expressed between
T
Reg
and naive T ells of healthy volunteers. CEB1 was demonstrated to interat with
various ylin subunits of CDKs in mammalian ells and its expression was highly
elevated by loss-of-funtion mutations of the tumor suppressor proteins P53 and RB
(retinoblastoma). over-expression of CEB1 resulted in up-regulated CDK ativity [209℄,
hene failitating ell proliferation. Another moleule inuening ell proliferation is
LST1 (leukoyte-spei transript 1). LST1 was shown to exert inhibitory eets
on lymphoyte proliferation and its expression was inreased in aeted blood and
synovium of rheumatoid arthritis patients [208℄. In the presented study, profound
down-regulation of LST1 expression was obeserved in T
Reg
versus naive T ells of loa-
lized (-1.8) and metastati (-6.7) RCC patients. As LST1 was desribed as a negative
regulator of lymphoyte proliferation, dereased expression may again indiate elevated
proliferation rates of T
Reg
ells in RCC resulting in inreased T
Reg
ell frequenies. A
reent study examining telomere length of CD4
+
CD25
+
T
Reg
ells from aner patients
supports this hypothesis [210℄. When ompared to healthy ontrols, aner T
Reg
ells
exhibited signiantly dereased levels of TREC (T ell reeptor exision irles), but
despite their in vivo proliferation telomere lengths were not shorter due to indution of
telomerase ativity. Thus, authors onlude that the inreased frequeny of T
Reg
ells in
PB of aner patients is rather aused by ative proliferation than by distribution from
other ompartments (i.e. seondary lymphoid organs or bone marrow). Taken together,
these results suggest a ombination of dereased suseptibility towards apoptosis and
enhaned proliferation to ontribute to elevated frequenies of T
Reg
ells in RCC.
Chemokines are small hemotati or -attratant ytokines that funtion as potent
ativators for leukoyte subpopulations. Their ations are mediated by a family of
7-transmembrane spanning G-protein-oupled reeptors growing onsiderably in size
until today. Chemokine reeptor (CCR) expression on dierent ell types as well as
their binding and response to spei hemokines are highly variable. The interation
of hemoattratants with leukoyti CCR initiates a series of oordinated biohemial
and ellular events inluding alterations in ion uxes, integrin avidity and transmem-
brane potential, hanges in ell shape, seretion of lysosomal enzymes, prodution of
superoxide anions, and enhaned loomotion [214℄. Tumor sereted hemokines in-
uene tumor metastasis, leukoyte inltration, regulation of the anti-tumor immune
response, angiogenesis and may at as growth fators [215℄. Regarding the obtained
expression prole of T
Reg
ells in RCC and health, several hemokine reeptors were
revealed to be strongly up-regulated. CCR10 expression was elevated in T
Reg
versus
naive T ells from healthy donors (+3.2). Its over-expression in T
Reg
ells inreased even
more in loalized (+5.0) and metastati (+8.4) RCC depending on disease stage. Fur-
thermore, CCR2, CCR6 and CCR8 were highly up-regulated in T
Reg
ells ompared to
their naive ounterparts but only in RCC patients. These three CCRs were not among
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the signiantly dierentially expressed genes disriminating T
Reg
from naive T ells in
healthy donors. Indution of all these CCRs may be a hint for an elevated attration of
T
Reg
ells into the tumor environment that in turn ould failitate tumor esape from
immune surveillane. Linehan et al.have previously suggested that tumors atively
protet themselves from immune destrution by reruitment of T
Reg
ells [172℄. They
even proposed tumor-derived fators in its miroenvironment that support the hemo-
taxis, proliferation and/or funtion of T
Reg
ells. Coulture of human CD4
+
CD25
+
T
ells with supernatants from primary panreati aner ell lines resulted in signiant
proliferation of the T
Reg
ells, while proliferation of CD4
+
CD25
-
, CD4 and CD8 T ells
ultured under idential onditions was inhibited. Furthermore, Jonuleit et al. showed
that soluble fators derived from primary tumor ultures (e.g. IL6, TGF-β, VEGF)
signiantly impaired DC maturation that in turn led to indution and subsequent
inreased prevalene of T
Reg
ells [216℄. Tumor-driven up-regulation of T
Reg
ells in
aner patients ould be also aused by the abundane of self-antigens provided by the
tumor. It has previously been shown that T
Reg
ells, whih are poorly proliferative in
vitro, an vigorously proliferate in vivo in response to self-antigen stimulation. Further-
more, TGF-β seretion by the tumor was suggested to promote onversion of non-T
Reg
into T
Reg
ells [172℄. Additionally, tumor-sided expression of hemokines ould ause
migration of T
Reg
ells to the tumor miroenvironment. In RCC, expression of nume-
rous hemokines was reported to be signiantly elevated ompared to adjaent normal
renal tissue. Among them, one an also nd hemokines whose orresponding reeptors
were revealed to be indued upon T
Reg
ells from RCC patients [218℄. For example,
learly inreased CCL4 (hemokine [C-C motif℄ ligand 4) expression was desribed
in RCC tumor tissue as inversely orrelated to tumor size and as a reruiter of lym-
phoyte inltration [219℄. CCL4, also known as MIP-1B (marophage-inammatory
protein-1 beta), is a ligand signalling through CCR8, whose expression was signiantly
indued in RCC T
Reg
ells ompared to their naive ounterparts (+3.7; loalized:+3.5;
metastati:+4.4) in the presented study. Thus, direted migration of T
Reg
ells towards
the tumor site in RCC patients ould be possible. Furthermore, over-expression of the
anti-apoptoti hemokine CCL1 that also binds to CCR8 was reported to substantially
promote growth of adult T-ell leukemia ells in an autorine feed bak loop [217℄.
As CD4
+
CD25
+
human thymoytes also express CCR8, involvement of CCL1-CCR8
interations in the spread of mature CD4
+
CD25
+
T ells into irulation was sug-
gested [54℄. Interestingly, also MCP-1 (monoyte hemoattratant protein-1, CCL2)
gene and protein expression was strongly indued upon CD40 signalling in mouse and
human RCC tumor ells showing potent hemotati ativity [220℄. This hemokine
mediates monoyte hemotaxis and was shown to be involved in monoyte inltration
in the inammatory response against tumors [208℄. CCR2, that is funtioning as its
reeptor, showed elevated expression in RCC T
Reg
ells (+2.1; +2.2; +2.1) ompared
to their naive ounterparts in this work and ould thus also trigger their reruitment
to the tumor site. In a mouse model, CCR2 transfeted CD4
+
CD25
+
Foxp3
+
T
Reg
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ells strikingly ameliorated progression of pneumonitis and sialadenitis due to more
pronouned migration towards CCL2 expressed in the lung and submandibular gland
[221℄. As desribed before, attration of monoytes and seretion of soluble fators
by the tumor ould additionally lead to insuient DC maturation resulting in T
Reg
ell aumulation [216℄. Another hemokine reeptor stronger expressed in T
Reg
ells
ompaired to naive T ells in RCC patients (+6.2; +5.0; +8.4) than in healthy on-
trols (+3.2) was CCR10, also known as GPR2 (G protein-oupled reeptor). CCR10 is
predominantly expressed on CD4
+
CLA
+
(utaneous lymphoyte antigen) irulating
T ells. Its ligand CCL27 is funtioning as a homing fator for these memory T ells
and is highly expressed in keratinoytes [186℄. Thus, CCR10 expression on T
Reg
ells
ould be also suggested as a reeptor for speial homing fators, as the surfae phe-
notype of T
Reg
ells resembles the one of memory T ells [42℄. CCL27 expression
was strongly up-regulated in skin lesions of atopi, ontat dermatitis, and psoriasis
patients. Neutralization of CCL27-CCR10 interations in mouse models of ontat
hypersensitivity and atopi dermatitis impaired lymphoyte reruitment and inhibited
allergen-indued skin inammation [186℄. Additionally, CCR10 and its ligand CCL27
were demonstrated to ontribute to the skin inltration of malignant T ells in u-
taneous T ell lymphoma [222℄. CCL28 is another ligand for CCR10, that is highly
expressed in human normal and pathologial olon, prostate, spleen and to a lesser
extent in PBMCs. Interestingly, CCL28 expression ould be also deteted in mouse
kidney. Reombinant human CCL28 displayed hemotati ativity for resting CD4
or CD8 T ells in vitro and CCL28-CCR10 interations were shown to be involved in
homeostati and inammatory responses in skin and gut [223℄. Well in line with the
ndings presented here, Eksteen et al. reently desribed a subset of CCR10-expressing
CD4
+
CD25
+
Foxp3
+
T
Reg
ells they isolated from hronially inamed human liver. In-
terestingly, these ells were deteted around bile duts that expressed inreased CCL28
levels due to epithelial inammation and migration towards this hemokine was on-
rmed in vitro. Authors onlude that CCR10 allows T
Reg
ells to respond to CCL28
sereted by epithelial ells resulting in the aumulation of CCR10
+
T
Reg
ells at mu-
osal surfaes [224℄. Similarly, attration of T
Reg
ells ould be aused by potential
seretion of CCL28 by the tumor in RCC patients. Furthermore, expression of CCR6
and its ligand CCL20 were strongly up-regulated in hepati, oloretal and panreati
aner and were desribed to ontribute to arinogenesis and progression of these ma-
lignanies [225℄. Elevated expression of CCR6 was also observed in CD4
+
CD25
+
T
Reg
ells ompared to CD4
+
CD25
-
naive T ells in RCC (+4.0; +3.5; +4.9) but not in
healthy donors in this study. In aordane with these results, Hirahara et al. reently
reported that the majority of human PB CD4
+
CD25
+
Foxp3
+
T
Reg
ells bear funtional
skin homing reeptors suh as CCR4, CCR6, CCR10 and demonstrated hemotati
responses of these ells towards their partiular ligands [226℄. Apart from mediating
homing to skin, it would be also oneivable, that expression of these reeptors is in-
dued during arinogenesis in RCC to reruit T
Reg
ells to the tumor and to failitate
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its evasion from immune surveillane. That appropriate loalization is indispensably
required for in vivo T
Reg
ell funtion and that migration behaviour of T
Reg
ell sub-
sets inuenes their in vivo suppressive apaity was reently desribed by Huehn and
o-workers [227℄. Thus, aberrant homing of RCC T
Reg
ells may also ause enhane-
ment of their regulatory abilities in the tumor environment and together with elevated
T
Reg
ell frequenies tumor immune esape ould be supported. Further prove for this
hypothesis is obtained by the observed indution of integrin expression in T
Reg
from
RCC patients. ITGB1 (integrin beta 1; +2.1; +2.0; +2.4) and ITGB5 (+3.1; +2.7;
+2.8) expression were signiantly up-regulated in RCC T
Reg
ompared to naive T
ells, but failed to show dierential expression between both T ell subsets in healthy
donors. The integrins omprise a large family of ell-surfae proteins that mediate
adhesion between ells, and between ells and the extraellular matrix. Interestingly,
T ell integrins are ativated by hemokine signalling to bind tightly to vasular sur-
faes during the migration of ativated lymphoytes into sites of inammation [29℄.
Elevated expression of ITGB5 has reently been desribed also in PB monoytes that
migrate to and aumulate in hypoxi areas of inammatory and tumor lesions [228℄.
The ICAMs (intraellular adhesion moleules) are members of the immunoglobulin su-
perfamily and serve as ell surfae ligands for the leukoyte integrins [29℄. ICAM1 is
involved in enhanement of tumor metastasis and mediates lymphoyti tumor yto-
toxiity. Interestingly, ICAM1 expression was shown to be up-regulated in response to
ytokines and through CD40 signalling in RCC [230, 229℄. Another important adhe-
sion moleule, known to bind integrins on T ells is VCAM1 (vasular ell adhesion
moleule 1). It is a ell surfae glyoprotein impliated in various pathophysiologi
onditions and VCAM1 expression was reported to be signiantly elevated in lear
ell and papillary RCC ompared to adjaent normal renal tissue [232℄. In breast
aner patients, up-regulation of VCAM1 expression in tumor ells additionally orre-
lated with short survival time [231℄. A very reent report interestingly demonstrated
that retroviral transfer of VCAM1 into an immune-suseptible aner ell line signi-
antly inreased its resistane towards vaine-indued immune response. In parallel,
the number of tumor-inltrating CD8
+
T ells was dramatially dereased in tumors
expressing VCAM1, although in vitro transwell migration assays showed the ability
of VCAM1 to promote CD8
+
T ell migration. While most RCCs analysed expressed
VCAM1, an RCC responding to vaination did not. Thus, authors onlude, that
tumor expression of VCAM1 represents a new mehanism of immune evasion and may
have important impliations for the development of immunotherapy for human RCC
treatment [233℄. Linking these ndings to the results obtained in the presented study,
up-regulation of CCRs and integrins on RCC T
Reg
ells aompanied by tumor-sided
expression of their spei ligands ould indeed lead to tumor-driven attration of
T
Reg
ells and their aumulation at tumor-sites. The partiular hemokines or adhe-
sion moleules expressed by the tumor may simultaneously impair migration of tumor
antigen-spei ytotoxi lymphoytes into malignant RCC tissue and attrated T
Reg
ells ould prevent tumor rejetion as atually intended.
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In addition to dereased apoptoti sensitivity, inreased proliferation and migration
to tumor sites, an augmented suppressive ativity of T
Reg
ells may be supposed to
ontribute to tumor immune esape. Studies examining inhibitory apaities of T
Reg
ells in aner patients gave ontraditory results. While some authors laim similar
regulatory funtion of T
Reg
ells from aner patients and healthy ontrols [198, 40℄,
other reports ould indeed demonstrate higher immunosuppressive ompetene of T
Reg
ells in aner patients. T
Reg
ells inltrating metastati lymph nodes in melanoma
patients were shown to suppress proliferation of CD8
+
and CD4
+
CD25
-
T ells more
potently than T
Reg
ells sorted from tumor-free lymph nodes of the same patient.
Furthermore, these T
Reg
ells strongly inhibited IL2 and IFN-γ prodution of naive
T ells [234℄. Compared to healthy donors, T
Reg
ells from patients suering from
epithelial malignanies have additionally been reported to exert inreased inhibition of
CD4
+
T ell proliferation [85℄.
4.3.3 More news about the phenotype of human T
Reg
ells in RCC
Using quantitative RT-PCR, onrmation of the miroarray approah ould be ex-
tended to the analysis of human regulatory and naive T ells isolated from RCC pa-
tients. Comparable to results obtained in healthy donors, signiantly elevated mRNA
expression of FOXP3, CCR10, TNFRSF1B, TRAF1 and LGALS3 was veried in T
Reg
versus naive T ells of RCC patients. Well in line with these results, inreased FOXP3
mRNA levels were reported previously in T
Reg
ompared to naive T ells isolated from
aner patients suering e.g. from CLL [41℄, metastati melanoma and even RCC [198℄.
No statistially signiant dierenes in FOXP3 mRNA levels were observed between
healthy volunteers and RCC patients due to high variability among donors, although
mean fold hanges in RCC patients (+19.2) were somehow higher ompared to healthy
ontrols (+11.6). Reports on that issue are also ontraditory. For example, Dannull
et al. laimed signiantly higher FOXP3 mRNA opy numbers in T
Reg
ells from RCC
patients [95℄, whereas Cesana et al. found no dierenes in FOXP3 mRNA expression
between RCC patients and healthy ontrols [198℄. To assess orrelation of mRNA and
protein expression levels, PBMCs from RCC patients were three-olour stained and
subjeted to FACS analyses. Thereby, a signiant inrease in FOXP3 and LGALS3
protein expression in RCC patient derived T
Reg
ompared to naive T ells ould be on-
rmed. In agreement with these ndings, elevated FOXP3 protein expression in RCC
T
Reg
versus naive T ells has been reported [198, 95℄. In ovarian aner tissue sam-
ples, FOXP3 mRNA expression was even suggested as a surrogate marker for indiret
quantitation of the T
Reg
ell inltration grade into tumor tissue. Thereby, high expres-
sion levels of FOXP3 have been assoiated with a dismal prognosis as well as with an
inferior overall and progression-free survival [91, 210℄. Consistent with other reports,
omparison of FOXP3 protein amounts between healthy ontrol and RCC patient de-
rived T
Reg
ells revealed similar expression levels in both donor groups [198, 95℄. Both
RCC studies analysed expression of additional T
Reg
ell-assoiated surfae moleules,
suh as GITR and CTLA4, that were found to be up-regulated on patient T
Reg
versus
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naive T ells, but showed similar expression levels when ompared to healthy donors.
Furthermore, this work is the rst publiation reporting elevated LGALS3 protein ex-
pression in RCC T
Reg
ells as well as inreased frations of CD4
+
T ells oexpressing
FOXP3 and LGALS3 or FOXP3 and TNFRSF1B when ompared to healthy donors.
In healthy donors, lear up-regulation of LGALS3 protein expression has previously
been demonstrated upon ativation in T
Reg
ells [197℄. Antigeni stimulation mediated
by a tumor, ould be similarly supposed to ativate T
Reg
ells in RCC patients that in
turn reat with a signiant up-regulation of LGALS3 expression.
As disussed before [hapter 4.2.3℄, LGALS3 and TNFRSF1B have been seleted as
potential new marker genes enabling disrimination of human regulatory from naive T
ells. As both genes were highly up-regulated in RCC as well as in healthy donor de-
rived T
Reg
versus naive T ells, their qualiation as new T
Reg
ell markers is further
underlined. These genes belong to the ones diering most between T ell subpopu-
lations, even independent from their origin. In this ontext, CCR10 again attrats
attention as it was found to be learly over-expressed on RCC T
Reg
ells ompared to
healthy donors and as it ould funtion as a very onvenient marker moleule due to
its expression on the ell surfae. As exat enumeration of T
Reg
ells in RCC is om-
pliated by the fat that CD4
+
T ells with negative or intermediate CD25 expression
levels may up-regulate CD25 on their surfae in response to antigeni stimulation by
the tumor [95℄, these moleules ould perhaps failitate detetion of T
Reg
ells. Over-
oming the lak of spei ell surfae markers ould help to larify many funtionally
relevant aspets of T
Reg
ells in tumor immunology that are urrently still unknown.
Although researh in T
Reg
ell biology is intensifying, it is e.g. still not lear, whether
T
Reg
ells in human tumors are primed mainly in the thymus or emerge in the periphery
due to antigen-spei stimulation [63℄.
Similar to the presented ndings in healthy donors, redued suseptibility of RCC
T
Reg
ells towards apoptosis ould be onrmed when ompared to their naive oun-
terparts. Unexpetedly, no signiant dierenes in apoptoti behaviour was observed
when omparing RCC to healthy donor derived T
Reg
ells. Thus, elevated frequenies
of T
Reg
ells in RCC patients seem to be aused rather by an inrease in proliferation
than by a derease in inidene of apoptoti ell death (for detailed disussion see hap-
ter 4.3.2). In AML and SCCHN (squamous ell arinoma of head and nek) patients,
PB-derived T
Reg
ells even ontained signiantly more apoptoti ells when ompared
to healthy donors but inreased proliferation rates of T
Reg
ells indeed ompensated for
this loss resulting in elevated T
Reg
ell frequenies [104℄. This T
Reg
ell expansion was
suspeted to be tumor-driven, e.g. as a response to mostly self-antigens derived from
the tumor ells [172℄. Paradoxially, naive T ells in the RCC patients analysed in this
study learly showed higher frations of apoptoti ells than naive T ells in healthy
donors. As disussed in detail in the previous hapter, this fat may point to inreased
indution of apoptosis in eetor T ells mediated by T
Reg
ells or the tumor itself that
ould in this way failitate tumor immune esape.
110 4 Disussion
4.4 Regulatory T ells in IBD
The gastrointestinal trat is the main interfae where the body enounters exogenous
antigens. It is ruial and hallenging that loal responses are tightly regulated to
avoid an immune reation against dietary antigens and ommensal ora while still
mounting an eient response against pathogens. Faults in maintenane of intestinal
homeostasis may lead to disease, induing loal and often also systemi inammation
[74℄. The omplex pathophysiologi mehanisms that trigger and maintain the two
forms of IBD, CD and UC, remain only partially understood. However, a large body of
data from animal models and funtional studies in humans indiate that IBD is aused
by an imbalane of the immune system haraterized by an exess of inammatory sti-
muli and mediators aompanied by an inadequate low number or funtion of ellular
omponents that down-regulate muosal immune responsiveness. As regulatory T ells
ontrol responses to self- and foreign antigens, they were demonstrated to be involved
in oral tolerane, to inhibit the ativation of T
H
1 ells against enteri baterial antigens
and to prevent and treat established olitis in animal models of IBD [235℄. Considering
the potent regulatory apaity of CD4
+
CD25
high
peripheral blood T ells in healthy
human individuals and the potential of miroarrays to deipher gene regulation events
that might ontribute to IBD pathogenesis, T
Reg
versus naive T ells of IBD patients
were ompared applying the Human T
Reg
Chip. To our knowledge, this is the rst
extensive analysis of gene expression in human T
Reg
ells from IBD patients, although
dierent miroarray studies investigating IBD have been previously performed. In-
testinal muosa samples have been subjeted to several exploratory gene expression
analyses aiming at improving lassiation between CD and UC as well as unravel-
ling gene regulation events leading to IBD pathogenesis [9℄. Burzynski et al. applied
miroarray analyses to PBMCs from IBD patients as these ells represent the more
linially aessible tissue and identied a set of 12 genes reliably disriminating CD
from UC patients [239℄. Similar to ndings obtained during the presented study, the
number of regulated genes was learly higher between CD patients and healthy donors
ompared to UC patients versus healthy ontrols.
Transfer of T
Reg
ells annot only prevent the development of olitis in animal
models but an even ure established disease by ating on adaptive as well as innate
immune system. It has been demonstrated that T
Reg
ells suppress T ell ativation
and proliferation in the lymphoid organs, thereby avoiding establishment of the di-
sease. Furthermore, they are able to aumulate in the inamed olon, urtailing the
muosal inammatory response while also reduing immune ativation in the lymphoid
organs in order to ounterat disease. These proesses do not neessarily employ the
same eetor mehanisms, and they learly have dierent migratory requirements. In
prevention of olitis, T
Reg
ells have to ontrol ativation of a predominantly naive
population of ells, while in ure of olitis, they have to deal with antigen-experiened
ells and an aggressive inammatory response. Although the knowledge about the
migratory behaviour of immune ells has greatly inreased in reent years, we are just
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starting to unravel what drives whih ells in whih diretion. The tissue speiity of
ativated and memory T ells is reversible, and has been demonstrated to be imprinted
in seondary lymphoid organs. T ells ativated in mesenteri lymph nodes (MLNs)
or Peyer's pathes exlusively will display gut tropism and DCs isolated from these se-
ondary lymphoid organs are suient to indue intestinal homing in T ells. However,
the mehanism by whih DCs mediate tissue imprinting is still poorly understood. A
signiant breakthrough has been the disovery that retinoi aid prodution by DCs
is essential for the indution of gut homing reeptors on T ells [74℄. Strikingly, an
exlusive and signiant down-regulation of RXRA (retinoid X reeptor alpha) was
observed in IBD-derived versus healthy T
Reg
ells (-4.2). RXRA is a nulear hormone
reeptor that mediates biologial eets of retinoids by its involvement in retinoi aid-
indued gene ativation. Thus, dereased expression of RXRA in IBD T
Reg
ells ould
lead to less responsiveness towards retinoi aid signalling and in onsequene to im-
paired gut-homing of T
Reg
ells. This hypothesis is supported by reent results of Maul
and o-workers reporting an insuient inrease of CD4
+
CD25
+
T
Reg
ells in intestinal
lesions from IBD patients ompared to divertiulitis patients to eiently ounterat
disease [235℄. The two main gut-assoiated homing moleules desribed to date are the
hemokine reeptor CCR9 and integrin α
4
β
7
, that in onerted ation with expression
of their ligands CCL25 and Mad-CAM1 help direting lymphoytes into the intestine.
Unfortunately, both moleules were not inluded in the oligonuleotide pool onstitu-
ting the applied Human T
Reg
Chip thus, potential involvement of altered CCR9 and/or
α
4
β
7
expression in impaired homing of T
Reg
ells towards the intestine remained in the
dark. But although CCR9 and α
4
β
7
are important for intestinal lymphoyte migration,
they are neither exlusive for that tissue nor absolutely essential for gut loalization
[74℄. Following ativation in MLNs, primed murine T ells were demonstrated to a-
quire a hemokine reeptor prole inluding CCR9, CCR6 and CXCR3 enabling them
for homing to the small intestine. However, CCR9
-/-
T ells also showed migration to
the lamina propria probably due to ompensation by paralleled expression of CCR2,
CCR5, CCR6, CCR8, CCR10, CXCR3 and CXCR6 [236℄. When omparing T
Reg
ver-
sus naive T ells in healthy donors and IBD patients, dierent hemokine reeptor
expression patterns were strikingly observed. While CCR5 (+2.2) and CCR10 (+3.3)
were up-regulated, CCR7 (-2.1) was revealed to be signiantly down-regulated in a
omparison of both T ell subsets in healthy donors. In ontrast to that, a signiant
over-expression of CCR6 (+2.0), CCR8 (+3.6) and an even higher up-regulation of
CCR10 (+5.6) was dislosed in IBD-derived T
Reg
versus naive T ells. Furthermore,
CCR4 expression (-6.3) was learly dereased in a diret omparison of IBD and healthy
T
Reg
ells. Considering these tremendous dierenes in hemokine reeptor expression
signatures between healthy volunteers and IBD patients and the fat that dierent
hemokine reeptors mediate distint migratory properties of T ell subsets it is on-
eivable that IBD T
Reg
ells may show aberrant migration behaviour. In this ontext,
it is worth notiing that a strong down-regulation in expression of various hemokines
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was also observed, suh as CCL3 (MIP1α, -6.4 in CD inative, -8.5 in UC inative),
CCL4 (-10.8 in ative CD, -4.5 in inative CD) and CCL5 (RANTES, -5.6 in IBD, -2.5
in health) in T
Reg
versus naive T ells from IBD patients. However, several reports
laim aumulation of FOXP3
+
T
Reg
ells in inamed tissues in IBD patients that is
suggested to be driven by inammation in the intestine whih would be well in line
with the demonstrated observation of elevated expression of CCR6, CCR8 and CCR10
in T
Reg
ells from IBD patients. Authors argue that the presene of FOXP3
+
T
Reg
ells underlines possible impotent regulatory apaity or nonresponsiveness to their
ativity under onditions of hroni intestinal inammation [238, 235℄. Thereby, lear
evidene that a lak of funtionally suient T
Reg
ells an lead to hroni intestinal
inammation emerged from a study of IPEX patients [238℄.
Maul et al. reported inreased presene of T
Reg
ells in PB of IBD patients in re-
mission ompared with ative disease and dereased T
Reg
ell frequenies in ative IBD
versus divertiulitis patients [235℄. As these disrepanies in T
Reg
ell numbers may be
attributed to dierenes in apoptosis and/or proliferation rates, having a loser look on
the presented gene expression patterns omparing T
Reg
versus naive T ells of ative
and inative CD patients as well as inative UC patients was espeially interesting.
Surprisingly, TNFRSF25 expression was signiantly elevated (+1.9) in T
Reg
ells ver-
sus naive T ells from ative CD patients, but was not dierentially expressed between
both T ell subsets in the remaining patient groups and healthy volunteers. TNFRSF25
is also known as death reeptor 3 (DR3) and was shown to regulate ell apoptosis and
thus lymphoyte homeostasis via stimulation of NF-kappa B ativity. TNFRSF25
knokout studies in mie interestingly suggested an involvement of this gene in the
removal of self-reative T ells in the thymus and gene dupliation was demonstrated
to be assoiated with rheumatoid arthritis. Upon T ell ativation, alternative spliing
of TNFRSF25 results in synthesis of then predominantly membrane-bound isoforms
ontrolling lymphoyte proliferation [208℄. In ontrast to that, TNFRSF1B exerts
anti-apoptoti ativity and was revealed to be over-expressed in T
Reg
versus naive T
ells of IBD patients in remission (+2.5 for inative CD, +2.1 for inative UC) but
not in ative IBD, thereby reahing similar fold hanges like in healthy donors (+2.5)
and RCC patients (+2.1). Strikingly, two polymorphisms in the TNFRSF1B gene were
desribed to ontribute greatly to an inreased risk of CD, even orrelating with disease
severity and responsiveness to therapy [82℄. Comparison of T
Reg
versus naive T ells for
all IBD patients independent from disease stage revealed exlusive over-expression of
another pro-apoptoti moleule, namely TNFRSF6 (Fas reeptor, +2.2). Interestingly,
inreased expression of its ligand TNFSF6 has been reported in IBD oloni lamina
propria thus maybe delivering required apoptoti stimuli [244℄. Furthermore, platelet
endothelial ell adhesion moleule-1 (PECAM1) is a homophili-binding member of
the immunoreeptor tyrosine-based inhibitory motif (ITIM) family of inhibitory reep-
tors that funtions prominently to prevent apoptosis in naturally ourring vasular
subjeted to programmed ell death stimuli. Human T lymphoytes laking PECAM1
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were shown to be far more sensitive than their PECAM1 expressing ounterparts to
multiple death signals, suggesting PECAM1 as a novel and potent suppressor of BAX
mediated apoptosis [240℄. Strikingly, PECAM1 belonged to the genes showing the
strongest derease in expression for a omparison in T
Reg
and naive T ells from IBD
patients (-5.2), thereby demonstrating a far more pronouned down-regulation in a-
tive CD (-7.4) than in inative UC (-3.3). In ontrast to that, PECAM1 expression
was only very slightly diminished between T
Reg
and naive T ells (-1.4) in healthy
donors. Taken together, these ndings ould at least in part explain dierent T
Reg
ell
frequenies in IBD patients depending on disease state.
Another defetive mehanism in CD is T ell resistane to apoptosis, leading to
inappropriate immune homeostasis and aumulation of ativated T ells in the tissues
enhaning inammation. T
Reg
ell indued apoptosis of eetor T ells has reently
been suggested as a potential mehanism of T
Reg
ell mediated immunosuppression and
was demonstrated to be dependent on GZMA, perforin and ITGB2. Interestingly, a
signiant down-regulation of GZMA was observed in T
Reg
versus naive T ells in IBD
patients suering from ative (-3.6) and inative (-3.7) CD, while ITGB2 expression
was slightly dereased in UC patients in remission (-1.5). In this ontext, the galetins
LGALS1 and LGALS3 may also play a role. LGALS1 was demonstrated to be able to
indue apoptosis in ativated T ells and was only found to be signiantly dierentially
expressed between T
Reg
and naive T ells from UC patients in remission, but not
in patients with ative IBD. Similarly, LGALS3 expression was not revealed to be
signiantly altered when omparing T
Reg
versus naive T ells in all IBD patient ohorts
examined, whereas its expression has been dislosed to be learly up-regulated between
both T ell subsets in healthy donors (+3.9). As desribed previously, LGALS3 may
at as a pro-apoptoti moleule when sereted extraellularily. Furthermore, CLL5
was the most down-regulated gene in T
Reg
versus naive T ells isolated from IBD
patients (-5.6) showing a far less derease in expression between both T ell subsets in
healthy donors (-2.5). Miromolar onentrations of CCL5 have been demonstrated to
indue apoptosis in human PB-derived T ells via the CCR5 hemokine reeptor, that
is interestingly up-regulated upon T ell ativation [243℄. Taken these results together,
it is oneivable that impaired T
Reg
ell mediated apoptosis indution in T eetor
ells may ontribute to IBD pathogenesis due to persistene of ativated intestinal T
ells.
Another interesting moleule revealed by the extensive miroarray study of human
T
Reg
and naive T ells in IBD is interleukin-23. IL23 is a heterodimeri ytokine
enoded by IL23A and the p40 subunit of IL12 (IL12B). IL23 an ativate STAT4
expression and stimulate the prodution of IFN-γ. While IL12 is mainly ating on naive
CD4
+
T ells, IL23 predominantly exerts its funtion on memory CD4
+
T ells [208℄.
Consistent with previous studies reporting elevated IL23 expression in CD muosa,
exlusive up-regulation of IL23A expression was found in T
Reg
versus naive T ells from
CD patients with ative disease. Whereas the entral role of IL12 in the generation
114 4 Disussion
of IFN-γ sereting ells and thus in the regulation of T
H
1 responses has long been
appreiated, there is now emerging evidene for an even more important role of IL23
in the manifestation of intestinal inammation. Mouse study results with targeted
deletion of the IL23/p19 subunit suggested that IL23-driven intestinal inammation
is mediated by prodution of IL6 and IL17. Moreover, administration of reombinant
IL23 aelerated the development of olitis in lymphoyte-deient RAG knokout mie
after reonstitution with CD4
+
T ells from IL10
-/-
mie [237℄. Elevated expression of
IL23A has additionally been reported in psoriati lesions ompared with nonlesional
skin and IL23 has been impliated in reruitment of inammatory ells in T
H
1 media-
ted autoimmune and hroni inammatory diseases [208℄. In summary, these results
suggest a ontribution of T
Reg
ell sereted IL23A to a shifted balane towards T
H
1
responses as seen in CD.
CD and UC have both been assoiated with disturbanes in vasular physiology,
inluding permeability and angiogenesis, that are in part regulated by endothelial in-
terellular juntions. These juntions are omposed of several adhesion moleules,
inluding PECAM1. Lower levels of this versatile ell adhesion moleule in its soluble
form were desribed in intestinal biopsies from patients suering from ative UC with
extensive loation [241℄. Furthermore, PECAM1 plays a signiant role in leukoyte
transendothelial migration by mediating homophili interations between endothelial
ells (EC) as well as between ECs and leukoytes, thus preserving vessel integrity. In-
reased PECAM1 expression has been demonstrated in patients suering from ative
multiple slerosis, neuroinammation due to HIV infetion and PECAM1 was shown to
be involved in Alzheimer disease pathogenesis [242℄. As previously desribed, dereased
PECAM1 levels were revealed in T
Reg
versus naive T ells from IBD patients (-5.2)
that were additionally far less pronouned in healthy donors (-1.4) thereby perhaps
indiating alterations in EC-leukoyte interations ontributing to IBD pathogenesis.
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Regulatory T ells have a far-reahing eet on our health by inuening the outome
of infetion, autoimmunity, graft survival, aner, and even allergy. Despite reent ad-
vanes in T
Reg
ell immunology, requirements for their development, maintenane, and
mode of ation in humans remain poorly dened as thus far, genomi studies on T
Reg
ells were restrited to murine models. To improve moleular haraterization of human
T
Reg
ells, a unique miroarray has been ompiled, the Human T
Reg
Chip, onsisting
of 350 T
Reg
ell assoiated genes. To ensure measurement of aurate and reliable
transription proles, this hip was validated in terms of ross-platform omparison to
Aymetrix, reproduibility in repeated experiments, reliability expressed as CV, spot-
ting quality, linearity of hybridization, and sensitivity. During this evaluation proess
the Human T
Reg
Chip emerged as a reliable and suitable tool to the sienti ommunity
failitating researh on human T
Reg
ells in health and disease. Afterwards, purity and
regulatory phenotype, expressed as fration of FOXP3 positive ells and suppressive
apaity, of MACS separated human CD4
+
CD25
+
regulatory and CD4
+
CD25
-
naive
T ells was onrmed. Miroarray analyses were performed by separately hybridizing
T
Reg
or naive T ell-derived RNA of 11 healthy volunteers, yielding 62 dierentially ex-
pressed genes after appliation of normalization and SAM algorithms to the data set.
Among them, expression of 21 "old friends" previously desribed in murine and/or
human T
Reg
ells lent greater reditability to the identiation of 41 "new players"
that have not been mentioned in the haraterization of T
Reg
ells at all before. Ap-
pliation of PathwayAssist software to the unique data set, revealed impliation of
these andidates in funtional key modules pointing to mehanisms ontrolling diverse
ellular proesses suh as survival/apoptosis, TCR signalling/ativation/proliferation
and dierentiation/maintenane of human T
Reg
ells in health. Furthermore, the vast
majority of genes have been reported to be involved in autoimmunity, tumor deve-
lopment, transplantation tolerane and even allergy - all representing disease senarios
thought to result at least partly from unbalaned T
Reg
ell ativity. T
Reg
ell spei
expression of ve seleted genes-of-interest, namely LGALS3, CCR10, TNFRSF1B,
CCR5 and TRAF1 was onrmed by real-time RT-PCR. Furthermore, FACS analysis
onrmed orrelation of TNFRSF1B, CCR10, LGALS3 and FOXP3 gene and protein
expression and demonstrated signiantly higher amounts of TNFRSF1B, LGALS3
and FOXP3 proteins in human CD4
+
CD25
+
regulatory ompared to CD4
+
CD25
-
naive T ells in healthy donors. LGALS3 as well as TNFRSF1B proteins were re-
vealed to be oexpressed with FOXP3 in a onsiderable fration of CD4
+
T ells,
although an even more extended population just oexpressed CD4 and one of the both
proteins-of-interest. It would be interesting to gure out, whether and how these T
ell subsets dier in their regulatory phenotype. Therefore, FOXP3
+
LGALS3
high/low
and FOXP3
+
TNFRSF1B
high/low
CD4
+
T ells should be sorted and ompared in mixed
lymphoyte reations regarding their suppressive apaity. During advaned analyses
116 5 Summary and Perspetives
of the ve seleted genes/proteins-of-interest, LGALS3 and TNFRSF1B emerged as
two new putative T
Reg
ell marker moleules, as their mRNA as well as protein over-
expression in healthy human T
Reg
ells was sustained at onstantly high levels even
after in vitro ativation with anti-CD3. Moreover, expression of both genes/proteins
were not onsiderably indued upon ativation in CD4
+
CD25
-
naive T ells and re-
mained learly lower than in ativated T
Reg
ells. Thereby, expression behaviour of
LGALS3 and TNFRSF1B resembled the one of FOXP3 supporting the role of both
moleules as new human T
Reg
ell markers. Next, suseptibility to apoptoti ell death
was ompared in T
Reg
versus naive T ells from healthy donors as miroarray analyses
revealed several genes partiipating in apoptosis ontrol. Applying ombined Annexin
V and propidium iodide staining, a lower apoptoti sensitivity of the regulatory T ell
fration ould indeed be demonstrated when ompared to their naive ounterparts in
healthy volunteers. As admittedly, the number of measured FACS events were rather
low due to limited ell numbers and the obtained data was probably highly inuened
by the applied gating strategy, results should be reassured by performing additional
apoptosis assays.
Using the expression signature of human T
Reg
ells from healthy donors as a refe-
rene, it was interesting to analyse ommonalities and dierenes in T
Reg
ell biology
in aner and hroni inammatory disease. First, T
Reg
ells from RCC patients were
investigated, suering either from loalized or metastati tumor growth. Signiant
higher CD4
+
CD25
high
T
Reg
ell frequenies ould be demonstrated in RCC patients
ompared to healthy donors, but no substantial dierenes in T
Reg
ell numbers were
found between loalized and metastati RCC. Thereby, elevated T
Reg
ell prevalene
in RCC was aompagnied by an inrease of total CD4
+
CD25
+
T ells, inorpora-
ting CD25
low
as well as CD25
dim
T ells. Suppressive apaity of T
Reg
ells should be
ompared between RCC patients and healthy donors to evaluate whether T
Reg
ells
in RCC display funtional deits in addition to their numerial exess. Gene ex-
pression analyses of RCC T
Reg
and naive T ells applying the Human T
Reg
Chip were
performed and allowed omparison of transriptional patterns between healthy donors
and RCC patients as well as omparison of expression signatures between loalized
and metastati tumor growth. Although no genes with opposed regulations ould be
revealed between all patient ohorts, numerous genes were deteted to be exlusively
dierentially expressed in T
Reg
versus naive T ells in only one of the donor groups.
Comparing T
Reg
versus naive T ells, the vast majority of genes interestingly showed
stronger regulation in RCC patients than in healthy donors and in metastati than in
loalized tumor growth. Furthermore, a rising number of regulated genes was identi-
ed omparing both T ell subsets in healthy donors via loalized to metastati RCC
patients. As espeially the fration of over-expressed andidates inreased dramatially
depending on stage of disease, a gain-of-funtion in RCC patient-derived T
Reg
ells may
be onluded. Disseting the gene expression pattern of RCC T
Reg
and naive T ells
dislosed several mehanisms probably supporting tumor immune esape. Numerous
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genes were identied ontributing to enhaned survival of RCC T
Reg
ells due to de-
reased suseptibility towards apoptosis. Together with andidates enabling inreased
proliferation rates of T
Reg
ells in RCC, these ndings may provide a possible expla-
nation for elevated T
Reg
ell frequenies in RCC. Furthermore, exlusive indution of
several homing reeptors and adhesion moleules was observed in RCC-derived T
Reg
ells that may lead to elevated attration of T
Reg
ells into the tumor environment.
To prove this hypothesis, it would be interesting to evaluate hemokine expression in
RCC tumors as these small hemotati ytokines mediate T
Reg
ell migration. Fur-
thermore, migration assays and immunohistohemistry omparing expression of the
indued hemokine reeptors on tumor inltrating T
Reg
ells and on T
Reg
ells in adja-
ent healthy renal tissue ould add exiting news about the homing behaviour of RCC
T
Reg
ells. Moreover, several genes were revealed to be able to onfer exaggerated
suppressive apaity to T
Reg
ells in RCC, suh as an augmented ability to indue
apoptoti ell death in anti-tumor eetor T ells. Taken together, all these funtional
modules ould at in onert to promote T
Reg
ell mediated tumor immune evasion.
Correlation of miroarray and quantitative real-time RT-PCR results was demonstrated
for FOXP3 as a well-haraterized T
Reg
ell gene and for the seleted "new players"
LGALS3, CCR10, TNFRSF1B and TRAF1. Comparing T
Reg
versus naive T ells, a
signiant derease in the fold hange of LGALS3 expression was observed in RCC
patients. Similar to healthy donors, FACS analyses revealed learly elevated FOXP3
and LGALS3 protein expression levels in T
Reg
versus naive T ells from RCC patients.
While the fration of FOXP3 positive ells within the CD4
+
CD25
high
T
Reg
subpopula-
tion was omparable between healthy donors and RCC patients, a signiantly higher
perentage of LGALS3 expressing ells was strikingly disovered among the RCC T
Reg
ells. This result ould point to an antigeni stimulation of RCC T
Reg
ells mediated
by the tumor, as LGALS3 expression was demonstrated to be learly indued upon
ativation of T
Reg
ells in healthy donors [197℄. Well in line with this nding, learly
larger CD4
+
T ell subpopulations were deteted oexpressing LGALS3 and FOXP3
as well as TNFRSF1B and FOXP3 in RCC patients ompared to healthy volunteers.
As observed for healthy donors, staining for Annexin V and propidium iodide with
subsequent FACS analyses revealed that RCC T
Reg
ells were also less suseptible to
apoptosis than their naive ounterparts. In ontrast to that, an enhaned protetion
from programmed ell death ould not be onrmed in RCC versus healthy donor-
derived T
Reg
ells, thus elevated frequenies of T
Reg
ells in RCC seem to be rather
aused by an inrease in proliferation. To prove this, proliferation rates in RCC- versus
healthy donor-derived T
Reg
ells should be assessed in appropriate proliferation assays.
Paradoxially, higher apoptoti rates were deteted in naive T ells from RCC patients,
supporting the presented idea of an inreased T
Reg
ell-mediated apoptosis indution
in eetor T ells ontributing to tumor immune esape. As the omposition of ells in
the blood stream might not be omparable to the onditions at the site of tumor deve-
lopment, omparison of gene expression patterns from PB-derived to tumor inltrating
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T
Reg
ells in RCC patients ould be very interesting. Furthermore, T
Reg
ell numbers
and hanges in gene expression from RCC patients should be investigated before and
after ytoredutive nephretomy, as the primary tumor (not only) in RCC has been
reognized to suppress anti-tumor eets [199, 40℄.
Sine T
Reg
ells have proven eetive in the prevention and down-regulation of IBD
in animal models, abnormalities in their suppressor funtion, frequeny or distribution
in the intestinal muosa are supposed to ontribute to IBD pathogenesis [235℄. These
fats led us to have a loser look on T
Reg
ells isolated from IBD patients, suering
either from UC or CD and presenting ative or inative state of disease. In ooperation
with Dr.Maul, dereased PB T
Reg
ell frequenies were demonstrated in ative IBD,
whereas T
Reg
ells were enrihed in PB of IBD patients presenting with inative state
of disease. Although T
Reg
ell numbers were inreased in inamed intestinal lesions
versus noninamed areas, T
Reg
ell presene was only insuiently enhaned ompared
to divertiulitis patients [235℄. To deipher gene regulation events and to identify
novel genes that might be involved in IBD pathogenesis, maintenane and progression,
omparative miroarray analyses of CD4
+
CD25
+
T
Reg
and CD4
+
CD25
-
naive T ells
were performed isolated from PB of IBD patients suering from ative CD, inative
CD or inative UC. Similar to results obtained from RCC patients, omparing this
IBD T
Reg
ell ngerprint to the obtained healthy referene expression pattern did not
reveal genes with opposite diretions in regulation but several andidates exlusively
dierentially expressed between T
Reg
and naive T ells in only one donor group. Genes
that were found to be regulated in both donor ohorts, again showed generally stronger
alterations in IBD patients. Diret omparison of T
Reg
ells between IBD patients
and healthy donors dislosed far more down-regulated than up-regulated genes that
ould point to loss-of-funtions in IBD-derived T
Reg
ells ontributing to insuient
regulatory apaity and thus to IBD pathogenesis. This extensive IBD miroarray
study even allowed omparative analysis of T
Reg
ells from IBD patients suering from
dierent stage of disease, suh as ative/inative CD and inative UC. Interestingly, the
number of genes dierentially expressed between T
Reg
and naive T ells signiantly
delined from ative to inative disease state, supporting the idea of a rapprohement
in T
Reg
ell gene expression of IBD patients in remission to healthy values. Strikingly,
tremendous dierenes in hemokine reeptor expression patterns were found between
T
Reg
and naive T ells in health and IBD that ould result in impaired homing of T
Reg
ells towards the intestine. Investigation of IBD- and healthy donor-derived T
Reg
ells in
migration assays ould thereby gain new insights into migration behaviour of T
Reg
ells
in hroni inammatory diseases. Furthermore, revelation of signiant over-expression
of several genes with pro-apoptoti funtions and down-regulation of anti-apoptoti
genes in ative IBD ompared to patients in remission or healthy donors ould lead
to insuient T
Reg
ell numbers as observed in IBD. Moreover, a funtional module
of dierentially expressed genes was deteted suggesting impaired T
Reg
ell mediated
apoptosis indution in T eetor ells thus leading to aumulation of ativated T ells
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in gut tissues and enhaning inammation in IBD. To prove this hypothesis, T
Reg
ells
from IBD patients and healthy volunteers should be ompared regarding their apoptoti
suseptibility and their ability to indue programmed ell death in T eetor ells in
appropriate apoptosis assays. Another interesting module dislosed during dissetion
of the gene expression patterns haraterizing T
Reg
ells in IBD indiated alterations in
EC-leukoyte interations. As onditions in the blood stream obviously dier from the
ones at the site of inammation, gene expression of gut-inltrating lymphoytes should
be analysed as well and should be ompared to the transriptional pattern obtained
from PB T
Reg
ells. Again, quantitative real-time RT-PCR onrmed the miroarray
data for FOXP3, LGALS3, CCR10, TNFRSF1B and TRAF1 gene expression. Thereby,
a signiantly dereased fold hange in expression of LGALS3 and TNFRSF1B was
observed in IBD-derived T
Reg
versus naive T ells when ompared to healthy donors,
whereas FOXP3 showed a learly elevated fold hange in the same omparison.
Taken together, the omprehensive sets of genes disriminating human regulatory
from naive T ells provide a dened starting point to unravel the unique harate-
ristis of T
Reg
ells in health and disease. The Human T
Reg
Chip onstruted and
validated here is available to the sienti ommunity and has proven as a useful tool
to study moleular mehanisms orhestrating T
Reg
ells under physiologi and diseased
onditions. In RCC and IBD patients, T
Reg
ells were demonstrated to display not
only numerial but also funtional deits that should be further disseted in order to
unravel their remaining mysteries. Broadening our knowledge about these important
immune regulators is essential for further development of new therapeuti approahes
exploiting T
Reg
ell potential in balaning peripheral tolerane.
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